

CITATION REPORT

List of articles citing

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

DOI: 10.2337/diacare.16.2.434
Diabetes Care, 1993, 16, 434-44.

Source: <https://exaly.com/paper-pdf/24047018/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2309	Epidemiology of Vascular Disease in Diabetes. 1-15		
2308	Acetylsalicylic Acid resistance in patients with type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease. 2014 , 30, 539-44		2
2307	Chick-embryo deaths traced to tincture of iodine. 1973 , 127, 581		
2306	Calendar of Events. 1992 , 12, 167-170		
2305	Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. 1993 , 36, 1175-84		311
2304	Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. 1993 , 3, 493-9		127
2303	Hypertension and diabetes. 1993 , 15, 1327-42		7
2302	Complications and Management of Diabetes: A Review of Current Research. 1994 , 6, 723-734		2
2301	Greater effect of diabetes on LDL size in women than in men. <i>Diabetes Care</i> , 1994 , 17, 1164-71	14.6	89
2300	From diagnosis and classification to complications and therapy. DCCT. Part II? Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 1994 , 17, 326-38	14.6	59
2299	American Association of Diabetes Educators. White paper on healthcare reform. 1994 , 20, 479-82		4
2298	Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. 1994 , 37, 585-91		50
2297	The role of diabetes mellitus and hypertriglyceridaemia as coronary risk factors in treated hypertension: 15 years of follow-up of antihypertensive treatment in middle-aged men in the Primary Prevention Trial in G ^o teborg, Sweden. 1994 , 235, 217-27		8
2296	Dyslipidaemia in non-insulin dependent diabetes: the need for a clinical intervention trial. 1994 , 24, 61-4		1
2295	Diabetic dyslipidemia. 1994 , 96, 25S-31S		35
2294	The dyslipoproteinemias of diabetes. 1994 , 110 Suppl, S27-33		30
2293	Future in lipid and lipoprotein research: from preventing clinical disease to preventing elevated risk factors. 1994 , 108 Suppl, S143-56		3

2292	Impact of cardiovascular disease on health care utilization in a defined diabetic population. 1994 , 47, 1133-42	35
2291	Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. 1994 , 15, 1300-31	483
2290	Cigarette smoking and diabetes: an update. 1994 , 11, 336-43	68
2289	Cholesterol rich apo B containing lipoproteins and smoking are independently associated with macrovascular disease in normotensive NIDDM patients. 1994 , 11, 740-7	6
2288	Lipoprotein disorders in diabetes mellitus. 1994 , 78, 143-61	68
2287	Cardiovascular death in patients with end-stage renal failure; strategies for prevention. 1994 , 9, 120-128	25
2286	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. 1994 , 91, 3662-5	190
2285	Prevention of macrovascular disease: absolute proof or absolute risk?. 1995 , 12, 561-2	
2284	National Standards for Diabetes Self-Management Education Programs. <i>Diabetes Care</i> , 1995 , 18, 100-16	14.6 66
2283	Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. 1995 , 76, 1173-6	107
2282	Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. 1995 , 75, 1130-4	69
2281	Analysis of the MRFIT screenees: a methodological study. 1995 , 237, 507-18	11
2280	Blood pressure changes in diabetes in urban Tanzania. 1995 , 32, 28-31	8
2279	The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. 1995 , 38, 318-25	123
2278	Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. 1995 , 38, 585-91	112
2277	Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. 1995 , 38, 1313-9	99
2276	Detection of coronary artery disease in diabetic patients. 1995 , 38, 726-31	49
2275	Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations?. 1995 , 38, 487-93	59

2274	Dyslipidemia and diabetes: a personal view. 1995 , 1, 433-9		
2273	Mortality risk by body weight and weight change in people with NIDDM. The WHO Multinational Study of Vascular Disease in Diabetes. <i>Diabetes Care</i> , 1995 , 18, 766-74	14.6	79
2272	Diabetes and hypertension: prognostic and therapeutic considerations. 1995 , 4, 329-38		7
2271	Albuminuria and 24-h ambulatory blood pressure in normoalbuminuric and microalbuminuric NIDDM patients. A longitudinal study. <i>Diabetes Care</i> , 1995 , 18, 1434-41	14.6	35
2270	Long-term glyceic control relates to mortality in type II diabetes. <i>Diabetes Care</i> , 1995 , 18, 1534-43	14.6	178
2269	U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease. 1995 , 44, 1249-1258		1551
2268	[Diabetes mellitus and atherosclerosis. Physiopathology of diabetic macroangiopathy]. 1995 , 16, 31-42		1
2267	Relationship between habitual diet and blood glucose and lipids in non-insulin dependent diabetes (NIDDM). 1995 , 15, 843-857		8
2266	Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: a population-based study. 1995 , 44, 1293-7		6
2265	Mortality from coronary heart disease and cerebrovascular disease and associated risk factors in diabetic patients in Osaka District, Japan. 1995 , 27, 77-83		21
2264	Absence of increased susceptibility of LDL to oxidation in type 1 diabetics. 1995 , 30, 195-203		6
2263	LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. 1995 , 113, 227-36		31
2262	Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. 1995 , 346, 869-72		317
2261	Review of new guidelines for management of dyslipidaemia. 1995 , 9, 867-90		4
2260	Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs. 1996 , 25, 217-242		44
2259	Heart disease in diabetes mellitus. 1996 , 25, 425-38		29
2258	Determinants for coronary heart disease in non-insulin-dependent diabetes mellitus: lessons from the diabetes intervention study. 1996 , 30 Suppl, 67-70		6
2257	Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilation. 1996 , 27, 1464-70		41

2256	Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. 1996 , 28, 573-9	285
2255	Blood pressure and end-stage renal disease in men. 1996 , 334, 13-8	1283
2254	Cardiovascular mortality and morbidity in type-2 diabetes mellitus. 1996 , 31 Suppl, S3-13	64
2253	Dysglycaemia and risk of cardiovascular disease. 1996 , 347, 949-50	134
2252	Lipids and atherogenesis in diabetes mellitus. 1996 , 124 Suppl, S43-7	11
2251	Diabetes mellitus in older patients. Is tight blood glucose control warranted?. 1996 , 8, 401-7	5
2250	Cardiovascular risk factors and the prediabetic syndrome. 1996 , 28, 363-70	23
2249	Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. 1996 , 28, 341-5	34
2248	Forum One: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus. 1996 , 124, 175-7	37
2247	Diet and the Role of Altered Carbohydrate Absorption in the Treatment of Noninsulin-Dependent Diabetes Mellitus. 1996 , 10, 29-36	1
2246	Management of patients with diabetes and "abnormal" blood pressure: selection of antihypertensive agents. 1996 , 2, 276-9	
2245	United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. 1996 , 124, 136-45	321
2244	Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. 1996 , 124, 123-6	68
2243	The relationships between cardiovascular risk factors and socio-economic status in people with diabetes. 1996 , 13, 72-9	34
2242	Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus. 1996 , 13, 139-44	29
2241	Treatment of dyslipoproteinaemia in diabetes mellitus. 1996 , 13, 297-312	16
2240	When to treat the hypertensive diabetic patient. 1996 , 10, 144-5	
2239	Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. 1996 , 39, 1540-5	160

2238	The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. 1996 , 39, 1655-61	77
2237	The DIAB-HYCAR Study. 1996 , 39, 1662-7	23
2236	Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. 1996 , 26, 519-25	32
2235	Diabetes, mortality and coronary heart disease in the prospective Dubbo study of Australian elderly. 1996 , 26, 66-74	24
2234	Hypertriglyceridemia and its Metabolic Consequences as a Risk Factor for Atherosclerotic Cardiovascular Disease in Non-Insulin-Dependent Diabetes Mellitus. 1996 , 12, 37-56	55
2233	Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. 1996 , 39, 453-61	94
2232	Ethnic differences in mortality from cardiovascular disease in the UK: do they persist in people with diabetes?. 1996 , 50, 137-9	65
2231	High mortality from cardiovascular disease and analysis of risk factors in Indian and Melanesian Fijians. 1996 , 25, 59-69	29
2230	Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. 1996 , 45 Suppl 3, S87-90	20
2229	The relative effectiveness of educational and behavioral instruction programs for patients with NIDDM: a randomized trial. 1996 , 22, 379-86	78
2228	The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. 1996 , 28, 323-33	83
2227	Early lifestyle intervention in patients with non-insulin-dependent diabetes mellitus and impaired glucose tolerance. 1996 , 28, 445-9	69
2226	Criteria for metabolic control and intervention in diabetes. 1996 , 45 Suppl 3, S120-2	9
2225	Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence. 1996 , 28, 357-62	10
2224	Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients. <i>Diabetes Care</i> , 1996 , 19, 419-22	14.6 55
2223	The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group. 1996 , 28, 439-44	34
2222	Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. <i>Diabetes Care</i> , 1996 , 19, 689-97	14.6 159
2221	Sex hormones and DHEA-SO4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. <i>Diabetes Care</i> , 1996 , 19, 1045-50	14.6 67

2220	The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. <i>Diabetes Care</i> , 1997 , 20, 469-71	14.6	69
2219	Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. 1997 , 82, 2257-60		124
2218	Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins. 1997 , 105 Suppl 2, 74-7		5
2217	Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). <i>Diabetes Care</i> , 1997 , 20, 614-20	14.6	1285
2216	Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. 1997 , 46, 1354-9		246
2215	Coronary artery disease and diabetes. 1997 , 78, 527-8		5
2214	Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. <i>Diabetes Care</i> , 1997 , 20, 163-9	14.6	216
2213	Hypertension education: an important and neglected part of the diabetes education curriculum?. 1997 , 23, 166-70		8
2212	The blood contribution to early myocardial reperfusion injury is amplified in diabetes. 1997 , 46, 1859-67		27
2211	U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. <i>Diabetes Care</i> , 1997 , 20, 1683-7	14.6	133
2210	Risk of End-stage Renal Disease in Diabetes Mellitus. 1997 , 278, 2069		172
2209	Pharmacological strategies to prevent macrovascular disease in NIDDM. 1997 , 46 Suppl 2, S131-4		7
2208	U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. <i>Diabetes Care</i> , 1997 , 20, 1435-41	14.6	66
2207	Carotid intima-media thickness in hyperlipidemic type I and type II diabetic patients. <i>Diabetes Care</i> , 1997 , 20, 276-80	14.6	38
2206	Aspirin therapy in diabetes. <i>Diabetes Care</i> , 1997 , 20, 1767-71	14.6	130
2205	Lipids, thrombosis and cardiovascular disease in diabetes. 1997 , 56, 273-80		1
2204	Epidemiology of non-insulin-dependent diabetes mellitus and its macrovascular complications. A basis for the development of cost-effective programs. 1997 , 26, 165-88		17
2203	Evidence-Based Performance and Outcome Measures for Diabetes Care. 1997 , 2, 124-133		4

2202	The impact of diabetes on survival among patients with first myocardial infarction. <i>Diabetes Care</i> , 1997 , 20, 704-8	14.6	76
2201	Increased incidence of moderate stenosis among patients with diabetes: substrate for myocardial infarction?. 1997 , 134, 1037-43		31
2200	Insulin resistance implications for type II diabetes mellitus and coronary heart disease. 1997 , 103, 152-62		172
2199	Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. 1997 , 1, 87-8		10
2198	Multifactorial aspects of the treatment of the type II diabetic patient. 1997 , 46, 1-4		36
2197	Glycation, oxidation, and lipoxidation in the development of diabetic complications. 1997 , 46, 14-21		76
2196	Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation. 1997 , 30, 1420-5		97
2195	Urinary albumin excretion rate and cardiovascular disease in Spaniard type 2 diabetic patients. 1997 , 36, 127-34		7
2194	Lack of association of lipoprotein (a) with coronary heart disease in Spaniard type 2 diabetic patients. 1997 , 35, 135-41		6
2193	The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. 1997 , 350 Suppl 1, S11-4		81
2192	The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it?. 1997 , 350 Suppl 1, S14-9		141
2191	Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. 1997 , 350 Suppl 1, S120-3		149
2190	What cardiologists need to know about diabetes. 1997 , 350 Suppl 1, S123-8		44
2189	The impact of cardiovascular disease on people with diabetes: the potential for prevention. 1997 , 350 Suppl 1, S129-32		38
2188	Lipoproteins and cardiovascular risk-from genetics to CHD prevention. 1997 , 4, 51-8		19
2187	Food group and macronutrient intakes, trial years 1-6, in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. 1997 , 65, 258S-271S		11
2186	Progress in population analyses of the insulin resistance syndrome. 1997 , 827, 1-12		15
2185	Effect of oral antidiabetics and insulin on lipids and coronary heart disease in non-insulin-dependent diabetes mellitus. 1997 , 827, 246-68		2

2184	Small dense low-density lipoprotein (LDL) in non-insulin-dependent diabetes mellitus (NIDDM). Impact of hypertriglyceridemia. 1997 , 827, 279-86	5
2183	The renal risks of smoking. 1997 , 51, 1669-77	120
2182	Effects of MCT/LCT and LCT emulsions on plasma lipids and nitrogen retention in streptozotocin-induced diabetic rats receiving total parenteral nutrition. 1997 , 13, 882-6	4
2181	Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. 1997 , 11, 137-41	23
2180	Five-year all-cause mortality of 1323 newly diagnosed middle-aged and elderly diabetic patients. Data from the population-based study, diabetes care in general practice, Denmark. 1997 , 11, 83-9	14
2179	Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?. 1997 , 80, 1287-94	13
2178	High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy. 1997 , 40, 610-3	40
2177	Shifts in doctor-patient communication during a series of outpatient consultations in non-insulin-dependent diabetes mellitus. 1997 , 30, 227-37	67
2176	The Postprandial State and the Risk of Atherosclerosis. 1997 , 14, S6-S11	16
2175	Recommendations for the nutritional management of patients with diabetes mellitus. 1998 , 52, 467-81	59
2174	Paradoxical decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. 1998 , 81, 1298-304	92
2173	Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification. 1998 , 82, 4R-8R	15
2172	Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. 1998 , 44, 249-56	16
2171	Broader metabolic control in diabetes management. 1998 , 14, S39-S43	
2170	Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. 1998 , 15, 386-92	16
2169	Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability. 1998 , 15, 870-7	16
2168	Reducing the cardiovascular consequences of diabetes mellitus. 1998 , 15, S69-S72	
2167	Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation. 1998 , 35, 161-4	37

2166	The Influence of Persimmon Peel and Persimmon Pulp on the Lipid Metabolism and Antioxidant Activity of Rats Fed Cholesterol. 1998 , 9, 223-227	76
2165	The effects of exercise on cardiovascular risk factors in Type 2 diabetes mellitus. 1998 , 15, 151-156	5
2164	Hypertension and macrovascular disease--the killing fields of NIDDM. 1998 , 39 Suppl, S27-33	11
2163	Dysglycaemia: a cardiovascular risk factor. 1998 , 40 Suppl, S9-14	10
2162	Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years. 1998 , 47, 1258-62	18
2161	Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. 1998 , 90, 181-90	82
2160	Multivessel balloon angioplasty should be abandoned in diabetic patients!. 1998 , 31, 20-2	4
2159	Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. 1998 , 31, 10-9	196
2158	The sulfonylurea controversy: more questions from the heart. 1998 , 31, 950-6	134
2157	Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. 1998 , 32, 1866-73	388
2156	[Heart pathology of extracardiac origin. XI. Cardiac repercussions of diabetes mellitus]. 1998 , 51, 661-70	7
2155	Insulin resistance and diabetes in the context of treatment of hypertension. 1998 , 3, 28-31	24
2154	Impact of dyslipidaemia. Lessons from clinical trials. 1998 , 14 Suppl 3, 1-9	1
2153	Effects of soybean oil and fish oil emulsions on glucose and lipid metabolism in streptozotocin-induced diabetic rats receiving total parenteral nutrition. 1998 , 22, 297-301	5
2152	A "touch of sugar" can be fatal. 1998 , 136, 762-4	1
2151	Cardiovascular risk continuum: implications of insulin resistance and diabetes. 1998 , 105, 4S-14S	124
2150	Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. 1998 , 339, 229-34	5170
2149	Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. 1998 , 137 Suppl, S65-73	117

2148 Stratégies actuelles de prise en charge du diabète de type 2. **1998**, 4, 13-28

2147 Diabetes in America: epidemiology and scope of the problem. *Diabetes Care*, **1998**, 21 Suppl 3, C11-4 14.6 294

2146 Issues surrounding tight glycemic control in people with type 2 diabetes mellitus. **1998**, 32, 896-905 18

2145 The burden of chronic hyperglycemia. *Diabetes Care*, **1998**, 21 Suppl 3, C32-4 14.6 18

2144 Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. *Diabetes Care*, **1998**, 21, 1138-45 14.6 641

2143 Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. **1998**, 158, 741-51 205

2142 Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. **1998**, 279, 119-24 469

2141 The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. **1998**, 19, 583-92 142

2140 Diabetes and coronary heart disease. **1998**, 339, 1714-5; author reply 1716 38

2139 The Involvement of Protein Kinase C-II in Glucose-Induced Rat Vascular Smooth Muscle Cell Proliferation. **1998**, 1, 207-218 2

2138 Regional blood flow dynamics in response to insulin and IGF-1 in diabetic animals. **1998**, 20, 67-83 10

2137 Effects of glucose and insulin on rat apolipoprotein A-I gene expression. **1998**, 273, 18959-65 96

2136 Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. *Diabetes Care*, **1998**, 21, 1167-72 14.6 367

2135 Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). **1998**, 316, 823-8 1367

2134 Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. **1998**, 139, 4067-72 57

2133 Multiple Risk Factors in Cardiovascular Disease. **1998**,

2132 Microalbuminuria and coronary heart disease in NIDDM: an incidence study. **1998**, 47, 1786-92 128

2131 Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). **1998**, 27, 636-41 48

2130	Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. <i>Diabetes Care</i> , 1998 , 21, 539-45	14.6	71
2129	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. 1998 , 317, 703-713		4477
2128	Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study. 1998 , 26, 200-5		11
2127	Diabetes: a time for excitement-and concern. Hopeful signs exist that the ravages of diabetes can be tamed. 1998 , 317, 691-2		12
2126	International Diabetes Federation Meeting, 1997, and other recent meetings. Atherosclerosis and related topics. <i>Diabetes Care</i> , 1998 , 21, 1356-63	14.6	2
2125	Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. 1998 , 88, 765-70		55
2124	Functional food science and substrate metabolism. 1998 , 80 Suppl 1, S47-75		31
2123	Plasma lipids and fatty acid synthase activity are regulated by short-chain fructo-oligosaccharides in sucrose-fed insulin-resistant rats. 1998 , 128, 1283-8		70
2122	Diabetes and atherosclerosis: mechanisms and management. 1998 , 4, 112-9		1
2121	Oxidative Stress and Cardiovascular Complications of Diabetes. 1998 , 14, 78-90		
2120	Insulin and cardiovascular risk factors in newly diagnosed diabetes mellitus patients. 1998 , 7, 97		
2119	Coronary artery disease and diabetes. 1999 , 105, 66-8, 71-2, 77-80		4
2118	6. Does the blood pressure need lowering?. 1999 , 170, 609-615		
2117	Type 2 diabetic subjects without prior myocardial infarction are at the same risk of coronary events as non-diabetic subjects with prior myocardial infarction. 1999 , 20, 473-5		2
2116	Diabetes mellitus and cerebrovascular disease. 1999 , 18, 1-14		63
2115	MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. 1999 , 20, 725-41		175
2114	Preclinical and clinical studies on safety and tolerability of repaglinide. 1999 , 107 Suppl 4, S144-8		11
2113	The KID Study VI: diabetic complications and associated diseases in younger type 2 diabetics still performing a profession. Prevalence and correlation with duration of diabetic state, BMI and C-peptide. 1999 , 107, 435-41		10

2112	Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. 1999 , 20, 738-59	83
2111	Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. 1999 , 4, 67-75	35
2110	Effect of hypertension on mortality in Pima Indians. 1999 , 100, 33-40	16
2109	Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. 1999 , 340, 677-84	757
2108	Metabolic control and morbidity of type 2 diabetic patients in a general practice network. 1999 , 16, 402-6	22
2107	Angiographic study of coronary artery disease in diabetic patients in comparison with nondiabetic patients. 1999 , 50, 997-1006	40
2106	Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. 1999 , 159, 2661-7	308
2105	A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism. 1999 , 17, 657-64	77
2104	Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. 1999 , 16, 358-72	17
2103	Diabetes mellitus in the family: perceptions of offspring's risk. 1999 , 16, 431-6	22
2102	Selective Increase of the Contractile Response to Endothelin-1 in Subcutaneous Arteries from Patients with Essential Hypertension. 1999 , 8, 9-15	8
2101	Programmable implantable insulin infusion devices and diabetes care. 1999 , 1, 89-96	1
2100	Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors: a study on a middle-aged and elderly population. 1999 , 29, 175-82	13
2099	Diabetic dyslipidaemia. 1999 , 29 Suppl 2, 12-6	35
2098	Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. 1999 , 1, 165-72	144
2097	Insulin resistance: an independent risk factor for cardiovascular disease?. 1999 , 1 Suppl 1, S23-31	36
2096	Cardiovascular risk in type 2 diabetes. 1999 , 1 Suppl 2, S24-36	11
2095	Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. 1999 , 16, 2-13	61

2094	Intensive lipid-lowering strategy in patients with diabetes mellitus. 1999 , 16, 500-8	17
2093	The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes. 1999 , 42, 944-8	55
2092	Second manifestations of ARterial disease (SMART) study: rationale and design. 1999 , 15, 773-81	286
2091	The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. 1999 , 13, 217-22	32
2090	Features of syndrome X develop in transgenic rats expressing a non-insulin responsive phosphoenolpyruvate carboxykinase gene. 1999 , 42, 419-26	15
2089	Sex- and BMI-related differences in risk factors for coronary artery disease in patients with type 2 diabetes mellitus. 1999 , 36, 147-53	9
2088	Lipid peroxidation and atherosclerosis in type II diabetes. 1999 , 134, 19-32	35
2087	Do pharmacologic differences among antihypertensive agents point to clinical benefits?. 1999 , 84, 22S-27S	1
2086	The diabetic patient as paradigm for selective antihypertensive therapy. 1999 , 2, 1-12	9
2085	Coronary stenting in diabetics: immediate and mid-term clinical outcome. 1999 , 47, 279-84	13
2084	United Kingdom prospective diabetes study (UKPDS): what now or so what?. 1999 , 15, 65-71	26
2083	Arterial hypertension and glycemia in non-diabetic subjects: is there an association independent of obesity?. 1999 , 15, 99-105	5
2082	Reducing the burden of diabetes: managing cardiovascular disease. 1999 , 15, 186-96	30
2081	Glycemic control and cardiovascular disease in type 2 diabetes: a review. 1999 , 15, 197-204	13
2080	Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. 1999 , 15, 274-82	53
2079	Strategies for the management of diabetic dyslipidaemia. 1999 , 58 Suppl 1, 47-51; discussion 75-82	15
2078	The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. 1999 , 33, 1269-77	51
2077	1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. 1999 , 21, 1009-60	410

2076	Effect of diabetes mellitus on formation of coronary collateral vessels. 1999 , 99, 2239-42	511
2075	Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. 1999 , 21, 167-79	31
2074	The effects of tolbutamide on lipoproteins, lipoprotein lipase and hormone-sensitive lipase. 1999 , 46, 99-108	20
2073	Preventive medicine in a diabetes clinic: an opportunity to make a difference. 1999 , 353, 606-8	6
2072	Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. 1999 , 100, 1134-46	1470
2071	Increased expression of tumor necrosis factor-alpha in diabetic macrovasculopathy. 1999 , 8, 145-51	23
2070	Association between low-density lipoprotein composition and its metabolism in non-insulin-dependent diabetes mellitus. 1999 , 48, 118-24	9
2069	Implications of the United Kingdom prospective diabetes study. 1999 , 26, 809-27	10
2068	Drug selection and the management of corticosteroid-related diabetes mellitus. 1999 , 25, 489-505	52
2067	Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. 1999 , 33, 1328-37	48
2066	Diabetic dyslipidaemia. 1999 , 13, 265-78	19
2065	Type 2 diabetes and macrovascular disease: epidemiology and etiology. 1999 , 138, S330-3	26
2064	Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). 1999 , 138, S353-9	60
2063	Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. 1999 , 137, 949-57	109
2062	Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet. 1999 , 29, 87-91	111
2061	Diabetes and the heart. 1999 , 60, 90-4	
2060	Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. 1999 , 159, 1339-47	119
2059	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 17, 151-183	467

2058	Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study. 1999 , 17, 1917-23	11
2057	1999 World Health Organization & International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 8, 9-43	42
2056	Intravascular ultrasound observations of atherosclerotic lesion formation and restenosis in patients with diabetes mellitus. 1999 , 2, 13-20	9
2055	The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. 1999 , 130, 89-96	318
2054	"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?. 2000 , 133, 549-54	32
2053	Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. 2000 , 133, 81-91	152
2052	Cigarette smoking and diabetic nephropathy. 2000 , 130, 85-93	4
2051	The Role of Non-High-Density Lipoprotein-Cholesterol in Evaluation and Treatment of Lipid Disorders. 2000 , 85, 2105-2108	
2050	Combating sloth as well as gluttony: the role of physical fitness in mortality among men with type 2 diabetes. 2000 , 132, 669-70	3
2049	Introducing a new component of the metabolic syndrome: low cholesterol absorption. 2000 , 72, 82-8	136
2048	HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. 2000 , 102, III90-4	21
2047	Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction. <i>Diabetes Care</i> , 2000 , 23, 882-3	14.6 22
2046	Cardiac and Plasma Catecholamine Responses to Exercise in Patients with Type 2 Diabetes: Prognostic Implications for Cardiac-Cerebrovascular Events. 2000 , 320, 24-30	13
2045	Coronary revascularization in patients with diabetes. 2000 , 7, 184-190	1
2044	Emerging concepts in metabolic abnormalities associated with coronary artery disease. 2000 , 15, 416-21	44
2043	Clinical trials of revascularization therapy in diabetics. 2000 , 15, 287-92	7
2042	Microinflammatory state in CRI, PD-/HD-patients. 2000 , 15, 149-154	1
2041	Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus. 2000 , 16, 82-7	17

2040	Management of lipids: comparison between patients with diabetes and ischaemic heart disease. 2000 , 17, 81-83	1
2039	An application of apo(a) isoforms for the clinical assessment of Lp(a). 2000 , 14, 53-8	2
2038	Cardiovascular disease risk reduction in patients with diabetes – is clinical practice effective?. 2000 , 17, 155-158	2
2037	Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. 2000 , 57, 590-600	128
2036	Risk factors for vascular disease in patients with diabetes. 2000 , 2 Suppl 2, S11-8	9
2035	Diabetes and vascular disease. 2000 , 2 Suppl 2, S1-5	5
2034	Postprandial glucose: the nondiabetic state. 2000 , 2 Suppl 1, S1-6	4
2033	The impact of antihypertensive therapy in type 2 diabetes. 2000 , 2 Suppl 1, S37-41	1
2032	Type 2 diabetes and atherosclerosis. 2000 , 2 Suppl 1, S21-30	14
2031	Diabetic dyslipidaemia. 2000 , 2 Suppl 1, S31-6	34
2030	Plasma endothelin in postmenopausal women with type 2 diabetes mellitus and metabolic syndrome: a comparison of oral combined and transdermal oestrogen-only replacement therapy. 2000 , 2, 293-8	12
2029	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. 2000 , 2, 263-70	2
2028	Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. 2000 , 2, 355-62	38
2027	Comparison of questionnaire, breath carbon monoxide and urine cotinine in assessing the smoking habits of Type 2 diabetic patients. 2000 , 17, 119-23	19
2026	Failure to reduce nicotine addiction in young adults with diabetes. 2000 , 17, 330-1	5
2025	Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group. 2000 , 17, 518-23	50
2024	Control of postprandial state abnormalities: meeting the challenge of type 2 diabetes?. 2000 , 30 Suppl 2, 19-24	2
2023	Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. 2000 , 247, 563-9	77

2022	Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. 2000 , 248, 67-76	126
2021	Revascularization strategies in patients with diabetes: evolving concepts. 2000 , 7, 153-8	0
2020	Management of type 2 diabetes: a challenge for patient and physician. 2000 , 40, 187-94	66
2019	Diabetes mellitus and coronary heart disease--from prevention to intervention: Part I. 2000 , 30, 351-9	8
2018	Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. 2000 , 30, 41-7	25
2017	Microvascular Perfusion and Transport in the Diabetic Heart. 2000 , 7, 163-181	42
2016	The Role of Nutrition Therapy in the Management of Diabetes Mellitus. 2000 , 3, 334-348	
2015	Oxidative damage in pregnant diabetic rats and their embryos. 2000 , 29, 1115-21	43
2014	Cardiovascular risk in diabetes: a brief review. 2000 , 14, 108-15	68
2013	Therapeutic objectives and their practical achievement in type 2 diabetes. 2000 , 14, 180-4	6
2012	Northwest Herts diabetic management system. 2000 , 62, 177-89	2
2011	The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group. 2000 , 21, 383-96	36
2010	Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. 2000 , 86, 897-902	98
2009	Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. 2000 , 16, 677-84	24
2008	The health status of diabetic patients receiving orthotic therapy. 2000 , 9, 233-40	17
2007	Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. 2000 , 43, 561-70	107
2006	Variation in the PPARAlpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. 2000 , 43, 673-80	166
2005	Restenosis and progression of coronary disease after balloon angioplasty in patients with diabetes mellitus. 2000 , 23, 890-4	24

2004	Diabetes and cardiovascular disease. 2000 , 2, 476-81	35
2003	The association between physical activity, physical fitness, and type 2 diabetes mellitus. 2000 , 26, 176-82	29
2002	Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. 2000 , 43, 1126-35	85
2001	The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. 2000 , 43, 218-26	100
2000	[Health promotion and cardiovascular risk factors. The level of knowledge among 510 inpatients of an acute coronary care unit]. 2000 , 95, 75-80	1
1999	Influence of life-related factors and participation in health examination on mortality in a 4.5-year follow-up of a rural cohort. 2000 , 5, 66-71	3
1998	Mortality and its Predictors in Type 2 Diabetes. 103-117	
1997	Indications for Treatment of Asymptomatic Carotid Stenosis. 2000 , 11, 247-264	2
1996	Hypertriglyceridemia and Coronary Heart Disease. 2000 , 85, 2098-2105	10
1995	Risk factors for coronary heart disease in diabetes. 2000 , 133, 154-6	30
1994	Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. 2000 , 6, 435-41	15
1993	Implementation and Evaluation of a Pharmacist-managed Diabetes Service. 2000 , 6, 488-493	35
1992	âRandom Thoughts and Opinions. 2000 , 85, 2110-2112	0
1991	Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats. 2000 , 35, 403-8	132
1990	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. 2000 , 321, 412-9	1350
1989	LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. 2000 , 20, 830-5	221
1988	Antihypertensive management in PD- and HD-patients. 2000 , 15, 135-136	
1987	Management of acute ischaemic heart disease. 2000 , 15, 143-144	2

1986	Preventing cardiovascular disease in hypertensive patients with type 2 diabetes: is there a superior antihypertensive therapy?. 2000 , 18, 1553-6		1
1985	Management of diabetic patients on dialysis. 2000 , 15, 141-142		
1984	Management of heart failure. 2000 , 15, 147-148		13
1983	Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. 2000 , 93, 567-74		27
1982	Management of dyslipidaemia. 2000 , 15, 129-130		1
1981	Management of patients with diabetic nephropathy. 2000 , 15, 139-140		5
1980	Management of diabetic patients with microalbuminuria. 2000 , 15, 137-138		
1979	Hypertension and diabetes: new therapeutic options. 2000 , 160, 1585-94		36
1978	Assessment of cardiovascular risk factors. 2000 , 15, 127-128		1
1977	Epidemiology and prevention of stroke, now and in the future. 2000 , 22, 14-7		21
1976	General management of hypertension. 2000 , 15, 131-132		1
1975	Hyperlipidemia: diagnostic and therapeutic perspectives. 2000 , 85, 2089-112		37
1974	Managing cardiovascular risk in patients with diabetes. 2000 , 84 Suppl 1, i23-5:discussion i50		
1973	Postchallenge plasma glucose and glycemc spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. <i>Diabetes Care</i> , 2000 , 23, 1830-4	14.6	438
1972	Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. <i>Diabetes Care</i> , 2000 , 23, 1395-400	14.6	89
1971	Lipoprotein concentrations and carotid atherosclerosis by diabetes status: results from the Insulin Resistance Atherosclerosis Study. <i>Diabetes Care</i> , 2000 , 23, 1006-11	14.6	24
1970	An integrative literature review of cardiac risk factor management in diabetes education interventions. 2000 , 26, 812-20		10
1969	Optimizing treatment of hypertension in patients with diabetes. 2000 , 283, 3177-9		51

1968	Benefits of antihypertensive therapy in older patients with hypertension. 2000 , 160, 149-50	16
1967	Prognostic significance of diabetes as a predictor of survival after cardiac catheterization. APPROACH Investigators. Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease. 2000 , 109, 543-8	7
1966	Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment. 2000 , 108, 238-45	24
1965	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. 2000 , 355, 253-259	2668
1964	Homeostasis model assessment in a population with mixed ethnicity: the 1992 Singapore National Health Survey. 2000 , 49, 159-68	37
1963	The global diabetes model: user friendly version 3.0. 2000 , 50 Suppl 3, S15-46	62
1962	High incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus. 2000 , 47, 37-44	50
1961	Lack of association between carotid intima-media thickness and methylenetetrahydrofolate reductase gene polymorphism or serum homocysteine in non-insulin-dependent diabetes mellitus. 2000 , 49, 718-23	29
1960	Effects of dietary fish oil on survival rate, plasma amino acid pattern, and inflammatory-related mediators in diabetic rats with sepsis. 2000 , 19, 313-8	9
1959	Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. 2000 , 139, 939-44	35
1958	The role of platelets in diabetes-related vascular complications. 2000 , 50, 1-16	93
1957	Diabetes mellitus, coronary heart disease incidence, and death from all causes in African American and European American women: The NHANES I epidemiologic follow-up study. 2000 , 53, 511-8	61
1956	Treating high-risk hypertensive patients. 2000 , 13, 68S-73S	3
1955	Clinical relevance of the oxidative stress concept. 2000 , 49, 30-4	35
1954	The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. 2000 , 49, 22-31	195
1953	Effects of pravastatin treatment on lipoprotein levels and composition in patients with type 2 diabetes mellitus and hypercholesterolemia. 2000 , 61, 107-118	1
1952	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. 2000 , 321, 405-12	5694
1951	Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. 2001 , CD001481	207

1950	Management of Hypertension in Patients with Diabetes Mellitus. 2000 , 7, 267-288	2
1949	Management of Dyslipidaemias. 2000 , 7, 83-109	3
1948	Hyperglycemia leads to ECG reevaluation. 2000 , 12, 246-8	
1947	Cardiovascular disease in diabetic patients. 2000 , 84, 81-93, viii	28
1946	Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes. 2000 , 9, 2601-17	7
1945	Diabetic dyslipidaemia: current treatment recommendations. 2000 , 59, 1101-11	33
1944	Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. 2000 , 60, 975-83	32
1943	Cholesterol absorption efficiency and sterol metabolism in obesity. 2000 , 153, 241-8	117
1942	HDL-cholesterol as a marker of coronary heart disease risk: the Qu [^] bec cardiovascular study. 2000 , 153, 263-72	246
1941	Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. 2000 , 148, 159-69	119
1940	Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. 2000 , 149, 315-22	27
1939	Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. 2000 , 150, 167-77	112
1938	Management of coronary artery disease: therapeutic options in patients with diabetes. 2000 , 36, 355-65	184
1937	Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. 2001 , 30, 983-97	50
1936	Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role?. 2001 , 61, 429-35	5
1935	Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. 2001 , 61, 1835-81	111
1934	Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. 2001 , 156, 209-16	31
1933	Homocysteine and cardiovascular disease in diabetes mellitus. 2001 , 159, 497-511	98

1932	New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. 2001 , 37, 1543-50	136
1931	Nutrition Management for Type 1 Diabetes. 2001 , 429-440	4
1930	Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus. 2001 , 76, 609-618	11
1929	Function of Vascular Endothelium. 2001 , 473-480	2
1928	Management of high-risk hypertensive patients with diabetes: potential role of angiotensin II receptor antagonists. 2001 , 3, 225-35	2
1927	Cardiovascular implications of insulin resistance and non-insulin-dependent diabetes mellitus. 2001 , 15, 768-77	5
1926	Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?. 2001 , 142, 857-63	38
1925	Impaired glucose metabolism predicts mortality after a myocardial infarction. 2001 , 79, 207-14	174
1924	Coronary artery calcium, coronary artery disease, and diabetes. 2001 , 53, 55-61	51
1923	Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. 2001 , 53, 113-20	19
1922	Diabetes mellitus--a special medical challenge from a Chinese perspective. 2001 , 54 Suppl 1, S19-27	30
1921	Apo(B)-dependent dyslipidemic phenotypes in type 1 diabetic patients. 2001 , 12, 496-502	1
1920	Hyperglycemia in diabetic rats reduces the glutathione content in the aortic tissue. 2001 , 69, 1039-47	30
1919	Clinical impact of posttransplant diabetes mellitus. 2001 , 33, 19S-22S	23
1918	Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. 2001 , 357, 905-910	711
1917	Left ventricular systolic and diastolic functional abnormalities in asymptomatic patients with non-insulin-dependent diabetes mellitus. 2001 , 14, 885-91	49
1916	Diabetes mellitus and coronary heart disease. 2001 , 30, 857-81	36
1915	Importancia del tabaco en el desarrollo del da ^o vascular en la diabetes mellitus. 2001 , 18, 320-326	

1914 Estratificaci3n de riesgo y prevenci3n secundaria postinfarto. **2001**, 8, 2380-2384

1913 Diabetes and hypertension. **2001**, 10, 311-21

31

1912 [Diabetes mellitus, inflammation and coronary atherosclerosis: current and future perspectives]. **2001**, 54, 751-63

19

1911 Predictors of macrovascular disease in patients with type 2 diabetes mellitus. **2001**, 76, 707-12

35

1910 [Cardiovascular risk and the new diagnostic categories for diabetes mellitus proposed by the American Diabetes Association]. **2001**, 28, 31-8

4

1909 El infarto de miocardio en el diab3tico: implicaciones cl3nicas, pron3sticas y terap3uticas en la era trombol3tico-intervencionista. **2001**, 25, 311-320

2

1908 Postoperative management of the diabetic patient. **2001**, 85, 1213-28

42

1907 Treatment for the procoagulant state in type 2 diabetes. **2001**, 30, 1011-30

25

1906 Pharmacotherapy of hypertension in patients with diabetes mellitus. **2001**, 2, 1805-16

4

1905 Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1. **2001**, 24, 37-41

19

1904 . **2001**,

0

1903 Pathophysiology of arterial thrombosis. **2001**, 279-292

1902 . **2001**,

16

1901 Management of diabetic nephropathy. **2001**, 94, 210-7

14

1900 Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. **2001**, 281, H1137-47

98

1899 Nutritional Management for Type 2 Diabetes. **2001**, 441-452

1

1898 The use of fibrates and of statins in preventing atherosclerosis in diabetes. **2001**, 12, 611-7

17

1897 Detection of coronary artery disease by stress thallium scintigraphy in diabetic patients. **2001**, 22, 287-9

8

1896	. 2001 , 8, 127-132	6
1895	Determinants of the severity and extent of coronary artery disease in patients with type-2 diabetes and in nondiabetic subjects. 2001 , 12, 99-106	19
1894	Cardiovascular disease in diabetes: prevention and intervention. 2001 , 8, 101-110	3
1893	The adequacy of current diagnostic criteria for diabetes. 2001 , 8, 88-94	2
1892	Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment. 2001 , 110, 111-4, 117-8, 121-3	6
1891	Altered susceptibility to ischemia-reperfusion injury in isolated-perfused hearts of short-term diabetic rats associated with changes in non-enzymatic antioxidants. 2001 , 85, 435-42	4
1890	How Should Hypertension be Managed in Diabetes?. 278-293	
1889	Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. 2001 , 135, 1079-83	42
1888	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. 2001 , 11, 474-490	5
1887	Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus. 2001 , 76, 609-618	20
1886	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. 2001 , 11, 368-383	3
1885	Clinical utility of the exercise ECG in patients with diabetes and chest pain. 2001 , 119, 1576-81	38
1884	Autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects is associated with urinary albumin excretion rate and 24-h ambulatory blood pressure: the Fredericia Study. 2001 , 50, 630-6	23
1883	Quality of care and diabetes mellitus. 2001 , 8, 58-66	2
1882	Population-based estimates of mortality associated with diabetes: use of a death certificate check box in North Dakota. 2001 , 91, 84-92	48
1881	High glucose induces ventricular instability and increases vasomotor tone in rats. 2001 , 44, 464-70	51
1880	Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicon MR controlled evaluation. 2001 , 44, 1118-20	148
1879	[Diabetic nephropathy as an excessive cardiovascular risk]. 2001 , 42 Suppl 1, S43-50, S52-3	

1878	CHD: a major burden in type 2 diabetes. 2001 , 38 Suppl 1, S3-8	24
1877	Clustering of cardiovascular risk factors in type 2 diabetes mellitus: prognostic significance and tracking. 2001 , 3, 17-23	24
1876	Treatment of high-risk diabetic patients with angiotensin II receptor blockers. 2001 , 3, 472-6	1
1875	Calcium antagonists in diabetic hypertension. 2001 , 3, 311-8	0
1874	What is hypertension in diabetes? Ambulatory blood pressure in 137 normotensive and normoalbuminuric Type 1 diabetic patients. 2001 , 18, 370-3	12
1873	Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects. 2001 , 18, 589-94	22
1872	HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic. 2001 , 18, 667-70	3
1871	Use of dobutamine stress echocardiography in detecting silent myocardial ischaemia in asymptomatic diabetic patients: a comparison with thallium scintigraphy and exercise testing. 2001 , 18, 900-5	36
1870	Dyslipidaemia and diabetes. 2001 , 18, 201-207	10
1869	Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. 2001 , 81, 523-34	43
1868	Lack of association of insulin resistance and carotid intimal medial thickness in non-diabetic Asian Indian subjects. 2001 , 17, 444-7	21
1867	Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy. 2001 , 8, 528-32	5
1866	Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. 2001 , 44 Suppl 2, S14-21	784
1865	Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. 2001 , 44 Suppl 2, S54-64	215
1864	Exercise training-induced triglyceride lowering negatively correlates with DHEA levels in men with type 2 diabetes. 2001 , 25, 1108-12	22
1863	Should we do an oral glucose tolerance test in hypertensive men with normal fasting blood-glucose?. 2001 , 15, 71-4	5
1862	Risk variables for coronary artery disease in Asian Indians. 2001 , 87, 267-71	26
1861	Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. 2001 , 88, 9H-15H	63

1860	Impaired glucose tolerance as a disease. 2001 , 88, 16H-9H		31
1859	Insulin resistance syndrome and type 2 diabetes mellitus. 2001 , 88, 38J-42J		40
1858	Global risk assessment in the presymptomatic patient. 2001 , 88, 17J-22J		8
1857	Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities. 2001 , 137, 82-92		1
1856	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins. 2001 , 15, 211-26		23
1855	Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. 2001 , 21, 1473-8		21
1854	Diabetes. 2001 , 59, 159-72		4
1853	A comparison of left ventricular abnormalities associated with glucose intolerance in African Caribbeans and Europeans in the UK. 2001 , 85, 643-8		12
1852	Vascular compliance is reduced in the early stages of type 1 diabetes. <i>Diabetes Care</i> , 2001 , 24, 2102-6	14.6	46
1851	Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes?. 2001 , 22, 1102-10		62
1850	Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). 2001 , 322, 15-8		641
1849	American Diabetes Association 60th Scientific Sessions, 2000: cardiovascular disease in diabetes. <i>Diabetes Care</i> , 2001 , 24, 399-404	14.6	4
1848	Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. 2001 , 50, 851-60		164
1847	Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. <i>Diabetes Care</i> , 2001 , 24, 1053-9	14.6	131
1846	Increased platelet and erythrocyte external cell membrane phosphatidylserine in type 1 diabetes and microalbuminuria. <i>Diabetes Care</i> , 2001 , 24, 2001-3	14.6	13
1845	Noninvasive assessment of the diabetic patient for coronary artery disease. <i>Diabetes Care</i> , 2001 , 24, 1519-21	14.6	14
1844	Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. <i>Diabetes Care</i> , 2001 , 24, 197-201	14.6	117
1843	Smoking and mortality among women with type 2 diabetes: The Nurses' Health Study cohort. <i>Diabetes Care</i> , 2001 , 24, 2043-8	14.6	81

1842	Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. <i>Diabetes Care</i> , 2001 , 24, 2091-6	14.6	200
1841	Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paroxonase 1 gene (Q192R) polymorphism?. 2001 , 144, 639-44		27
1840	Coronary heart disease in the first 30 years of the 21st century: challenges and opportunities: The 33rd Annual James B. Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association. 2001 , 103, 2428-35		29
1839	Diabetic heart disease: clinical considerations. 2001 , 85, 463-9		24
1838	Familial aggregation of coronary artery calcium in families with type 2 diabetes. 2001 , 50, 861-6		137
1837	Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. 2001 , 161, 397-405		1050
1836	Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. <i>Diabetes Care</i> , 2001 , 24, 228-33	14.6	222
1835	Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. 2001 , 2, 31-6		46
1834	Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. <i>Diabetes Care</i> , 2001 , 24, 1821-33	14.6	589
1833	Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. 2001 , 286, 421-6		1695
1832	Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. <i>Diabetes Care</i> , 2001 , 24, 1629-33	14.6	74
1831	Smoking and diabetes in Chinese men. 2001 , 77, 240-3		28
1830	The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. <i>Diabetes Care</i> , 2001 , 24, 1335-41	14.6	113
1829	Lipids and diabetes mellitus: a review of therapeutic options. 2002 , 18 Suppl 1, s58-74		3
1828	Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). 2002 , 39, 22-8		116
1827	Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. 2002 , 106, 407-11		113
1826	Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. <i>Diabetes Care</i> , 2002 , 25, 512-6	14.6	944
1825	Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. 2002 , 324, 939-42		248

1824	The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes. <i>Diabetes Care</i> , 2002 , 25, 9-15	14.6	19
1823	Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. 2002 , 51, 1076-82		237
1822	Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. 2002 , 287, 3215-22		513
1821	Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. 2002 , 162, 1737-45		253
1820	Self-management interventions for people with chronic conditions in primary care: Examples from arthritis, asthma and diabetes. 2002 , 61, 365-378		58
1819	Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. 2002 , 106, 2085-90		1236
1818	Protecting the kidneys and cardiovascular system in type 2 diabetes. 2002 , 2, 77-79		0
1817	Vascular disease and survival in patients with type 2 diabetes and nephropathy. 2002 , 2, 137-142		1
1816	Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. 2002 , 2, 143-148		18
1815	Comparison of a homogeneous assay with a precipitation method for the measurement of HDL cholesterol in diabetic patients. <i>Diabetes Care</i> , 2002 , 25, 1914-8	14.6	11
1814	What should cardiologists be telling general practitioners/family physicians?. 2002 , 4, F54-F59		
1813	Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes. 2002 , 95, 371-7		17
1812	Arterial stiffness and insulin resistance. 2002 , 2, 157-64		13
1811	Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. 2002 , 162, 273-9		116
1810	Insulin resistance and the metabolic syndrome-a challenge of the new millennium. 2002 , 56 Suppl 1, S25-9		185
1809	Mechanisms of vascular disease in hypertension with special reference to diabetes. 2002 , 2, 139-48		1
1808	Treating high blood pressure in diabetes: the evidence. 2002 , 2, 127-37		5
1807	alpha-Tocopherol Inhibits IL-8 synthesis induced by thrombin and high glucose in endothelial cells. 2002 , 34, 49-54		15

1806	Dysglycemia: a key cardiovascular risk factor. 2002 , 2, 165-74		13
1805	Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk. 2002 , 2, 383-9		5
1804	Lipids in type 2 diabetes. 2002 , 2, 59-66		12
1803	Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. 2002 , 105, 1727-33		434
1802	Impaired fasting glucose, blood pressure and cardiovascular disease mortality. 2002 , 40, 458-63		92
1801	UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. 2002 , 33, 1776-81		336
1800	Review: Managing the diabetic patient with angina. 2002 , 2, 169-175		
1799	Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. 2002 , 51, 3069-76		153
1798	Aspirin use and counseling about aspirin among patients with diabetes. <i>Diabetes Care</i> , 2002 , 25, 965-70	14.6	34
1797	Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. <i>Diabetes Care</i> , 2002 , 25, 1418-24	14.6	40
1796	Recognising and treating the diabetic patient in cardiovascular care. 2002 , 1, 171-81		3
1795	Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. 2002 , 287, 2570-81		1786
1794	Multiple drug targets in the management of type 2 diabetes. 2002 , 3, 203-21		25
1793	Asymptomatic aortic dissection in Marfan syndrome. 2002 , 87, 66		6
1792	Type II diabetes does not prevent the recruitment of collateral vessels and the normal reduction of myocardial ischaemia on repeated balloon inflations during angioplasty. 2002 , 87, 61-6		6
1791	Prognostic value of dobutamine-atropine stress myocardial perfusion imaging in patients with diabetes. <i>Diabetes Care</i> , 2002 , 25, 1637-43	14.6	19
1790	Is neuropathic ulceration the key to understanding increased mortality due to ischaemic heart disease in diabetic foot ulcer patients? A population approach using a proportionate model. 2002 , 30, 553-9		13
1789	Platelets and Cardiovascular Disease. 2002 , 1, 273-288		99

1788	Clinical trial evidence for cardiovascular risk reduction in type 2 diabetes. 2002 , 16, 24-43	3
1787	Atherogenic Lipid Phenotype and Lipoprotein (a) in Diabetes. 2002 , 12, 243-259	3
1786	. 2002 , 9, 369-376	30
1785	Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The Gu ^a Study. 2002 , 20, 1965-71	10
1784	Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. 2002 , 20, 1743-51	126
1783	Relationship between serum carotenoids and hyperglycemia: a population-based cross-sectional study. 2002 , 12, 357-66	41
1782	Angiographic comparison of coronary artery disease in Arab women with and without type II diabetes mellitus. 2002 , 11 Suppl 2, 63-8	3
1781	Insulin resistance and cardiovascular disease. 2002 , 2, S9-S11	3
1780	Pioglitazone âcurrent profile. 2002 , 2, S18-S23	2
1779	Lipid-lowering therapy in people with type 2 diabetes. 2002 , 13, 617-23	13
1778	Hyperglycemia and heart dysfunction: an oxidant mechanism contributing to heart failure in diabetes. 2002 , 25, 485-8	6
1777	Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. 2002 , 106, 2442-7	309
1776	Heritability of carotid artery intima-medial thickness in type 2 diabetes. 2002 , 33, 1876-81	138
1775	Molecular mechanisms of diabetic cardiovascular disease. 2002 , 5, 183-7	1
1774	Update on the management of diabetes and hypertension. 2002 , 4, 3-10	9
1773	Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. 2002 , 40, 946-53	272
1772	Leukocyte count and vascular function in Type 2 diabetic subjects with treated hypertension. 2002 , 163, 175-81	31
1771	Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipidemia, but not type 2 diabetes mellitus. 2002 , 164, 337-46	25

1770	Dietary fibre in treatment of diabetes: myth or reality?. 2002 , 34 Suppl 2, S140-4	14
1769	alpha-Tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. <i>Diabetes Care</i> , 2002 , 25, 524-9	14.6 46
1768	Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. 2002 , 51, 808-12	76
1767	Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. 2002 , 1, 329-36	38
1766	Treatment of microalbuminuria in patients with type 2 diabetes mellitus. 2002 , 1, 163-73	24
1765	[Cardiovascular events linked to the new diagnostic categories of diabetes mellitus]. 2002 , 29, 343-7	2
1764	Evaluaci³n del riesgo cardiovascular global en la pr³ctica cl³nica. 2002 , 6, 1-3	
1763	Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. 2002 , 2, 15-21	25
1762	The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?. 2002 , 11, 328-38	9
1761	Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. 2002 , 108, 151-60	78
1760	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 2002 , 359, 1004-10	1297
1759	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 2002 , 360, 7-22	6581
1758	Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type 2 diabetes and microalbuminuria: An open-label, uncontrolled study. 2002 , 63, 216-226	3
1757	Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. 2002 , 72, 59-66	36
1756	Diabetic dyslipidemia. 2002 , 3, 47-51	139
1755	Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans. 2002 , 51, 1223-9	10
1754	Exercise electrocardiography has similar diagnostic utility for men with and without diabetes. 2002 , 6, 52-53	
1753	The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. 2002 , 9, 618-26	118

1752	Clinical implications of aldosterone blockade. 2002 , 144, S12-8	26
1751	Diabetes mellitus as a contributor to the risk of acute myocardial infarction. 2002 , 55, 1082-7	29
1750	Are there meaningful differences in blood pressure control with current antihypertensive agents?. 2002 , 15, 14S-21S	9
1749	Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. 2002 , 15, 108S-114S	12
1748	Influence of type 2 diabetes mellitus on cardiovascular disease mortality: findings from the Hawaii-Los Angeles-Hiroshima study. 2002 , 57, 61-9	20
1747	Relationships of apolipoprotein B(100) with the metabolic syndrome in Type 2 diabetes mellitus. 2002 , 57, 199-207	9
1746	The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. 2002 , 24, 1062-71	15
1745	Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. 2002 , 24, 1426-38	9
1744	Functional assessment of heart rate variability: physiological basis and practical applications. 2002 , 84, 1-14	349
1743	Diabetes y coraz^ n. 2002 , 19, 28-39	
1742	Hipertensi^ n arterial y diabetes. Avances terap^ uticos. 2002 , 99, 73-80	
1741	Prevalence of the Metabolic Syndrome: Impact on Cardiovascular Risk Epidemiology â Population-Based Study from Malm^ n [Sweden]. 2002 , 2, 273-278	1
1740	Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. 2002 , 40, 781-8	83
1739	Cardiovascular events in patients with type 2 diabetes. 2002 , 2, S4-S8	
1738	[Management of cardiovascular risk factors in type 2 diabetes mellitus]. 2002 , 59, 415-21	
1737	IGF-I promotes a shift in metabolic flux in vascular smooth muscle cells. 2002 , 283, E465-71	17
1736	Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. 2002 , 76, 1007-15	264
1735	Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. 2002 , 123, 1114-9	34

1734	Controlling hypertension to reduce the risk of stroke. 2002 , 17, 186-91	2
1733	A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. 2002 , 90, 27G-33G	116
1732	Addressing the insulin resistance syndrome: a role for the thiazolidinediones. 2002 , 12, 354-62	36
1731	Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design. 2002 , 16, 271-6	60
1730	Importance of blood pressure control in patients with diabetes mellitus. 2002 , 16, 87-91	1
1729	Diabetes and macrovascular disease. 2002 , 16, 235-45	79
1728	Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. 2002 , 16, 401-15	58
1727	Effects of vitamin A and insulin on the antioxidative state of diabetic rat heart: a comparison study with combination treatment. 2002 , 20, 75-80	26
1726	An introduction to new advances in diabetes. 2002 , 18 Suppl 1, S1-6	2
1725	Where thiazolidinediones will fit. 2002 , 18 Suppl 2, S30-5	6
1724	Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. 2002 , 18 Suppl 3, S82-5	55
1723	The impacts of health examinations and smoking on disease mortality risk in Japan: a longitudinal cohort of 720,611 Japanese life insured persons. 2002 , 7, 169-72	2
1722	Robert Graves Memorial Lecture. Diabetes and atherosclerosis--a gut review. 2002 , 171, 105-9	1
1721	Hyperglycaemia: the relation to dyslipidaemia and atherosclerosis. 2002 , 171, 161-4	
1720	Cardiovascular disease: much more aggressive in patients with type 2 diabetes. 2002 , 4, 134-42	24
1719	Glucose and insulin management in the post-MI setting. 2002 , 2, 37-44	2
1718	[Primary prevention of cardiovascular diseases by nonpharmacological means]. 2002 , 97, 77-87	2
1717	Impact of the atherosclerotic process in patients with diabetes. 2002 , 39 Suppl 2, S22-8	23

1716	Cardiovascular prevention before admission reduces mortality following acute myocardial infarction in patients with diabetes. 2002 , 251, 325-30	9
1715	How hyperglycemia promotes atherosclerosis: molecular mechanisms. 2002 , 1, 1	291
1714	What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. 2002 , 4 Suppl 1, S19-25	11
1713	Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. 2002 , 4 Suppl 1, S5-12	34
1712	Angiographic distribution of lower extremity atherosclerosis in patients with and without diabetes. 2002 , 19, 366-70	72
1711	Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. 2002 , 19, 201-11	81
1710	Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. 2002 , 19, 317-21	83
1709	Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with Type 2 diabetes mellitus--a randomized prospective study. 2002 , 19, 385-92	79
1708	Glycemic index in chronic disease: a review. 2002 , 56, 1049-71	263
1707	Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. 2002 , 16, 815-7	12
1706	Type 2 diabetes outcomes. 2002 , 10 Suppl 1, 22S-26S	5
1705	Evaluation of risk factors for development of complications in Type II diabetes in Europe. 2002 , 45, S23-8	155
1704	The influence of cardiovascular disease on quality of life in type 2 diabetics. 2002 , 11, 249-61	46
1703	Diabetic heart dysfunction: is cell transplantation a potential therapy?. 2003 , 8, 213-9	12
1702	Recent developments in the treatment of type 2 diabetes mellitus. 2003 , 17, 151-8	5
1701	The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. 2003 , 17, 265-85	63
1700	New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. 2003 , 26, III19-24	24
1699	Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. 2003 , 46, 760-5	515

1698	Target blood pressure for patients with type 2 diabetes is difficult to achieve in the setting of a busy diabetes clinic. 2003 , 172, 168-70	4
1697	Management of Diabetes with Coronary Artery Disease. 2003 , 5, 75-88	1
1696	Microalbuminuria and diabetic cardiovascular disease. 2003 , 5, 350-7	8
1695	Optimal medical management of angina. 2003 , 5, 259-65	2
1694	Mechanisms of endothelial dysfunction in the metabolic syndrome. 2003 , 3, 289-92	57
1693	Diagnosis of CAD in patients with diabetes: who to evaluate. 2003 , 3, 19-27	3
1692	Lipid abnormalities in the metabolic syndrome. 2003 , 3, 65-72	12
1691	Heart disease in diabetic patients. 2003 , 3, 223-9	57
1690	Management of diabetic and hypertensive cardiovascular disease. 2003 , 5, 309-15	2
1689	Circadian rhythms in cardiac gene expression. 2003 , 5, 445-53	22
1688	[Arterial hypertension and metabolic syndrome]. 2003 , 28, 674-85	3
1687	[Diabetic cardiopathy: pathogenesis, diagnosis and therapy]. 2003 , 44, 806-12, 814-8	3
1686	[Diabetic complications. Micro and macroangiopathic end-organ damage]. 2003 , 44, 840-6, 848-52	7
1685	Incidence, prevalence and coronary heart disease risk level in known Type 2 diabetes: a sentinel practice network study in the Basque Country, Spain. 2003 , 46, 899-909	43
1684	Under-prescribing of cardiovascular therapies for diabetes in primary care. 2003 , 58, 835-41	21
1683	[Diabetes and lipids]. 2003 , 153, 469-73	
1682	Silent coronary artery disease in patients with type 2 diabetes mellitus. 2003 , 40, 176-80	23
1681	Retrospective analysis of cardiovascular outcomes in patients with type 2 diabetes mellitus after the first acute myocardial infarction. 2003 , 40 Suppl 2, S354-7	1

1680	A prospective study of cardiovascular disease in patients with Type 2 diabetes. 6.3 years of follow-up. 2003 , 17, 235-42	16
1679	Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients. 2003 , 17, 135-40	8
1678	Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. 2003 , 17, 169-78	53
1677	The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones. 2003 , 17, 218-28	18
1676	Cardiovascular complications of diabetes: prevention and management. 2003 , 5, 22-37	5
1675	Effect of diabetes on early and late survival after isolated first coronary bypass surgery in multivessel disease. 2003 , 125, 144-54	61
1674	Improving aspirin prophylaxis in a primary care diabetic population. 2003 , 23, 73-9	19
1673	Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement. 2003 , 23, 659-65	52
1672	Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. 2003 , 91, 68-71	31
1671	Value of postoperative blood glucose in predicting complications and length of stay after coronary artery bypass grafting. 2003 , 92, 74-6	51
1670	Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. 2003 , 92, 10K-16K	200
1669	Diabetes mellitus and heart failure. 2003 , 9, 133-9; quiz 140-1	25
1668	Statin therapy for the treatment of diabetic dyslipidemia. 2003 , 19, 280-7	11
1667	DIABETES JOURNAL WATCH The Heart Protection Study and diabetes. 2003 , 20, 5-7	1
1666	Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. 2003 , 2, 16	87
1665	Insulin resistance--the new goal!. 2003 , 28, 167-74	13
1664	Study of Heart and Renal Protection (SHARP). 2003 , S207-10	210
1663	Traditional cardiac risk factors in individuals with chronic kidney disease. 2003 , 16, 118-27	71

1662	The genetics of atherothrombotic disorders: a clinician's view. 2003 , 1, 1381-90	31
1661	Diabetes and cardiovascular disease. 2003 , 5 Suppl 1, S11-8	8
1660	Evidence-based treatment of hypertension in patients with diabetes mellitus. 2003 , 5, 13-26	8
1659	Influence of apolipoprotein E genotype on the response to caloric restriction in type 2 diabetic patients with hyperlipidaemia. 2003 , 5, 345-8	9
1658	The neointimal response to endovascular injury is increased in obese Zucker rats. 2003 , 5, 415-23	9
1657	How do people with Type 2 diabetes perceive and respond to cardiovascular risk?. 2003 , 20, 355-60	41
1656	Prediction of cardiovascular risk in people with diabetes. 2003 , 20, 515-27	19
1655	Prevalence of diabetes and/or ischaemic heart disease in classes of increasing carotid artery atherosclerosis: an ultrasonographic study. 2003 , 20, 670-6	9
1654	Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter?. 2003 , 20, 915-20	102
1653	Self-reported heart attack in Mexican-American elders: examination of incidence, prevalence, and 7-year mortality. 2003 , 51, 923-9	6
1652	Measuring arterial stiffness in diabetic patients. 2003 , 20, 25-30	0
1651	Increased statin prescribing in patients with diabetes after the introduction of the NSF for Coronary Heart Disease. 2003 , 20, 313-317	1
1650	Glycosylated human oxyhaemoglobin activates nuclear factor-kappaB and activator protein-1 in cultured human aortic smooth muscle. 2003 , 140, 681-90	21
1649	Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. 2003 , 17, 37-44	41
1648	How well are hypertension and albuminuria treated in type II diabetic patients?. 2003 , 17, 413-8	11
1647	Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. 2003 , 17, 103-14	14
1646	[Tackling lipaemia in diabetes mellitus in primary care]. 2003 , 32, 240-52	1
1645	Protecci ^o n del riesgo vascular del paciente diab ^e tico hipertenso. 2003 , 20, 127-135	

1644 ¿Hay que reducir el colesterol LDL de todos los diabéticos por debajo de 100 mg/dl?. **2003**, 120, 717

1643 The Heavy Burden of Cardiovascular Disease in Type 2 Diabetes. **2003**, 1-10

1642 Benefits of Dietary Fiber for Cardiovascular Disease and Diabetes. **2003**, 227-241

1641 Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. **2003**, 171, 1-13 163

1640 Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. **2003**, 41, 1013-20 207

1639 34th Bethesda Conference: Task force #3--What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis?. **2003**, 41, 1886-98 104

1638 Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. **2003**, 42, 328-35 289

1637 Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. **2003**, 42, 1017-21 31

1636 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. **2003**, 348, 383-93 3185

1635 NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. **2003**, 52, 1210-4 1145

1634 Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. *Diabetes Care*, **2003**, 26, 2713-21 14.6 254

1633 Examining therapeutic goals: population versus individual-based approaches. **2003**, 16, 26S-30S 5

1632 Recommendations for special populations: diabetes mellitus and the metabolic syndrome. **2003**, 16, 41S-45S 59

1631 Risk factors for myocardial infarction in Brazil. **2003**, 146, 331-8 71

1630 Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. **2003**, 146, 351-8 114

1629 Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. **2003**, 5, 202-9 72

1628 Who should be treated with combination therapy as initial treatment for hypertension?. **2003**, 5, 21-8 3

1627 Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. **2003**, 108, 1655-61 342

1626	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. 2003 , 361, 2005-16	2185
1625	The effect of diabetes combined with stroke on disability, self-rated health, and mortality in older Mexican Americans: results from the Hispanic EPESE. 2003 , 84, 725-30	46
1624	Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretion. 2003 , 52, 1038-42	3
1623	How to ADVANCE prevention of cardiovascular complications in type 2 diabetes. 2003 , 52, 24-8	7
1622	Effects of soy isoflavone supplementation on plasma glucose, lipids, and antioxidant enzyme activities in streptozotocin-induced diabetic rats. 2003 , 23, 67-75	19
1621	Underuse of evidence-based treatment modalities in diabetic patients with non-ST elevation acute coronary syndrome. A prospective nation wide study on acute coronary syndrome (FINACS). 2003 , 61, 39-48	12
1620	Pre-diabetes, insulin resistance, inflammation and CVD risk. 2003 , 61 Suppl 1, S9-S18	101
1619	A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. 2003 , 25, 2006-21	27
1618	Beneficial effect of aqueous garlic extract on the vascular reactivity of streptozotocin-diabetic rats. 2003 , 85, 139-44	39
1617	From cholesterol levels to risk analysis: the revolution of the Heart Protection Study. 2003 , 1253, 217-222	
1616	Predictive value of myocardial tomoscintigraphy in asymptomatic diabetic patients after percutaneous coronary intervention. 2003 , 90, 165-73	8
1615	Current concepts of cardiovascular diseases in diabetes mellitus. 2003 , 89, 123-34	36
1614	Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. 2003 , 90, 219-27	25
1613	Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. 2003 , 145, 285-91	80
1612	Effects of isolated post-challenge hyperglycemia on mortality in American Indians: the Strong Heart Study. 2003 , 13, 182-8	15
1611	Improving survival with metformin: the evidence base today. 2003 , 29, 6S36-43	47
1610	Metformin and vascular protection: a diabetologist's view. 2003 , 29, 6S113-6	3
1609	What's in a risk factor? "He who strikes the ball". 2003 , 29, 6-13	299

1608	The challenge of poorly controlled diabetes mellitus. 2003 , 29, 101-9	17
1607	Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey. 2003 , 29, 241-9	13
1606	Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?. 2003 , 29, 470-6	34
1605	Cardiovascular disease in patients who have diabetes. 2003 , 21, 399-413, vii	26
1604	Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. 2003 , 6, 1-7	289
1603	Microalbuminuria y proteinuria cl ^í nica como principales predictores de morbimortalidad cardiovascular en pacientes con diabetes tipo 2. 2003 , 203, 526-531	9
1602	Efectividad antihipertensiva y tolerabilidad de lercanidipino en diab ^é ticos, en pacientes con hipertensi ^ó n sist ^ó lica aislada y en ancianos. An ^á lisis de subgrupos del estudio ELYPSE. 2003 , 20, 347-353	
1601	Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. 2003 , 139, 824-34	100
1600	Pathogenesis and management of diabetic dyslipidemia. 2003 , 2, 231-45	9
1599	Clinical use of nifedipine GITS in the treatment of hypertension: an overview. 2003 , 4, 95-106	8
1598	Preventing macrovascular disease in patients with type 2 diabetes mellitus. 2003 , 3, 283-97	14
1597	Losartan for LIFE in hypertension with left ventricular hypertrophy?. 2003 , 4, 115-8	2
1596	Clinical trials: Evidence and unanswered questions--hyperlipidaemia. 2003 , 16 Suppl 3, 25-32	12
1595	The platelet in diabetes: focus on prevention of ischemic events. <i>Diabetes Care</i> , 2003 , 26, 2181-8	14.6 252
1594	Value of coronary artery calcium scanning by computed tomography for predicting coronary heart disease in diabetic subjects. <i>Diabetes Care</i> , 2003 , 26, 905-10	14.6 77
1593	The degree of albuminuria is related to left ventricular hypertrophy in hypertensive diabetics and is associated with abnormal left ventricular filling: a pilot study. 2003 , 54, 671-8	9
1592	Identifying risk factors in a mostly overweight patient population with coronary artery disease. 2003 , 54, 181-6	2
1591	Prevalence of conventional risk factors in patients with coronary heart disease. 2003 , 290, 898-904	950

1590	The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. <i>Diabetes Care</i> , 2003 , 26, 360-6	14.6	254
1589	Management of stable angina. 2003 , 79, 332-6		5
1588	Cost-outcome benefits of fibrate therapy in type 2 diabetes. 2003 , 3, 124-130		4
1587	Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. <i>Diabetes Care</i> , 2003 , 26, 16-23	14.6	287
1586	Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. <i>Diabetes Care</i> , 2003 , 26, 2081-7	14.6	113
1585	LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. 2003 , 23, 853-8		146
1584	Use of antibiotics is not associated with decreased risk of myocardial infarction among patients with diabetes. <i>Diabetes Care</i> , 2003 , 26, 2100-6	14.6	4
1583	Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. 2003 , 17, 1289-91		163
1582	The relationship between primary care physicians' adherence to guidelines for the treatment of diabetes and patient satisfaction: findings from a pilot study. 2003 , 20, 563-9		32
1581	Biological variation of lipoprotein(a) in a diabetic population. Analysis of the causes and clinical implications. 2003 , 41, 1075-80		5
1580	Pharmacological management of hyperlipidaemia. 2003 , 3, 204-210		3
1579	Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. 2003 , 290, 486-94		1200
1578	Clinical significance, pathogenesis, and management of postprandial hyperglycemia. 2003 , 163, 1306-16		226
1577	Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. 2003 , 23, 1035-41		116
1576	Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. 2003 , 24, 987-1003		3146
1575	Prediction of coronary heart disease in middle-aged adults with diabetes. <i>Diabetes Care</i> , 2003 , 26, 2777-84	14.6	108
1574	Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?. <i>Diabetes Care</i> , 2003 , 26, 991-7	14.6	32
1573	Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers. <i>Diabetes Care</i> , 2003 , 26, 3209-14	14.6	44

1572	Approaches to cardiovascular disease and its treatment. <i>Diabetes Care</i> , 2003 , 26, 3342-8	14.6	6
1571	Cardiovascular disease and diabetes. <i>Diabetes Care</i> , 2003 , 26, 230-7	14.6	23
1570	Cellular aspects of intestinal lipoprotein assembly in <i>Psammomys obesus</i> : a model of insulin resistance and type 2 diabetes. 2003 , 52, 2539-45		64
1569	Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. 2003 , 24, 1406-13		117
1568	Response to Ostberg and Hurel. <i>Diabetes Care</i> , 2003 , 26, 961-962	14.6	
1567	Preventable hospitalization among elderly Medicare beneficiaries with type 2 diabetes. <i>Diabetes Care</i> , 2003 , 26, 1344-9	14.6	85
1566	Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia. 2003 , 23, 2070-7		44
1565	Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance. 2003 , 8, 253-60		46
1564	Clinical studies on coronary revascularization in patients with type 2 diabetes. 2003 , 24, 1087-103		44
1563	Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats. 2003 , 41, 1330-5		14
1562	Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. 2003 , 34, 2471-4		78
1561	Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. 2003 , 88, 516-23		54
1560	Diabetes, the renin-angiotensin system and heart disease. 2003 , 1, 225-38		3
1559	. 2003 , 14, 329-334		8
1558	Diabetes mellitus and hypertension: a mandate for intense treatment according to new guidelines. 2003 , 10, 363-9		6
1557	Prevention of type 2 diabetes and its macrovascular complications: whom, when, and how should we treat?. 2003 , 10, 229-236		2
1556	Metabolic effects of antihypertensive treatment: long live the debate. 2003 , 21, 1459-62		8
1555	Bibliography. 2003 , 14, 349-352		4

1554	Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. 2003 , 14, 567-73	35
1553	Therapy and clinical trials -- coronary heart disease: current and future perspectives. 2003 , 14, 333-5	
1552	Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. <i>Diabetes Care</i> , 2003 , 26, 961; author reply 961-2	14.6 2
1551	Using insulin as a drug rather than as a replacement hormone during acute illness: a new paradigm. 2003 , 5, 323-33	1
1550	The insulin resistance syndrome and coronary artery disease. 2003 , 14, 335-48	43
1549	New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. 2003 , 75, S53-24	459
1548	Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes. 2003 , 11, 262-74	23
1547	Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity. 2003 , 138, 357-60	38
1546	Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. 2003 , 138, 542-9	307
1545	Diabetes mellitus and coronary artery disease: therapeutic considerations. 2003 , 5, 119-28	4
1544	Type 2 diabetes and the vegetarian diet. 2003 , 78, 610S-616S	120
1543	Primary vascular access surgery in a well defined geographical region: long-term results of autogenous arteriovenous fistulas. 2003 , 92, 210-4	6
1542	References. 2003 ,	
1541	Clinical Impact of Coronary Collateral Vessels in Patients with Acute Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention. 2003 , 33, 1093	
1540	O papel da proteí na quinase C no desenvolvimento das complicaç ões vasculares do diabetes mellitus. 2003 , 47, 654-662	3
1539	Effects of high glucose concentrations on the endothelial function of the renal microcirculation of rabbits. 2003 , 81, 161-5, 156-60	9
1538	New Insights into the Combined Burden of Type 2 Diabetes and Hypertension. 2003 , 3, 25-33	1
1537	Statins in the Primary Prevention of Atherosclerosis-Related Events. 2004 , 53-92	

1536	Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. 2004 , 91, 480-6	24
1535	The control of lipids with a statin. 2004 , 15, 611-614	
1534	Effect of hyperglycemia on stroke outcomes. 2004 , 10 Suppl 2, 34-9	34
1533	. 2004 ,	1
1532	Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. 2004 , 11, 341-7	34
1531	[Cardiac risk profile in diabetes mellitus and impaired fasting glucose]. 2004 , 38, 529-36	31
1530	[Prevalence of micro and macroangiopathic chronic complications and their risk factors in the care of out patients with type 2 diabetes mellitus]. 2004 , 50, 263-7	32
1529	[Vascular dementia -- diagnosis, prevention and treatment]. 2004 , 31, 330-8	4
1528	Statins and diabetes. 2004 , 4, 321-32	18
1527	Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?. 2004 , 20, 359-67	10
1526	Nontraditional risk factors for cardiovascular disease in diabetes. 2004 , 25, 153-75	126
1525	The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. 2004 , 112, 75-9	40
1524	Diabetes and cardiovascular risk evaluation and management in primary care: progress and unresolved issues - rationale for a nationwide primary care project in Germany. 2004 , 112, 157-70	10
1523	[Therapeutic options in patients with diabetes mellitus type 2 and coronary artery disease: intensified secondary prevention versus percutaneous or surgical revascularization]. 2004 , 129, 1385-9	2
1522	Epidemiology of diabetes. 2004 , 44, 397-405	159
1521	Durability of glycemic control: a feature of the thiazolidinediones. 2004 , 6, 179-89	4
1520	Blood pressure control and nephroprotection in diabetes. 2004 , 44, 431-8	19
1519	The case for insulin treatment early in type 2 diabetes. 2004 , 71, 385-6, 391-2, 394 passim	26

1518	Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. 2004 , 25, 10-6		457
1517	Cardiorespiratory Fitness and Visceral Fat Impact the Relationship between Psychological Fitness and Metabolic Syndrome in Japanese Males with Type 2 Diabetes Mellitus. 2004 , 2, 172-9		4
1516	Compliance with recommendations for lipid management among patients with type 2 diabetes in an academic family practice. 2004 , 17, 101-7		20
1515	Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. 2004 , 44, 637-42		101
1514	White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes. <i>Diabetes Care</i> , 2004 , 27, 216-22	14.6	148
1513	Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. 2004 , 160, 531-9		100
1512	Standards of medical care in diabetes. <i>Diabetes Care</i> , 2004 , 27 Suppl 1, S15-35	14.6	503
1511	Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. 2004 , 110, 22-6		263
1510	Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. 2004 , 164, 1737-48		81
1509	Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. 2004 , 50, 1184-8		118
1508	Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. 2004 , 15 Suppl 1, S12-20		10
1507	Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. 2004 , 109, 867-73		134
1506	Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients. 2004 , 53, 2455-60		189
1505	Dyslipidemia and the metabolic syndrome. <i>Diabetes Care</i> , 2004 , 27, 3009-16	14.6	16
1504	Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors. 2004 , 1, 34-9		18
1503	Sex differences in age-related stiffening of the aorta in subjects with type 2 diabetes. 2004 , 44, 67-71		84
1502	Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. <i>Diabetes Care</i> , 2004 , 27, 2887-92	14.6	82
1501	Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4,284 cases. <i>Diabetes Care</i> , 2004 , 27, 1137-42	14.6	40

1500	Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. 2004 , 47, S55-63		30
1499	The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. <i>Diabetes Care</i> , 2004 , 27, 2015-20	14.6	114
1498	A new device to introduce self-injection of insulin by his non-dominant hand in a patient with hemiplegia. 2004 , 6, 505-9		3
1497	Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. 2004 , 164, 1627-32		91
1496	Variations in diabetes care and the influence of office systems. 2004 , 19, 12-8		2
1495	CHD Prevalence in Americans Age 50 Years and Older Using NCEP and WHO Definitions of Metabolic Syndrome. 2004 , 21, 179-190		1
1494	Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. 2004 , 292, 2227-36		587
1493	Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?. 2004 , 101, 185-93		48
1492	Treating dyslipidaemia in the patient with type 2 diabetes. 2004 , 6, C28-C33		6
1491	Cholesterol as a risk factor for stroke: the fugitive?. 2004 , 35, 1523-4		17
1490	Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. 2004 , 164, 982-8		230
1489	Cholesterol and stroke. 2004 , 14, 25-36		2
1488	Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. 2004 , 53 Suppl 3, S39-47		77
1487	Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. <i>Diabetes Care</i> , 2004 , 27, 2689-94	14.6	176
1486	Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. 2004 , 90, 264-9		33
1485	Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. 2004 , 20, 1253-68		214
1484	IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. 2004 , 6, 836-43		10
1483	Postprandial hyperlipidemia after a fat loading test in minority adolescents with type 2 diabetes mellitus and obesity. 2004 , 17, 853-64		19

1482	What are the clinical manifestations of cardiovascular disease in diabetes? Ten year analysis from a clinic based population. 2004 , 4, 190-194	1
1481	Principles of Diabetes Mellitus. 2004 ,	
1480	Role of clinical pathologies in myocardial injury following ischaemia and reperfusion. 2004 , 61, 512-21	33
1479	High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. 2004 , 24, 858-63	18
1478	Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. 2004 , 11, 412-5	21
1477	Diabetic patients who smoke: are they different?. 2004 , 2, 26-32	69
1476	Helicobacter pylori and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study. 2004 , 11, 471-6	7
1475	The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. 2004 , 58, 494-503	7
1474	The importance of fat in the diabetic diet. 2004 , 58, 8-11	0
1473	A review of the efficacy of rosuvastatin in patients with type 2 diabetes. 2004 , 58, 30-40	9
1472	Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate. 2004 , 6, 299-307	4
1471	Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes. 2004 , 6, 69-77	20
1470	Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. 2004 , 21, 305-10	117
1469	Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. 2004 , 21, 252-5	128
1468	The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus. 2004 , 21, 285-9	16
1467	Effects of glycaemic control on cardiovascular disease in diabetic American Indians: the Strong Heart Study. 2004 , 21, 311-7	11
1466	The prevalence of coronary heart disease in Type 2 diabetic patients in Italy: the DAI study. 2004 , 21, 738-45	23
1465	Effects of a structured health education programme by a diabetic education nurse on cardiovascular risk factors in Chinese Type 2 diabetic patients: a 1-year prospective randomized study. 2004 , 21, 1274-9	36

1464	Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. 2004 , 21, 1280-7	80
1463	An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. 2004 , 31, 8-13	49
1462	Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. 2004 , 34, 205-9	51
1461	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. 2004 , S59-62	56
1460	Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors. 2004 , 19, 1181-91	27
1459	Coronary artery bypass surgery in diabetic patients. 2004 , 19, 36-40	14
1458	Pathophysiology and long-term management of the metabolic syndrome. 2004 , 12 Suppl, 174S-80S	18
1457	Left ventricular diastolic dysfunction: risks, identification, and treatment. 2004 , 19, 31-6	
1456	Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: a planned subgroup analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). 2004 , 24, 389-94	21
1455	Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. 2004 , 490, 187-97	124
1454	M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart. 2004 , 497, 65-74	22
1453	Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. 2004 , 93, 848-53	42
1452	Usefulness of hyperglycemia in predicting renal and myocardial injury in patients with diabetes mellitus undergoing percutaneous coronary intervention. 2004 , 94, 1027-9	9
1451	Cardiac spectroscopy: techniques, indications and clinical results. 2004 , 14, 1034-47	19
1450	Prandial glucose regulation in the glucose triad: emerging evidence and insights. 2004 , 25, 195-202	19
1449	Percutaneous coronary intervention in diabetics. 2004 , 5, 277-85	6
1448	Epidemiology and burden of cardiovascular disease. 2004 , 27, III2-6	58
1447	Linking gene expression to function: metabolic flexibility in the normal and diseased heart. 2004 , 1015, 202-13	182

1446	Some considerations about the composition, in vivo detection and therapeutic approaches to the coronary atherosclerotic plaques in diabetes mellitus. 2004 , 18, 51-3	
1445	Effect of type 2 diabetes on various electrophoretic characteristics of low-density lipoprotein particles in women. 2004 , 47, 2114-7	9
1444	Hopes, disillusion and more hopes from vitamin C. 2004 , 61, 209-19	60
1443	Fibrinogen and fibrin clot structure in diabetes. 2004 , 29, 470-9	41
1442	[Diabetes mellitus type 2: coronary calcifications as a predictor of coronary artery disease]. 2004 , 29, 488-95	4
1441	Diabetic dyslipidaemia: past, present and future. 2004 , 21, 78-85	2
1440	Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. 2004 , 3, 6	21
1439	The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. 2004 , 3, 9	59
1438	The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. 2004 , 21, 52-8	213
1437	Increasing of oxidative stress from mitochondria in type 2 diabetic patients. 2004 , 20, 399-404	28
1436	Glucose control in diabetes. 2004 , 20 Suppl 2, S1-8	35
1435	Coronary anatomy and left ventricular ejection fraction in patients with type 2 diabetes admitted for elective coronary angiography. 2004 , 62, 432-8	11
1434	Art ^h ropathie diab ^é tique des membres inf ^é rieurs. 2004 , 1, 117-132	0
1433	Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. 2004 , 20, 215-23	42
1432	Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. 2004 , 4, 87-106	21
1431	Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. 2004 , 20, 1437-45	76
1430	Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. 2004 , 20, 1087-94	11
1429	Type 2 Diabetes and Disease Management: Exploring the Connections. 2004 , 7, S-11-S-22	2

1428	Coronary atherosclerosis in diabetic subjects: clinical significance, anatomic characteristics, and identification with in vivo imaging. 2004 , 22, 527-40, vi	6
1427	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. 2004 , 110, 921-7	573
1426	Atherosclerosis: ¿mantequilla en las arterias?. 2004 , 8, 1-6	
1425	Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. 2004 , 33, 377-92, table of contents	16
1424	Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. 2004 , 22, 505-9, v	20
1423	Síndrome metabólico y enfermedad cardiovascular en población diabética asistida en Atención Primaria. 2004 , 21, 339-346	
1422	Diabetes mellitus y riesgo cardiovascular. Recomendaciones del Grupo de Trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes. 2004 , 16, 74-78	2
1421	Metabolic Syndrome as a Cardiovascular Risk Factor in Patients With Type 2 Diabetes. 2004 , 57, 507-513	2
1420	Atherosclérose: du beurre sur les artères?. 2004 , 1, 27-36	
1419	Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. 2004 , 43, 8-14	155
1418	Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. 2004 , 44, 1047-52	84
1417	Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria. 2004 , 44, 2142-8	40
1416	Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. 2004 , 173, 1-12	202
1415	Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. 2004 , 64, 1181-96	61
1414	Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment: an observational study in 38 016 patients in primary care. 2004 , 24, 217-25	5
1413	Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. <i>Diabetes Care</i> , 2004 , 27, 530-7	14.6 186
1412	Diabetes in the elderly and in women: cardiovascular risks. 2004 , 22, 541-51, vi	17
1411	Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2. 2004 , 57, 507-513	9

1410	Fluvastatin and fluvastatin extended release: a clinical and safety profile. 2004 , 2, 641-52	15
1409	[Underutilization of acetylsalicylic acid of cardiovascular prevention in patients with diabetes mellitus]. 2004 , 122, 101-3	1
1408	Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. 2004 , 339, 85-90	48
1407	Fasting homocysteine levels in adults with type 1 diabetes and retinopathy. 2004 , 341, 27-32	12
1406	Clustering of components of the metabolic syndrome and risk for development of type 2 diabetes in Japanese male office workers. 2004 , 63, 185-94	11
1405	Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines?. 2004 , 65, 125-33	28
1404	Type II Diabetes Mellitus and impaired glucose tolerance in Yemen: prevalence, associated metabolic changes and risk factors. 2004 , 65, 275-81	30
1403	Ankle brachial pressure index and carotid intima-media thickness as atherosclerosis markers in Japanese diabetics. 2004 , 66, 269-75	27
1402	Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients. 2004 , 66, 245-52	8
1401	High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. 2004 , 1672, 36-45	41
1400	Suppression of 3-deoxyglucosone and heparin-binding epidermal growth factor-like growth factor mRNA expression by an aldose reductase inhibitor in rat vascular smooth muscle cells. 2004 , 314, 370-6	8
1399	Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. 2004 , 37, 959-68	170
1398	Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus. 2004 , 36, 40S-49S	26
1397	Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients. 2004 , 53, 77-83	22
1396	Should oral glucose tolerance test be a routine examination after a myocardial infarction?. 2004 , 97, 21-4	11
1395	Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. 2004 , 147, 1117-24	27
1394	Lessons learned from recent clinical trials in hypertensive diabetics: what's good for the kidney is good for the heart and brain. 2004 , 17, 7S-10S; quiz A2-4	6
1393	Insights into the biology of diabetic vascular disease: what's new?. 2004 , 17, 2S-6S; quiz A2-4	36

1392	The importance of blood pressure control in the patient with diabetes. 2004 , 116 Suppl 5A, 30S-38S	75
1391	Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). 2004 , 14, 686-95	116
1390	The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. 2004 , 6, 437-42; quiz 443-4	9
1389	Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. 2004 , 6, 690-6; quiz 697	13
1388	Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommendations. 2004 , 30, 3S3-18	44
1387	Comparison of men with impaired fasting glycaemia to controls and to diabetic subjects with fasting glycaemia from 7.0 to 7.7 mmol/l: clinical, nutritional and biological status. 2004 , 30, 167-74	6
1386	Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. 2004 , 30, 327-33	10
1385	Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. 2004 , 63, 582-92	657
1384	Hyperlipidemia des diabéticos. 2004 , 1, 106-116	1
1383	Tratamiento no farmacológico y farmacológico de la diabetes mellitus. 2004 , 9, 1000-1007	
1382	Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. 2004 , 363, 757-67	860
1381	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. 2004 , 364, 685-96	2928
1380	Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. 2004 , 26, 439-46	18
1379	How important is optimal blood pressure control?. 2004 , 26 Suppl A, A3-11	17
1378	Insulin resistance-associated cardiovascular disease: potential benefits of conjugated linoleic acid. 2004 , 79, 1159S-1163S	29
1377	Diabetes and the heart. 2004 , 65, 646-7	
1376	Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. 2004 , 22, 1613-22	98
1375	Cardiovascular outcomes among participants with diabetes in the recent large statin trials. 2004 , 15, 439-46	28

- 1374 Review: Aldosterone – the future challenge in cardiovascular disease?. **2004**, 4, 370-376 2
- 1373 Preventing cardiovascular disease in diabetes. **2004**, 4, 311-4
- 1372 Art^o fiopatie diab^o tique des membres inf^o hieus. **2004**, 1, 1-11
- 1371 Altered exercise gas exchange as related to microalbuminuria in type 2 diabetic patients. **2004**, 125, 1292-8 20
- 1370 Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PRESi^o ñ Arterial en Diab^o ticos tipo Dos) study. **2004**, 22, 217-22 14
- 1369 Latin American consensus on diabetes mellitus and hypertension. **2004**, 22, 2229-41 11
- 1368 Insulin resistance and vascular disease. **2004**, 9, 54-61 2
- 1367 The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetes. **2004**, 6, G3-G7 2
- 1366 Diet composition and the risk of type 2 diabetes: epidemiological and clinical evidence. **2004**, 92, 7-19 129
- 1365 Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. **2004**, 291, 1857-63 72
- 1364 Acute hyperglycemia alters von Willebrand factor but not the fibrinolytic system in elderly subjects with normal or impaired glucose tolerance. **2004**, 15, 629-35 5
- 1363 Diet, nutrition and the prevention of type 2 diabetes. **2004**, 7, 147-65 234
- 1362 Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. **2004**, 22, 1937-44 131
- 1361 Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. **2004**, 13, 601-5 13
- 1360 Myocardial effects of halothane and sevoflurane in diabetic rats. **2004**, 100, 1179-87 16
- 1359 Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. **2004**, 22, 1769-77 64
- 1358 Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments. **2004**, 59, 329-39 3
- 1357 Application of pressure-derived myocardial fractional flow reserve in assessing the functional severity of coronary artery stenosis in patients with diabetes mellitus. **2004**, 68, 993-8 35

1356	Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. 2004 , 68, 427-34	87
1355	Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. 2004 , 164, 1917-24	168
1354	Treatment of hypertension in patients with diabetes. 2004 , 164, 1850-7	59
1353	Clinical Practice Guidelines and Performance Indicators as Related—But Often Misunderstood—Tools. 2004 , 30, 48-56	
1352	Clinical practice guidelines and performance indicators as related—but often misunderstood—tools. 2004 , 30, 163-71	17
1351	Nutritional Recommendations in Diabetes Management. 2004 , 1-17	0
1350	Strategies for the prevention of type 2 diabetes and cardiovascular disease. 2005 , 7, D18-D22	5
1349	Epidemiology of the diabetic heart. 2005 , 16 Suppl 1, S3-S10	23
1348	Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. 2005 , 112, I311-6	104
1347	Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets. 2005 , 117, 17-20, 23-7	2
1346	Plant sterols are efficacious in lowering plasma LDL and non-HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabetic persons. 2005 , 81, 1351-8	71
1345	Macrovascular Disease. 2005 , 10, 279-298	1
1344	Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. 2005 , 142, 813-20	54
1343	Community pharmacy Target Intervention Program to improve aspirin use in persons with diabetes. 2005 , 45, 17-22	18
1342	The prevalence of silent ischemia in Turkish patients with type 2 diabetes mellitus. 2005 , 205, 351-5	6
1341	Dose-dependent autonomic dysfunction in chronic L-NAME-hypertensive diabetic rats. 2005 , 46, 563-9	15
1340	Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. 2005 , 26, 1255-61	224
1339	Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients. 2005 , 109, 297-302	15

1338	Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-Los Angeles-Hiroshima study. 2005 , 69, 259-64	179
1337	Imaging of myocardial metabolism. 2005 , 12, 345-58	22
1336	Is aspirin effective in diabetic patients? Yes. 2005 , 3, 2612-4	5
1335	Patterns of antihypertensive therapy among patients with diabetes. 2005 , 20, 842-6	24
1334	Cardiovascular risk factors in type 2 diabetic patients: multifactorial intervention in primary care. 2005 , S55-62	15
1333	What have we learned from clinical trials on prevention?. 2005 , S101-6	2
1332	Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. 2005 , 7, 88-97	58
1331	Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. 2005 , 7, 642-53	40
1330	Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). 2005 , 22, 306-11	31
1329	The potential of motivational interviewing. 2005 , 22, 353	3
1328	Effect of lower diagnostic thresholds on estimates of prevalence of impaired fasting glucose (IFG). 2005 , 22, 353-4	4
1327	New carotid plaque formation is very common in adult patients with Type 2 diabetes mellitus. 2005 , 22, 355-6	4
1326	Serum levels of L-arginine analogues and glutathione peroxidase and catalase gene variants in Type 2 diabetes mellitus patients. 2005 , 22, 356-7	3
1325	ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. 2005 , 22, 882-8	52
1324	The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris. 2005 , 22, 1326-33	7
1323	Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. 2005 , 22, 1558-65	24
1322	Type 2 diabetes mellitus: a cardiovascular perspective. 2005 , 59, 798-816	38
1321	Diabetes mellitus and stroke. 2006 , 60, 48-56	78

1320	Debunking the 'only 50%' myth: prevalence of established risk factors in New Zealanders with self-reported ischaemic heart disease. 2005 , 29, 405-11	2
1319	Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. 2005 , 257, 531-9	58
1318	Association of LMNA 1908C/T polymorphism with cerebral vascular disease and diabetic nephropathy in Japanese men with type 2 diabetes. 2005 , 63, 317-22	11
1317	Impact of total and central obesity on vascular mortality in patients undergoing coronary angiography. 2005 , 29, 785-91	33
1316	ADVANCE: action in diabetes and vascular disease. 2005 , 19 Suppl 1, S27-32	21
1315	Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. 2005 , 59, 1345-55	97
1314	Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study 'Men born in 1914' from Malm ^o Sweden. 2005 , 29, 182-9	53
1313	New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. 2005 , 30, 241-79	20
1312	Lipid management in patients with diabetes mellitus. 2005 , 96, 26E-32E	19
1311	Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. 2005 , 19, 80-7	19
1310	Endothelin-mediated remodeling in aortas of diabetic rats. 2005 , 21, 367-75	31
1309	Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. 2005 , 61, 225-30	21
1308	Prevalence of symptomatic and silent stress-induced perfusion defects in diabetic patients with suspected coronary artery disease referred for myocardial perfusion scintigraphy. 2005 , 32, 60-9	18
1307	An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. 2005 , 48, 17-26	156
1306	Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. 2005 , 48, 156-63	75
1305	Relationship between HbA(1)c and mortality in a Japanese population. 2005 , 48, 230-4	40
1304	Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. 2005 , 48, 2667-74	69
1303	Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. 2005 , 48, 1229-37	190

1302	Increased augmentation of central blood pressure is associated with increases in carotid intima-media thickness in type 2 diabetic patients. 2005 , 48, 1654-62	36
1301	Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?. 2005 , 48, 1445-53	86
1300	The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. 2005 , 48, 1684-99	307
1299	Expression and function of receptors for insulin-like growth factor-I and insulin in human coronary artery smooth muscle cells. 2005 , 48, 2155-61	27
1298	Rapid monitoring of diabetes-induced lipid peroxidation by Fourier transform infrared spectroscopy: evidence from rat liver microsomal membranes. 2005 , 339, 36-40	100
1297	The ONTARGET/TRANSCEND Trial Programme: baseline data. 2005 , 42 Suppl 1, S50-6	35
1296	Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes. 2005 , 22, 527-42	7
1295	Metabolic control analysis of the Warburg-effect in proliferating vascular smooth muscle cells. 2005 , 12, 827-34	33
1294	KHK-Diagnostik bei Diabetes mellitus. 2005 , 1, 91-97	0
1293	The impact of antidiabetic therapies on cardiovascular disease. 2005 , 7, 50-7	16
1292	Atherosclerosis and restenosis: is there a role for RAGE?. 2005 , 5, 11-6	32
1291	Diabetes and brain aging: epidemiologic evidence. 2005 , 5, 59-63	71
1290	Antihypertensive treatment and new-onset diabetes mellitus. 2005 , 7, 298-303	16
1289	Hypertension control: results from the Diabetes Care Program of Nova Scotia registry and impact of changing clinical practice guidelines. 2005 , 4, 11	2
1288	Strokes and diabetes. 2005 , 22, 215-221	2
1287	Regional variation in the prescribing for diabetes and use of secondary preventative therapies in Ireland. 2005 , 14, 537-44	17
1286	[Risk factors associated with acute myocardial infarction in the S ^ˆ ˆ Paulo metropolitan region: a developed region in a developing country]. 2005 , 84, 206-13	11
1285	Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. 2005 , 5, S1-S15	

1284	Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2 diabetic patients. 2005 , 12, 344-52	24
1283	Genetics of the Metabolic Syndrome. 2005 , 401-450	3
1282	Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. 2005 , 5, 28-35	13
1281	The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. 2005 , 36, 2538-43	118
1280	Platelet in progression of atherosclerosis: a potential target in diabetic patients. 2005 , 1, 159-65	7
1279	Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands. 2005 , 1, 89-102	2
1278	Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. 2005 , 1, 145-58	3
1277	2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment. <i>Diabetes Care</i> , 2005 , 28, 2795-802	14.6
1276	Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes. 2005 , 2, 88-93	11
1275	Standards of Medical Care in Diabetes. <i>Diabetes Care</i> , 2005 , 28, S4-S36	14.6 815
1274	Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. 2005 , 16, 2170-9	249
1273	Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. 2005 , 111, 2072-85	263
1272	The glucose tolerance test, but not HbA(1c), remains the gold standard in identifying unrecognized diabetes mellitus and impaired glucose tolerance in hypertensive subjects. 2005 , 56, 571-9	9
1271	Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. 2005 , 112, 2397-402	90
1270	The association between left ventricle diastolic dysfunction and endothelial dysfunction and the results of stress myocardial SPECT in asymptomatic patients with type 2 diabetes. 2005 , 33, 473-82	12
1269	Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. <i>Diabetes Care</i> , 2005 , 28, 2176-80	14.6 75
1268	Risk factors for concomitant peripheral arterial occlusive disease in patients with coronary artery disease: is there a difference between diabetic and non-diabetic patients?. 2005 , 60, 122-8	
1267	Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. 2005 , 21, 989-98	60

1266	Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity. 2005 , 58, 483-7		13
1265	Einfluss von Widerstandstraining auf Parameter des Glukosestoffwechsels bei Gesunden, Typ-2-Diabetikern und Individuen mit Anzeichen einer Insulinresistenz. 2005 , 30, 261-272		1
1264	[Diabetes and stroke]. 2005 , 130, 291-6		4
1263	CARDS on the table: should everybody with type 2 diabetes take a statin?. 2005 , 21, 357-62		9
1262	The vascular endothelium in diabetes: a practical target for drug treatment?. 2005 , 9, 101-17		18
1261	Cyclic relationships between diabetic nephropathy and cardiovascular risk factors. 2005 , 3, 203-12		
1260	The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. <i>Diabetes Care</i> , 2005 , 28, 1668-74	14.6	46
1259	No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease. <i>Diabetes Care</i> , 2005 , 28, 1675-9	14.6	9
1258	Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. <i>Diabetes Care</i> , 2005 , 28, 101-7	14.6	122
1257	Role of surgical revascularization in diabetic patients with coronary artery disease. 2005 , 3, 249-60		1
1256	Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. <i>Diabetes Care</i> , 2005 , 28, 595-9	14.6	109
1255	Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. 2005 , 54, 2514-24		107
1254	Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. 2005 , 21, 665-82		89
1253	Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. 2005 , 19, 591-3		51
1252	Inflammatory, atherothrombotic aspects of type 2 diabetes. 2005 , 21 Suppl 1, S5-12		16
1251	Ischemia imaging and plaque imaging in diabetes: complementary tools to improve cardiovascular risk management. <i>Diabetes Care</i> , 2005 , 28, 2787-94	14.6	21
1250	Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. <i>Diabetes Care</i> , 2005 , 28, 355-9	14.6	225
1249	Relationship between HbA1c level and peripheral arterial disease. <i>Diabetes Care</i> , 2005 , 28, 1981-7	14.6	86

1248	Pathobiology and cell interactions of platelets in diabetes. 2005 , 2, 16-23		48
1247	Dobutamine stress echocardiography in diabetes. 2005 , 5, 42-46		
1246	Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes. 2005 , 16, 1069-75		109
1245	Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. 2005 , 54, 1573-80		59
1244	Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2005 , 165, 1401-9		206
1243	Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). <i>Diabetes Care</i> , 2005 , 28, 1151-7	14.6	309
1242	Review: Blood pressure reduction in the metabolic syndrome and type 2 diabetes: current concepts. 2005 , 5, 320-324		1
1241	Diabetes in later life. 2005 , 15, 27-38		1
1240	Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. 2005 , 81, 1-6		74
1239	Review: Defining the role of statins in diabetes. 2005 , 5, 55-62		1
1238	The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. 2005 , 90, 5698-703		133
1237	Total risk factor management in patients with type 2 diabetes. 2005 , 66, 529-33		
1236	The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. 2005 , 26, 1369-78		105
1235	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. 2005 , 366, 1267-78		5108
1234	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAZone Clinical Trial In macroVascular Events): a randomised controlled trial. 2005 , 366, 1279-89		3186
1233	Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. 2005 , 366, 1849-61		2421
1232	Factores metabólicos de riesgo cardiovascular. Relevancia epidemiológica. Tratamiento farmacológico. Situaciones de especial relevancia. 2005 , 9, 3032-3043		
1231	The brain of the elderly diabetic patient. 2005 , 31 Spec No 2, 5S92-5S97		15

1230	Cardiovascular risks in type 2 diabetes and secondary cardiovascular prevention. 2005 , 31, 503-6	0
1229	Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. 2005 , 180, 113-8	108
1228	Development of atherosclerosis in the diabetic BALB/c mice. Prevention with Vitamin E administration. 2005 , 182, 259-65	45
1227	Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. 2005 , 6, 3-6	43
1226	What is the most effective strategy for managing diabetic dyslipidaemia?. 2005 , 6, 21-7	7
1225	Control de la hipertensi ³ n arterial y de otros factores de riesgo cardiovascular en poblaci ³ n de alto riesgo asistida en Atenci ³ n Primaria. Estudio EVENTO. 2005 , 31, 53-60	2
1224	Genetic epidemiology of diabetes. 2005 , 115, 1431-9	172
1223	The role of intensive glycemic control in the management of patients who have acute myocardial infarction. 2005 , 23, 109-17	5
1222	The role of lipid management in diabetes. 2005 , 23, 153-64, vi	
1221	Hypertension in special populations. 2005 , 25, 210-4	2
1220	Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. 2005 , 23, 139-52	24
1219	Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the DETECT program. 2005 , 21, 619-30	83
1218	Relative contributions of cardiorespiratory fitness and visceral fat to metabolic syndrome in patients with diabetes mellitus. 2005 , 3, 213-20	7
1217	The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes. 2005 , 6, 2483-91	19
1216	Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. 2005 , 6, 2209-21	13
1215	Statins and LDL-cholesterol lowering: an overview. 2005 , 21 Suppl 6, S9-16	35
1214	Place of drug therapy in the treatment of carotid stenosis. 2005 , 19, 597-622	4
1213	Management of diabetic dyslipidemia: need for reappraisal of the goals. 2005 , 5, 83-91	7

1212	Anthropometric characteristics, dietary patterns and risk of type 2 diabetes mellitus in Vietnam. 2005 , 24, 229-34	25
1211	Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. 2005 , 21, 163-72	19
1210	Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. 2005 , 7, 669-78	12
1209	The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. 2005 , 54, 1236-42	42
1208	Diabetic patients with acute coronary syndromes in the UK: high risk and under treated. Results from the prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK). 2005 , 100, 79-84	17
1207	Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. 2005 , 104, 251-6	18
1206	Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR-alpha, PPAR-gamma, and LPL mRNA expressions. 2005 , 77, 3344-54	92
1205	Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. 2005 , 27, 166-73	21
1204	Dietary soy prevents brain Na ⁺ , K ⁽⁺⁾ -ATPase reduction in streptozotocin diabetic rats. 2005 , 69, 107-12	14
1203	Metabolic response to oral lipid overload in diabetes and impaired glucose tolerance. 2005 , 69, 36-43	11
1202	Postprandial hypertriglyceridemia and carotid intima-media thickness in north Indian type 2 diabetic subjects. 2005 , 69, 142-50	23
1201	Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. 2005 , 68 Suppl1, S43-7	18
1200	The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. 2005 , 68 Suppl 2, S3-14	75
1199	Hypertension: a review and rationale of treatment. 2005 , 51, 548-614	8
1198	Cardiovascular protection in patients with type 2 diabetes mellitus: Considerations about the tightness of blood pressure control and the choice of treatment. 2005 , 16, 154-159	8
1197	Antihyperlipidemic effect of Eugenia jambolana seed kernel on streptozotocin-induced diabetes in rats. 2005 , 43, 1433-9	126
1196	Non-HDL-cholesterol, waist circumference and the HOMA index: Correlations in the healthy. 2005 , 1, 183-184	3
1195	Burden of disease associated with overweight and obesity among U.S. military retirees and their dependents, aged 38-64, 2003. 2005 , 41, 63-9	37

1194	Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. 2005 , 15, 204-11	41
1193	Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. 2005 , 15, 368-72	21
1192	Effects of dietary phytic acid on serum and hepatic lipid levels in diabetic KK mice. 2005 , 25, 869-876	34
1191	Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment. 2005 , 149, 104-11	5
1190	The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. 2005 , 149, 13-9	65
1189	Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance. 2005 , 150, 168-74	4
1188	Screening for coronary artery disease in patients with diabetes: a Bayesian strategy of clinical risk evaluation and exercise echocardiography. 2005 , 150, 1074-80	11
1187	Protecting renal function in the hypertensive patient: clinical guidelines. 2005 , 18, 112S-119S	22
1186	Combination of site of infarct, unrecognized glucose intolerance, and reinfarction after acute myocardial infarction in normotensive subjects is determinant of the development of subsequent systemic hypertension: a pilot study. 2005 , 18, 1294-9	
1185	Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. 2005 , 118, 939-47	70
1184	The importance of tight glycaemic control. 2005 , 118, 7S-11S	69
1183	[Effectiveness of control of cardiovascular risk factors in type 2 diabetic population of Ciudad Real province]. 2005 , 205, 218-22	13
1182	Age and kidney function are the primary correlates of fasting plasma total homocysteine levels in non-diabetic and diabetic adults. Results from the 1999-2002 National Health and Nutrition Examination Survey. 2005 , 2, 13	3
1181	Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. 2005 , 65, 137-52	12
1180	Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update. 2005 , 65, 433-45	7
1179	Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus : an open, multicentre, observational study. 2005 , 25, 337-40	7
1178	Heart Failure and Cardiac Dysfunction in Diabetes. 2005 , 555-578	
1177	Diabetes Mellitus and Heart Disease. 2005 , 579-628	

1176	Grado de control de la presi ^o n arterial en un grupo de pacientes con diabetes mellitus tipo 2. 2005 , 52, 493-497		
1175	Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. 2005 , 45, 1622-30		267
1174	Metabolic syndrome and risk of cardiovascular events after myocardial infarction. 2005 , 46, 277-83		122
1173	Glucose for the heart: too much of a good thing?. 2005 , 46, 49-50		8
1172	Epidemiology of Hypertension. 2005 , 16-28		3
1171	Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. 2005 , 23, 193-210		8
1170	Management of diabetic dyslipidemia. 2005 , 34, 1-25, v		29
1169	Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. <i>Diabetes Care</i> , 2005 , 28, 799-805	14.6	195
1168	The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2005 , 28, 2289-304	14.6	1574
1167	Oxidative stress in insulin-resistant conditions: cardiovascular implications. 2005 , 4, 343-51		26
1166	Diabetes and Cardiovascular Disease. 2005 ,		6
1165	Is there a rationale for insulin therapy in pre-diabetic individuals?. 2006 , 5, 385-93		5
1164	Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. <i>Diabetes Care</i> , 2006 , 29, 2518-27	14.6	525
1163	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 28, 1462-536		1418
1162	Stroke prevention in diabetes and obesity. 2006 , 4, 487-502		15
1161	Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. 2006 , 32, 562-70		55
1160	Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention. 2006 , 6, 15-40		20
1159	Recent developments in the treatment of atherosclerosis. 2006 , 21, 1-15		11

1158	Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. 2006, 37, 577-617	1174
1157	Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. 2006, 32 Spec No2, 2S48-51	4
1156	Characteristics and six-month outcomes in a cohort of 8288 diabetic and non-diabetic patients with previous history of acute coronary syndrome or stroke: the French PREVENIR 3 survey. 2006, 32, 460-6	7
1155	Primary prevention of cardiovascular events and type 2 diabetes: should we prioritize our interventions?. 2006, 32, 559-67	8
1154	Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients. 2006, 32, 625-31	24
1153	[Myocardial infarction in patients with diabetes: comparative series of 85 patients with 16 patients without diabetes]. 2006, 35, 207-11	
1152	[Management of hypertension in patients with diabetes]. 2006, 35, 1041-6	0
1151	Myocardial perfusion imaging in diabetes mellitus. 2006, 22, 16A-21A	5
1150	Myocardial perfusion imaging in diabetes mellitus. 2006, 22 Suppl A, 22A-25A	1
1149	Noninvasive assessment of coronary artery disease in diabetic patients: the role of stress echocardiography. 2006, 22 Suppl A, 26A-33A	3
1148	Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. 2006, 368, 1651-9	275
1147	Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. 2006, 23, 780-7	26
1146	[What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?]. 2006, 2, 51-74	5
1145	Multiple metabolic risk factors and total and cardiovascular mortality in men with low prevalence of obesity. 2006, 187, 123-30	9
1144	Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. 2006, 189, 241-6	71
1143	Diabetes and the metabolic syndrome--when is it best to intervene to prevent?. 2006, 7, 3-10	16
1142	Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist. 2006, 7, 37-42	9
1141	Diabetes mellitus--overview. 2006, 11, 703-15	17

1140	Epidemiologic perspectives of risk for developing diabetes and diabetes complications. 2006 , 41, 487-98, v		1
1139	Diabetic dyslipidemia. 2006 , 35, 491-510, vii-viii		167
1138	Impact of type 2 diabetes mellitus on aortic elastic properties in normotensive diabetes: Doppler tissue imaging study. 2006 , 19, 1471-81		26
1137	Morbimortalidad por cardiopatía isquémica en el paciente diabético. 2006 , 53, 405-417		1
1136	[Ankle-brachial index in patients with diabetes mellitus: prevalence and risk factors]. 2006 , 206, 225-9		17
1135	[Can we benefit from determination of the ankle-arm index in primary care consultations?]. 2006 , 38, 358-61		2
1134	Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. 2006 , 13, 555-61		70
1133	Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). <i>Diabetes Care</i> , 2006 , 29, 1478-85	14.6	409
1132	The metabolic syndrome and cardiovascular disease. 2006 , 38, 64-80		139
1131	Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. 2006 , 47, 598-604		193
1130	Prognostic value of pharmacological stress echocardiography in diabetic and nondiabetic patients with known or suspected coronary artery disease. 2006 , 47, 605-10		62
1129	Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. 2006 , 47, 65-71		179
1128	Association of vascular risk factors with increasing glycemia even in normoglycemic subjects in an older Chinese population: the Guangzhou Biobank Cohort Study. 2006 , 55, 1035-41		15
1127	Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. 2006 , 55, 1053-9		88
1126	Effect of vanadyl sulfate on the status of lipid parameters and on stomach and spleen tissues of streptozotocin-induced diabetic rats. 2006 , 53, 271-7		60
1125	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). 2007 , 28, 88-136		889
1124	Determinants of normoglycemia and contribution to cardiovascular risk factors in a Chinese population: the Hong Kong Cardiovascular Risk Factor Study. 2006 , 29, 528-35		6
1123	Determinants of sustained uncontrolled blood pressure in a national cohort of persons with diabetes. 2006 , 19, 161-9		14

1122	A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring. 2006 , 151, 754.e7-754.e17	21
1121	Dental management of patients with diabetes. 2006 , 50, 591-606, vii	11
1120	Characterisation of receptors for IGF-I and insulin; evidence for hybrid insulin/IGF-I receptor in human coronary artery endothelial cells. 2006 , 16, 258-66	27
1119	Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients. 2006 , 60, 161-8	55
1118	The implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization. 2006 , 71, 290-8	46
1117	Enhancement of serum lipoprotein lipase mass levels by intensive insulin therapy. 2006 , 72, 61-7	6
1116	Impact of diabetes on health-related quality of life in a population study in Japan. 2006 , 73, 51-7	40
1115	Inflammation, insulin resistance and carotid IMT in first degree relatives of north Indian type 2 diabetic subjects. 2006 , 73, 205-10	13
1114	The role of polyol pathway in high glucose-induced endothelial cell damages. 2006 , 73, 227-34	44
1113	Effect of a diet and exercise intervention on oxidative stress, inflammation and monocyte adhesion in diabetic men. 2006 , 73, 249-59	68
1112	Lipid management reduces cardiovascular complications in individuals with diabetes and prediabetes. 2006 , 9, 102-7; quiz 108-9	6
1111	Challenges and risks in attaining the systolic blood pressure goal of . 2006 , 8, 50-2	1
1110	Impact of blood pressure vs. glycemic factors on target organ damage in patients with type 2 diabetes mellitus. 2006 , 8, 404-10	8
1109	Managing multiple cardiovascular risk factors: state of the science. 2006 , 8, 12-22	13
1108	Women in Pakistan have a greater burden of clinical cardiovascular risk factors than men. 2006 , 106, 348-54	25
1107	The relation between impaired glucose tolerance and slow coronary flow. 2006 , 111, 142-6	27
1106	Management of cardiovascular risk factors in people with diabetes in primary care: cross-sectional study. 2006 , 120, 654-63	12
1105	Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. 2006 , 16, 543-9	112

1104	Coronary Restenosis after Drug-Eluting Stent Implantation in Diabetic Patients. 2006 , 36, 1	2
1103	Current Status of Aspirin User in Korean Diabetic Patients Using Korean Health Insurance Database. 2006 , 30, 363	7
1102	Evolving treatment paradigms for vascular risk reduction in type 2 diabetes. 2006 , 6, S1-S12	
1101	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. 2006 , 113,	347
1100	Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials. 2006 , 1, 21-33	4
1099	[Comparison of coronary angiography findings in diabetic and non-diabetic women with non-ST-segment-elevation acute coronary syndrome]. 2006 , 86, 150-5	4
1098	Diabetes, Obesity and Cardiovascular Disease – Therapeutic Implications. 2006 , 167-199	
1097	Efficacy Evaluation of Atorvastatin in Korean Hyperlipidemic Patients with Type 2 Diabetes Mellitus. 2006 , 30, 292	3
1096	[Physiological effects of exercise training in patients with type 1 diabetes]. 2006 , 50, 1005-13	9
1095	Pioglitazone for type 2 diabetes mellitus. 2006 ,	3
1094	Exercise, Metabolic Syndrome and Type 2 Diabetes. 2006 , 77-93	
1093	Type 2 Diabetes. 2006 ,	
1092	Downregulation of peroxisome proliferator activated receptor gamma co-activator 1alpha in diabetic rats. 2006 , 47, 901-10	12
1091	Coronary heart disease in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors. 2006 , 61, 13-20	16
1090	Predominance of small dense low-density lipoproteins and abnormal glucose regulation in patients with acute coronary syndrome. 2006 , 70, 393-401	10
1089	Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. 2006 , 1, 429-440	5
1088	Management of dyslipidemia in diabetes. 2006 , 14, 125-35	55
1087	Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. 2006 , 110, 109-16	37

1086	Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity. 2006 , 110, 409-25	112
1085	Rosiglitazone for type 2 diabetes mellitus. 2006 ,	
1084	Pioglitazone for type 2 diabetes mellitus. 2006 , CD006060	35
1083	European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. 2006 , 24, 2482-5	25
1082	Total cardiovascular risk: a new treatment concept. 2006 , 24, S17-24	20
1081	Cardiovascular disease: strategies for risk assessment and modification. 2006 , 21, S20-42; quiz S43-5	7
1080	Hemostasis alterations in metabolic syndrome (Review). 2006 , 18, 969	3
1079	Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. 2006 , 27, 713-21	298
1078	Evaluation du risque vasculaire global en pratique courante: pourquoi et comment?. 2006 , 1, 1-3	
1077	Ath ⁺ foscl ⁺ rose: du beurre sur les art ⁺ r ⁺ es?. 2006 , 1, 1-6	
1076	Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. 2006 , 194, 404-10	77
1075	Glycated hemoglobin as a marker of cardiovascular risk. 2006 , 17, 637-43	53
1074	European Society of Hypertension Scientific Newsletter: update on hypertension management: prevention of type 2 diabetes mellitus with antihypertensive drugs. 2006 , 24, 2478-82	6
1073	Diabetes and cardiovascular disease: does sugar matter?. 2006 , 13, 99-102	
1072	Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation. 2006 , 3, 229-234	2
1071	Reassessment of cardiovascular risk in diabetes. 2006 , 17, 644-52	8
1070	Statins: are any questions unanswered?. 2006 , 17, 418-25	9
1069	European Society of Hypertension Scientific Newsletter: control of hypertension in patients with peripheral artery disease. 2006 , 24, 2477-8	1

1068	Metabolic Syndrome. 2006,	
1067	Sex differences of risk factors for acute myocardial infarction in Japanese patients. 2006, 70, 513-7	48
1066	Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. 2006, 5, 15	42
1065	Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes. 2006, 5, 21	16
1064	Diabetes and dyslipidaemia. 2006, 8, 355-64	27
1063	Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. 2006, 23, 609-16	119
1062	The MTHFR CT polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with Type 2 diabetes. 2006, 23, 529-36	24
1061	Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. 2006, 23, 775-9	21
1060	The metabolic syndrome: 'to be or not to be, that is the question. 2006, 23 Suppl 3, 16-8	2
1059	Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes. 2006, 4, 574-80	29
1058	Reduction of Risk Factors for Cardiovascular Complications by BM 17.0744. 2006, 17, 246-264	2
1057	Calcium antagonists in patients with type 2 diabetes and hypertension. 2003, 21, 105-18	13
1056	Evidence for prescribing exercise as therapy in chronic disease. 2006, 16 Suppl 1, 3-63	814
1055	Hyperglycaemia acutely decreases circulating dehydroepiandrosterone levels in healthy men. 2006, 64, 46-52	2
1054	Undiagnosed dysglycaemia and inflammation in cardiovascular disease. 2006, 36, 544-51	21
1053	Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. 2006, 31, 153-9	21
1052	Metabolic syndrome: focus on dyslipidemia. 2006, 14 Suppl 1, 41S-49S	142
1051	Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. 2006, 18, 311-5	25

1050	Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease. 2006 , 69, 1899-903	21
1049	Asymptomatic patients with diabetes mellitus should be screened for coronary artery disease. 2006 , 13, 609-15	12
1048	Effects of Strobilanthes crispus tea aqueous extracts on glucose and lipid profile in normal and streptozotocin-induced hyperglycemic rats. 2006 , 61, 7-12	27
1047	How to revascularize patients with diabetes mellitus: bypass or stents and drugs?. 2006 , 95, 195-203	13
1046	[Experiences collected in more than 2,300 diabetics undergoing coronary artery bypass grafting: patients with a specific risk profile]. 2006 , 95 Suppl 1, i7-13	0
1045	Prevalence of myocardial ischaemia as assessed with myocardial perfusion scintigraphy in patients with diabetes mellitus type 2 and mild anginal symptoms. 2006 , 33, 1468-76	8
1044	Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. 2006 , 49, 49-55	72
1043	Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). 2006 , 49, 1761-9	255
1042	The effect of diabetes and stroke at baseline and during follow-up on stroke mortality. 2006 , 49, 2309-16	27
1041	Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes. 2006 , 49, 2618-26	78
1040	The increased angiotensin II (type 1) receptor density in myocardium of type 2 diabetic patients is prevented by blockade of the renin-angiotensin system. 2006 , 49, 3067-74	14
1039	Treatment of lipid disorders in patients with diabetes. 2006 , 8, 37-45	5
1038	Cholesterol lowering to prevent stroke: who, when, and how?. 2006 , 8, 496-502	
1037	Diabetes and stroke: part one--risk factors and pathophysiology. 2006 , 8, 23-8	25
1036	Genetics of macrovascular complications in diabetes. 2006 , 6, 162-8	9
1035	Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. 2006 , 6, 219-24	35
1034	Proxidant and antioxidant status in patients of type II Diabetes Mellitus with IHD. 2006 , 21, 118-22	17
1033	Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes. 2006 , 175, 36-41	1

1032	Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. 2006 , 45, 29-35	26
1031	Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. 2006 , 1, 95-101	52
1030	Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. 2006 , 203, 24-9	112
1029	Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. 2006 , 50, 721-31	166
1028	Statement of the problem. 2006 , 97, 3G-8G	260
1027	Modifications of coronary risk factors. 2006 , 97, 41G-52G	17
1026	Metabolic syndrome and hyperglycemia: congruence and divergence. 2006 , 98, 982-5	30
1025	Predictors of improved left ventricular systolic function in an urban cardiomyopathy program. 2006 , 98, 1622-6	3
1024	Trimetazidine-induced enhancement of myocardial recovery during reperfusion: a comparative study in diabetic and non-diabetic rat hearts. 2006 , 37, 700-8	9
1023	Diabetes mellitus and anesthesia. 2006 , 24, 579-97	6
1022	Dislipemia diabética, síndrome metabólico y riesgo cardiovascular. 2006 , 6, 13G-23G	
1021	Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state. 2006 , 20, 40-4	12
1020	Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. 2006 , 20, 14-20	21
1019	The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. 2006 , 20, 75-80	41
1018	The metabolic syndrome: prevalence, CHD risk, and treatment. 2006 , 20, 121-32	59
1017	Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. 2006 , 67, 666-676	3
1016	National Stroke Association guidelines for the management of transient ischemic attacks. 2006 , 60, 301-13	155
1015	Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. 2006 , 8, B20-B25	18

1014	The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects. 2006 , 27, 905-12		48
1013	[Success of blood pressure reduction in diabetic patients]. 2006 , 131 Suppl 8, S247-51		0
1012	Macroangiopathy in adults and children with diabetes: risk factors (part 2). 2006 , 38, 706-20		9
1011	Management of Dyslipidemia in Special Populations. 2006 , 19, 63-78		0
1010	Risk factors for stroke in type 2 diabetes mellitus. 2006 , 3, 57-60		13
1009	Preventive Cardiology. 2006 ,		
1008	The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. 2006 , 12, 1567-79		10
1007	Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. 2006 , 48, 271-7		73
1006	Novel concepts of statin therapy for cardiovascular risk reduction in hypertension. 2006 , 12, 1593-609		14
1005	Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. 2006 , 290, H2480-97		76
1004	Reducing vascular risk in the diabetic patient: implications from the FIELD study. 2006 , 3, S16-S20		1
1003	Effects of Different Insulin Regimes on Postprandial Myocardial Perfusion Defects in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2006 , 29, 95-100	14.6	63
1002	Screening for silent coronary heart disease in type 2 diabetes: clinical application of American Diabetes Association guidelines. <i>Diabetes Care</i> , 2006 , 29, 692-4	14.6	20
1001	Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. 2006 , 92, 1119-24		74
1000	Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. 2006 , 3, 147-58		43
999	Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. 2006 , 17, 2928-36		115
998	Complex relationship between blood pressure and mortality in type 2 diabetic patients: a follow-up of the Botnia Study. 2006 , 47, 168-73		43
997	Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective. 2006 , 1, 209-20		12

996	Overcoming barriers to effective blood pressure control in patients with hypertension. 2006 , 22, 1545-53	70
995	Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. 2006 , 291, H1489-506	323
994	Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. 2006 , 2, 635-46	
993	Type-2 diabetes and carotid stenosis: a proposal for a screening strategy in asymptomatic patients. 2006 , 11, 93-9	27
992	Implications of the global diabetes epidemic. 2006 , 3, S2-S5	2
991	Mortality after myocardial infarction in patients with diabetes mellitus. 2007 , 93, 1504-6	13
990	Smoking rates and the state of smoking interventions for children and adolescents with chronic illness. 2006 , 118, e471-87	53
989	The effects of fibrates on lipid metabolism and inflammation in type 2 diabetes. 2006 , 3, S6-S9	4
988	Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. 2006 , 92, 650-7	57
987	PPAR α ; Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?. 2006 , 2, 47-60	2
986	Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. 2006 , 9, 356-62	43
985	Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. 2006 , 332, 1115-24	221
984	Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. 2006 , 4, 179-84	10
983	Cardiovascular risk factors in the Mexican population. 2006 , 28, 677-87	16
982	Treatment Disparities in the Care of Patients With and Without Diabetes Presenting With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Diabetes Care</i> , 2006 , 29, 9-14	14.6 52
981	Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. <i>Diabetes Care</i> , 2006 , 29, 2064-71	14.6 203
980	Effects of PPAR α on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?. 2006 , 4, 161-71	9
979	The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. 2006 , 22, 343-50	18

978	Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. <i>Diabetes Care</i> , 2006 , 29, 391-7	14.6	134
977	Smoking and Diabetes: Helping Patients Quit. 2006 , 24, 133-137		5
976	Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. <i>Diabetes Care</i> , 2006 , 29, 1220-6	14.6	410
975	Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. 2006 , 26, 2275-80		129
974	Standards of medical care in diabetes--2007. <i>Diabetes Care</i> , 2007 , 30 Suppl 1, S4-S41	14.6	1171
973	Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients: a Meta-Analysis: Response to Balducci et al.. <i>Diabetes Care</i> , 2007 , 30, e26-e26	14.6	1
972	Insulin resistance and postprandial hyperglycemia the bad companions in natural history of diabetes: effects on health of vascular tree. 2007 , 3, 268-73		13
971	Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. 2007 , 56, 499-505		62
970	The state of lipid control in patients with diabetes in a public health care centre. 2007 , 19, 16-21		6
969	Blood pressure, antihypertensive treatment and factors associated with good blood pressure control in hypertensive diabetics: the Tarmidas study. 2007 , 21, 664-72		5
968	A comparative study of the prevalence of the metabolic syndrome and its components in type 2 diabetic patients in two Caribbean islands using the new International Diabetes Federation definition. 2007 , 113, 202-10		13
967	Dobutamine stress echocardiography and the effect of revascularization on outcome in diabetic and non-diabetic patients with chronic ischaemic left ventricular dysfunction. 2007 , 9, 1038-43		14
966	A new rat model of diabetic macrovascular complication. 2007 , 73, 504-11		16
965	Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. 2007 , 28, 3059-66		64
964	The additive prognostic value of wall motion abnormalities and coronary flow reserve during dipyridamole stress echo. 2008 , 29, 79-88		86
963	Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. 2008 , 23, 1346-54		38
962	Increased echolucency of carotid plaques in patients with type 2 diabetes. 2007 , 38, 2074-8		36
961	Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. 2007 , 357, 28-38		618

960	Effects of hypertension and type 2 diabetes mellitus on the risk of total cardiovascular events in Japanese patients with hypercholesterolemia: implications from the Japan Lipid Intervention Trial (J-LIT). 2007 , 30, 119-23	9
959	Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. 2007 , 167, 921-7	106
958	Clinical efficacy and cost-effectiveness of rosuvastatin. 2007 , 7, 31-9	
957	Body mass index, waist circumference, and waist-hip ratio on the risk of total and type-specific stroke. 2007 , 167, 1420-7	145
956	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). 2007 , 9, C3-C74	25
955	CD36 deficiency rescues lipotoxic cardiomyopathy. 2007 , 100, 1208-17	192
954	Atherosclerosis in type 2 diabetes: a role for fibrate therapy?. 2007 , 4, 368-74	20
953	Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects. 2007 , 67, 306-16	17
952	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 25, 1105-87	3825
951	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. 2007 , 13 Suppl 1, 1-68	446
950	The evaluation of cardiac and peripheral arterial disease in patients with diabetes mellitus. 2007 , 32, 109-42	3
949	Comparison of different regression analyses for identifying risk factors in obese and nonobese patients with coronary artery disease. 2007 , 58, 543-9	1
948	Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. 2007 , 298, 1180-8	947
947	High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. 2007 , 48, 218-25	29
946	Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. 2007 , 115, 909-17	180
945	Vascular inflammatory markers in early-onset obese and type 2 diabetes subjects before and after three months' aerobic exercise training. 2007 , 4, 231-4	28
944	Admission glycaemia and outcome in patients with acute coronary syndrome. 2007 , 4, 346-52	14
943	New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia. 2008 , 72, 633-40	18

942	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. 2007,	3
941	Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. 2007, 333, 145-53	40
940	Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade. 2007, 71, 524-9	45
939	Is central obesity a good predictor of carotid atherosclerosis in Japanese type 2 diabetes with metabolic syndrome?. 2007, 54, 695-702	16
938	Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. 2007, 85, 1236-43	174
937	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. 2007, 25, 871-6	18
936	Optimal control of blood pressure in patients with diabetes reduces the incidence of macro and microvascular events. 2007, 25, 57-12	19
935	The sympathetic nervous system and the metabolic syndrome. 2007, 25, 909-20	275
934	Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. 2007, 25, 1205-13	73
933	Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. 2007, 25, 1311-7	88
932	Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease. 2007, 4, 125-139	
931	A 74-year-old woman with diabetes. 2007, 297, 196-204	12
930	Quality of diabetes care among adults with serious mental illness. 2007, 58, 536-43	92
929	Anesth [^] sie et r [^] animation du patient diab [^] tique. 2007, 4, 1-22	4
928	The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. 2007, 47, 642-52	35
927	Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. 2007, 120, 439-46	43
926	QTc and autonomic neuropathy in diabetes: effects of acute hyperglycaemia and n-3 PUFA. 2007, 17, 712-8	25
925	A Modern Perspective on β -Blocker Use in Hypertension: Clinical Trials and Their Influence on Clinical Practice. 2007, 9, 10-18	8

924	Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients. 2007 , 9, 883-8	4
923	What should our blood pressure goal be in patients with diabetes?. 2007 , 9, 823-6	1
922	Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. 2007 , 9, 842-9	14
921	Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease. 2007 , 9, 16-25	2
920	Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?. 2007 , 153, 67-73	32
919	Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. 2007 , 153, 507-14	41
918	Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. 2007 , 154, 815-23, 823.e1-6	70
917	Risk-factor clustering and cardiovascular disease risk in hypertensive patients. 2007 , 20, 599-607	49
916	Improving the Prognosis in Patients With Diabetes: What Will ADVANCE Tell Us?. 2007 , 20, S19-S22	
915	Benefits of First-Line Combination of Perindopril and Indapamide in Clinical Practice for Patients With Hypertension and Diabetes. 2007 , 20, S9-S14	4
914	Optimizing cardiovascular outcomes in diabetes mellitus. 2007 , 120, S3-11	147
913	Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. 2007 , 120, S18-25	24
912	Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. 2007 , 5, 52-63	27
911	High glucose downregulates the number of caveolae in monocytes through oxidative stress from NADPH oxidase: implications for atherosclerosis. 2007 , 1772, 364-72	36
910	HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. 2007 , 1772, 549-55	12
909	Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. 2007 , 358, 679-85	53
908	Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. 2007 , 379, 53-8	7
907	Effects of a myocardial ischaemia-guided therapeutic program on survival and incidence of coronary events in asymptomatic patients with diabetes: the ARCADIA study. 2007 , 33, 459-65	3

906	Short term efficacy of a lifestyle intervention programme on cardiovascular health outcome in overweight Indigenous Australians with and without type 2 diabetes mellitus. The healthy lifestyle programme (HELP). 2007 , 75, 65-71	24
905	Angiographic coronary artery disease is associated with progressively higher levels of fasting plasma glucose. 2007 , 75, 207-13	12
904	Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes. 2007 , 77, 70-6	33
903	Hypertension in people with diabetes in sub-Saharan Africa: revealing the hidden face of the iceberg. 2007 , 77, 293-9	39
902	Correlations of urinary albumin excretion and atherosclerosis in Japanese type 2 diabetic patients. 2007 , 77, 414-9	4
901	Statin pre-treatment protects brain against focal cerebral ischemia in diabetic mice. 2007 , 138, 254-8	25
900	D-Psicose inhibits the expression of MCP-1 induced by high-glucose stimulation in HUVECs. 2007 , 81, 592-9	37
899	The influence of a history of diabetes on treatment and outcome in acute myocardial infarction, during two time periods and in two different countries. 2007 , 119, 319-25	13
898	Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. 2007 , 120, 79-84	18
897	High mortality in diabetic patients with acute myocardial infarction: cardiovascular co-morbidities contribute most to the high risk. 2007 , 121, 184-8	21
896	Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. 2007 , 193, 283-91	29
895	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. 2007 , 60, 525.e1-525.e64	7
894	Diabetes mellitus tipo 2 y riesgo cardiovascular. Un modelo de arteriosclerosis precoz y acelerada. 2007 , 19, 143-146	
893	Efecto, en la práctica clínica, de la fluvastatina de liberación prolongada en los lípidos séricos en pacientes con diabetes tipo 2 y dislipemia. 2007 , 19, 240-246	0
892	Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. 2007 , 112, 375-84	247
891	Alterations in energy metabolism in cardiomyopathies. 2007 , 39, 594-607	69
890	Objetivos del tratamiento antihipertensivo en la población diabética: situación actual y perspectivas futuras. 2007 , 33, 219-222	
889	Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. 2007 , 45, 645-654; discussion 653-4	270

888	Vascular Biology Protocols. 2007 ,	1
887	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 16, 135-232	247
886	Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. 2007 , 5, 147-59	6
885	Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach. 2007 , 5, 201-11	3
884	Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). 2007 , 116, 151-7	524
883	Estimating the burden of disease attributable to diabetes in South Africa in 2000. 2007 , 12, 65-71	5
882	Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. 2007 , 64, 1603-10	9
881	Mitochondrial dysfunction in atherosclerosis. 2007 , 100, 460-73	534
880	Assessment of two culturally competent diabetes education methods: individual versus individual plus group education in Canadian Portuguese adults with type 2 diabetes. 2007 , 12, 163-87	32
879	Assessment of the Patient With Diabetes for Coronary Heart Disease Risk: Review and Personal Reflection. 2007 , 31, 153-163	1
878	Current perioperative treatment of patients with type 1 and type 2 diabetes. 2007 , 24, 365-82; vii	2
877	[Effect of a global intervention in the integral control of multiple risk factors in patients at high or very high cardiovascular risk. CIFARC 2 project]. 2007 , 207, 112-20	7
876	Factores predictivos del riesgo de enfermedad cardiovascular en los pacientes con diabetes tipo 2 e hipercolesterolemia. Estudio ESODIAH. 2007 , 60, 251-258	2
875	[Prognostic value of high blood pressure in diabetic patients]. 2007 , 128, 495-7	
874	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. 2007 , 60, 968.e1-94	29
873	¿La diabetes mellitus es un equivalente de riesgo coronario? Resultados de un metaanálisis de estudios prospectivos. 2007 , 60, 1167-1176	17
872	Efectos beneficiosos de la adición de ezetimiba a dosis máximas de estatinas en el control de los lípidos séricos en pacientes con diabetes mellitus tipo 2. 2007 , 54, 139-144	
871	Factors Predictive of Cardiovascular Disease in Patients With Type-2 Diabetes and Hypercholesterolemia. ESODIAH Study. 2007 , 60, 251-258	1

870	Is Diabetes Mellitus a Coronary Heart Disease Equivalent? Results of a Meta-Analysis of Prospective Studies. 2007 , 60, 1167-1176	
869	Lifestyle and outcome among patients with type 2 diabetes. 2007 , 1303, 160-171	6
868	The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. 2007 , 49, 1772-80	321
867	Additional prognostic value of coronary flow reserve in diabetic and nondiabetic patients with negative dipyridamole stress echocardiography by wall motion criteria. 2007 , 50, 1354-61	145
866	Rosiglitazone for type 2 diabetes mellitus. 2007 , CD006063	49
865	Management of hypertension in diabetes mellitus. 2007 , 2, 341-357	
864	[The role of post-prandial lipids in atherogenesis: particularities of diabetes mellitus]. 2007 , 51, 222-31	3
863	Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus. 2007 , 20, 118-23	18
862	Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. 2007 , 12, 2957-66	106
861	Silent myocardial ischemia screening in patients with diabetes mellitus. 2007 , 51, 285-93	16
860	[Cardiovascular disease in diabetes mellitus: classical and non-classical risk factors]. 2007 , 51, 257-67	7
859	Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. 2007 , 117, 3930-9	225
858	Adiponectin gene and cardiovascular risk in type 2 diabetic patients: a review of evidences. 2007 , 51, 153-9	15
857	[State-of-the-art in the treatment of chronic coronariopathy in diabetic patients: evidences and controversies based in clinical trials]. 2007 , 51, 319-26	
856	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. 2007 , 3, 71-99	1
855	Risk factors of atherosclerotic diseases. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerosis cardiovascular diseases for Japanese. 2007 , 14, 267-77	44
854	Current perspectives on hypertension and metabolic syndrome. 2007 , 13, S3-5	11
853	Diabetes Mellitus. 2007 , 697-711	1

852	Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. 2007 , 13, 11-6	41
851	All-cause mortality among Japanese-Brazilians according to nutritional characteristics. 2007 , 23, 2145-56	3
850	Metabolic effects of a conversion from rosiglitazone to pioglitazone in Native American patients with type 2 diabetes. 2007 , 20, 349-53	2
849	. 2007 ,	2
848	Diabetes and Stroke / Transient Ischaemic Attacks. 175-198	
847	Diabetes for Cardiologists. 258-279	
846	Effectiveness of a specialist nurse-led intervention clinic in the management of cardiovascular risk factors in diabetes. 2007 , 4, 100-105	6
845	Physiopathologie de la dyslipidémie du syndrome métabolique et du diabète de type 2. 2007 , 21, 9-16	5
844	Serum leptin and its relation to anthropometric measures of obesity in pre-diabetic Saudis. 2007 , 6, 18	13
843	'Correction:' Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with pre-existent coronary artery disease. 2007 , 6, 19	14
842	Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. 2007 , 6, 20	62
841	Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study. 2007 , 6, 25	17
840	The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. 2007 , 6, 35	55
839	A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. 2007 , 16, 1065-71	71
838	Metabolic syndrome: from global epidemiology to individualized medicine. 2007 , 82, 509-24	121
837	Glucose, insulin, diabetes and mechanisms of arterial dysfunction. 2007 , 34, 677-82	60
836	ISPAD Clinical Practice Consensus Guidelines 2006-2007. Microvascular and macrovascular complications. 2007 , 8, 163-70	77
835	Dyslipidemia and other cardiovascular risk factors in a Canadian First Nation pediatric population with type 2 diabetes mellitus. 2007 , 8, 384-90	35

834	Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. 2007 , 9, 127-9	21
833	Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. 2007 , 9, 81-6	25
832	Dyslipidaemia in diabetic patients: time for a rethink. 2007 , 9, 609-16	19
831	Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. 2007 , 9, 767-80	157
830	Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. 2007 , 24, 541-9	32
829	Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). 2007 , 24, 1313-21	27
828	The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study. 2007 , 24, 1352-60	15
827	Hyperglycaemia and cardiovascular disease. 2007 , 262, 145-56	42
826	Impact of adherence to statins on coronary artery disease in primary prevention. 2007 , 63, 698-708	74
825	Managing Comorbid Disorders in the Uremic Diabetic Patient. 2007 , 10, 225-230	2
824	Postchallenge hyperglycaemic spike associate with arterial stiffness. 2007 , 61, 397-402	25
823	Should oral glucose tolerance testing be mandatory following acute myocardial infarction?. 2007 , 61, 680-3	9
822	Glucose tolerance testing for all?. 2007 , 61, 541-3	
821	Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. 2007 , 61, 909-15	52
820	Association of left ventricular diastolic function abnormalities with aortic elastic properties in asymptomatic patients with type 2 diabetes mellitus. A tissue doppler echocardiographic study. 2008 , 62, 1358-65	13
819	Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus. 2007 , 99, 3B-5B	181
818	Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. 2007 , 99, 27B-40B	109
817	Diabetic endovascular disease: role of coronary artery revascularization. 2007 , 99, 105B-112B	19

816	Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 2007 , 99, 4i-20i	155
815	Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. 2007 , 99, 21i-33i	385
814	Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 2007 , 99, 34i-43i	125
813	Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 2007 , 99, 44i-55i	102
812	Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). 2007 , 100, 1336-40	18
811	Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?. 2007 , 116, 287-305	75
810	Racial disparities in diabetes a century ago: evidence from the pension files of US Civil War veterans. 2007 , 64, 1766-75	5
809	Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus. 2016 , 15, 50	19
808	Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. 2016 , 25, 235-40	2
807	The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes. 2016 , 15, 43	30
806	Are active and passive smoking associated with cardiometabolic risk factors in adolescents? The CASPIAN-III Study. 2016 , 36, 181-8	22
805	Diabetes complications in childhood and adolescent onset type 2 diabetes-a review. 2016 , 30, 951-7	33
804	Prevalent diabetes mellitus in patients with heart failure and disease determinants in sub-Saharan Africans having diabetes with heart failure: a protocol for a systematic review and meta-analysis. 2016 , 6, e010097	5
803	Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. 2016 , 15, 1083-93	17
802	No Time to Waste: in Support of Aggressive and Immediate Management of Hypertension. 2016 , 18, 26	3
801	Effects of pharmacist-led patient education on diabetes-related knowledge and medication adherence: A home-based study. 2016 , 75, 421-433	11
800	Gender differences in the relationship between diabetes process of care indicators and cardiovascular outcomes. 2016 , 26, 219-24	12
799	Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. 2016 , 202, 291-6	23

798	Approach to diabetes management in patients with CVD. 2016 , 26, 165-79	28
797	APOA II genotypes frequency and their interaction with saturated fatty acids consumption on lipid profile of patients with type 2 diabetes. 2016 , 35, 907-11	10
796	Sympathovagal balance and 1-h postload plasma glucose in normoglycose tolerant hypertensive patients. 2016 , 53, 41-7	3
795	Type 2 Diabetes. 2016 ,	2
794	Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes. 2016 , 8, 354-62	10
793	Pre-hypertension, pre-diabetes or both: which is best at predicting cardiovascular events in the long term?. 2017 , 31, 382-387	15
792	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. 2017 , 13, 365-374	24
791	Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. 2017 , 33, e2877	2
790	Longitudinal association between fasting blood glucose concentrations and first stroke in hypertensive adults in China: effect of folic acid intervention. 2017 , 105, 564-570	16
789	Evidence-based goals in LDL-C reduction. 2017 , 106, 237-248	55
788	Homozygous carriers of the TCF7L2 rs7903146 T-allele show altered postprandial response in triglycerides and triglyceride-rich lipoproteins. 2017 , 7, 43128	9
787	Survival of macrovascular disease, chronic kidney disease, chronic respiratory disease, cancer and smoking in patients with type 2 diabetes: BioBank Japan cohort. 2017 , 27, S98-S106	16
786	Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. 2017 , 119, 195-207	27
785	Type 2 diabetes. 2017 , 389, 2239-2251	935
784	Electrocardiogram QRS duration and associations with telomere length: A cross-sectional analysis in Australian rural diabetic and non-diabetic population. 2017 , 50, 450-456	2
783	A review of chemical therapies for treating diabetic hypertension. 2017 , 18, 909-923	5
782	Cardiovascular risk assessment in patients with diabetes. 2017 , 9, 25	84
781	MicroRNAs in Diabetes and Its Vascular Complications. 2017 , 39-59	

780	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). 2017 , 136, 1193-1203	33
779	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. 2017 , 19, 62	3
778	VEGF-B: friend or foe to the heart in times of nutrient excess?. 2017 , 313, H244-H247	2
777	Prevalence and determinants of comorbid diabetes and hypertension: Evidence from non communicable disease risk factor STEPS survey, India. 2017 , 11 Suppl 1, S459-S465	24
776	MicroRNA-99a inhibits insulin-induced proliferation, migration, dedifferentiation, and rapamycin resistance of vascular smooth muscle cells by inhibiting insulin-like growth factor-1 receptor and mammalian target of rapamycin. 2017 , 486, 414-422	14
775	Non-coding RNAs in the Vasculature. 2017 ,	
774	Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction. 2017 , 2, 111-114	1
773	Management of Hyperglycemia and Diabetes in Orthopedic Surgery. 2017 , 17, 13	38
772	Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential. 2017 , 172, 50-62	148
771	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. 2017 , 2, 370-380	98
770	Long-term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population-based case-control study. 2017 , 34, 522-530	10
769	Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes. 2017 , 26, 211-218	6
768	The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. 2017 , 6, 1339-1349	45
767	Antidiabetic Drug Alogliptin Protects the Heart Against Ischemia-reperfusion Injury Through GLP-1 Receptor-dependent and Receptor-independent Pathways Involving Nitric Oxide Production in Rabbits. 2017 , 70, 382-389	6
766	'Just like a normal pain', what do people with diabetes mellitus experience when having a myocardial infarction: a qualitative study recruited from UK hospitals. 2017 , 7, e015736	3
765	Diabetes-mediated myelopoiesis and the relationship to cardiovascular risk. 2017 , 1402, 31-42	27
764	Paradox of Appropriate Implantable Cardioverter-Defibrillator Therapy: Saving Lives But Revealing an Increased Mortality Risk. 2017 , 6,	1
763	Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. 2017 , 8, 999-1013	9

762	Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. 2017 , 40, 795-806		44
761	Étude de cohorte des travailleurs postés diabétiques d'une entreprise algérienne (1995-2014). 2017 , 11, 300-306		3
760	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. <i>Diabetes Care</i> , 2017 ,	14.6	53
759	Raman spectroscopy imaging reveals interplay between atherosclerosis and medial calcification in the human aorta. 2017 , 3, e1701156		38
758	Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes. 2017 , 6, 649-657		11
757	A longitudinal study of DNA methylation as a potential mediator of age-related diabetes risk. 2017 , 39, 475-489		36
756	Retinopathy and left ventricular hypertrophy in patients with chronic kidney disease: Interrelationship and impact on clinical outcomes. 2017 , 249, 372-376		3
755	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. 2017 , 18, 1101-1114		7
754	Refining Long-Term Prediction of Cardiovascular Risk in Diabetes - The VILDIA Score. 2017 , 7, 4700		8
753	Protective effects of <i>Cynara scolymus</i> leaves extract on metabolic disorders and oxidative stress in alloxan-diabetic rats. 2017 , 17, 328		30
752	Platelets, diabetes and myocardial ischemia/reperfusion injury. 2017 , 16, 71		42
751	The Immunology of Cardiovascular Homeostasis and Pathology. 2017 ,		7
750	Atherosclerosis. 2017 , 1003, 121-144		37
749	Dual-Imaging Stress Echocardiography for Prognostic Assessment of High-Risk Asymptomatic Patients with Diabetes Mellitus. 2017 , 30, 149-158		7
748	Diabetes mellitus and long-term mortality of ovarian cancer patients. A systematic review and meta-analysis of 12 cohort studies. 2017 , 33, e2868		15
747	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. 2017 , 33, 366-377		19
746	Epac2a-null mice exhibit obesity-prone nature more susceptible to leptin resistance. 2017 , 41, 279-288		16
745	Extrem niedrige LDL-Cholesterinkonzentrationen durch moderne lipidsenkende Therapien. 2017 , 17, 54-57		

744	Protocol for the specialist supervised individualised multifactorial treatment of new clinically diagnosed type 2 diabetes in general practice (IDA): a prospective controlled multicentre open-label intervention study. 2017 , 7, e017493	1
743	[Function of Perivascular Nerves in Insulin Resistance-induced Hypertension]. 2017 , 137, 1367-1371	0
742	. 2017 ,	0
741	Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!. 2017 ,	
740	Prevalence of Conventional Risk Factors in Acute Coronary Syndrome Patients in Eastern Part of Nepal. 2017 , 6, 48-55	0
739	Exposure to High Glucose Concentration Decreases Cell Surface ABCA1 and HDL Biogenesis in Hepatocytes. 2017 , 24, 1132-1149	5
738	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. 2017 , 13, 69-79	6
737	Markers of Oxidative Stress and Antioxidant Defense in Romanian Patients with Type 2 Diabetes Mellitus and Obesity. 2017 , 22,	31
736	Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E-Deficient Mice. 2017 , 1, e92-e100	3
735	Role of Cholesterol in Heart Disease. 2017 ,	
734	Global Trends in Cardiovascular Disease. 2017 , 301-329	3
733	Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. 2017 , 2017, 9842450	0
732	Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros. 2017 , 2017, 8927473	11
731	Prevalence of selected cardiometabolic risk factors among adults in urban and semi-urban hospitals in four sub-Saharan African countries. 2017 , 28, 147-153	4
730	ATIVIDADE FÍSICA E MODULAÇÃO DO RISCO CARDIOVASCULAR. 2017 , 23, 21-25	6
729	Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications. 2017 , 17, 67	8
728	Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. 2017 , 16, 143	34
727	The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. 2017 , 16, 207	56

726	Risk prediction for Korean shift workers in Y power plant to prevent cardiovascular disease. 2017 , 9, 222-228		
725	Medicina interna perioperatoria - Il paziente chirurgico complesso: il ruolo dell'Internista nell'ospedale snello, a misura del paziente, organizzato per intensit� di cure. 2017 , 5, 1		0
724	[Management of diabetes in patients with hypertension]. 2017 , 34 Suppl 2, 30-34		1
723	Effect of Dyslipidaemia on Arrhythmia in Diabetic Patients. 2017 , 46, 20-24		
722	Metabolic syndrome remission after Roux-en-Y gastric bypass or sleeve gastrectomy. 2017 , 10, 393-402		19
721	The association of triglycerides and total cholesterol concentrations with newly diagnosed diabetes in adults in China. 2017 , 8, 103477-103485		9
720	Evaluating personality as a moderator of the association between life events stress and cardiovascular reactivity to acute stress. 2018 , 126, 52-59		24
719	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. 2018 , 11, 2-14		4
718	Current practice of usual clinic blood pressure measurement in people with and without diabetes: a survey and prospective 'mystery shopper' study in UK primary care. 2018 , 8, e020589		7
717	The Role of and Its Contributions to the Field of Diabetes: A Profile in Progress. <i>Diabetes Care</i> , 2018 , 41, 241-249	14.6	1
716	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. 2018 , 39, 2255-2262		28
715	Risk of acute coronary syndrome and peripheral arterial disease in chronic liver disease and cirrhosis: A nationwide population-based study. 2018 , 270, 154-159		16
714	Coronary artery plaque characterization using MDCT in symptomatic and asymptomatic subgroups of diabetic and non-diabetic population-a comparative retrospective study. 2018 , 34, 355-364		0
713	Accounting for Selection Bias in Studies of Acute Cardiac Events. 2018 , 34, 709-716		11
712	Reduced Long-Term Risk of Aortic Aneurysm and Aortic Dissection Among Individuals With Type 2 Diabetes Mellitus: A Nationwide Observational Study. 2018 , 7,		37
711	Bayesian multivariate meta-analysis of multiple factors. 2018 , 9, 261-272		9
710	Blood Pressure Control and Cardiovascular/Renal Outcomes. 2018 , 47, 175-184		8
709	No Impact of Pre-existing Cardiovascular Disease on Prescribing Patterns of Sulphonylureas in Denmark - A Registry-based Nationwide Study. 2018 , 122, 606-611		1

708	Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80 mmHg: What's the Evidence?. 2018 , 42, 166-172		2
707	Prospective, Cluster-Randomized Trial to Implement the Ottawa Model for Smoking Cessation in Diabetes Education Programs in Ontario, Canada. <i>Diabetes Care</i> , 2018 , 41, 406-412	14.6	8
706	One-hour glucose value as a long-term predictor of cardiovascular morbidity and mortality: the Malm ^o Preventive Project. 2018 , 178, 225-236		11
705	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 2018 , 137, 1571-1582		198
704	Metformin monotherapy for adults with type 2 diabetes mellitus. 2018 ,		3
703	Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. 2018 , 23, 419-437		53
702	Association Between Metabolic Syndrome and Microvascular and Macrovascular Disease in Type 2 Diabetic Mellitus. 2018 , 355, 342-349		7
701	SNP in microRNA sequences or binding sites of miRNAs: association with type 2 diabetes mellitus susceptibility and in silico analysis. 2018 , 38, 330-337		1
700	[Type 2 Diabetes and Vascular Endothelial Dysfunction]. 2018 , 40, 65-75		9
699	Influence of Diabetes Mellitus on Outcomes in Patients After Left Ventricular Assist Device Implantation. 2018 , 106, 555-560		6
698	Treatment outcomes in diabetic patients with chronic limb-threatening ischemia. 2018 , 68, 487-494		11
697	Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?. 2018 , 44, 143-149		22
696	Mortality and Macrovascular Risk in Elderly With Hypertension and Diabetes: Effect of Intensive Drug Therapy. 2018 , 31, 220-227		7
695	Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction. 2018 , 10, 200-212		2
694	Diabetes Mellitus and Exercise Physiology in the Presence of Diabetic Comorbidities. 2018 , 255-287		
693	Carbohydrate restriction with postmeal walking effectively mitigates postprandial hyperglycemia and improves endothelial function in type 2 diabetes. 2018 , 314, H105-H113		12
692	Coronary artery bypass grafting versus percutaneous coronary intervention in patients with noninsulin treated type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. 2018 , 34, e2951		4
691	Blood Pressure-Lowering Targets in Patients With Diabetes Mellitus. 2018 , 34, 644-652		0

690	The role of urotensin-II and its receptors in sepsis-induced lung injury under diabetic conditions. 2018 , 818, 457-469	19
689	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice	2178
688	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 71, e13-e115	1567
687	Target Blood Pressure in Patients with Diabetes. 2018 , 19, 7	
686	Mitochondria and Heart Disease. 2018 ,	
685	FORMULATION OF IMMEDIATE RELEASE (IR) ATORVASTATIN CALCIUM PELLETS AND SUSTAINED RELEASE (SR) GLIBENCLAMIDE FOR FIXED-DOSE COMBINATION DOSAGE FORM. 2018 , 11, 159	1
684	Cardiovascular Diseases in Patients with Renal Transplantation. 2018 ,	
683	OBSOLETE: Diabetes Mellitus. 2018 ,	
682	Risk factors for self-reported diabetes among Bhutanese adults: A nationally representative survey data analysis. 2018 , 13, e0206034	2
681	Cardiac troponin I, fructosamine, and cardiovascular parameters in dogs with diabetes mellitus. 2018 , 50, 129-133	
680	Psychological interventions for behavioral adjustments in diabetes care - a value-based approach to disease control. 2018 , 11, 145-155	6
679	Health care and therapeutic education program for newly diagnosed type 2 diabetes: A new approach in primary care. 2018 , 65, 486-499	1
678	The First Harmonic of Radial Pulse as an Early Predictor of Silent Coronary Artery Disease and Adverse Cardiac Events in Type 2 Diabetic Patients. 2018 , 2018, 5128626	6
677	Intravascular evaluation of coronary atherosclerotic lesions among Egyptian diabetic patients with acute coronary syndromes. 2018 , 70, 237-241	0
676	Health care and therapeutic education program for newly diagnosed type 2 diabetes: A new approach in primary care. 2018 , 65, 486-499	4
675	Cardiovascular sexual dimorphism in a diet-induced type 2 diabetes rodent model, the Nile rat (<i>Arvicanthis niloticus</i>). 2018 , 13, e0208987	6
674	Principle of Management of Type 2 Diabetes: From Clinical, Public Health and Research Perspectives. 2018 ,	1
673	Ethnic Diversities, Hypertension and Global Cardiovascular Risk. 2018 ,	

672	Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. 2018 , 103, 3611-3619	18
671	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 138, e484-e594	242
670	Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study. 2018 , 17, 236	13
669	Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients. 2018 , 10, e3030	2
668	Long-term Prognosis and Clinical Characteristics of Patients with Newly Diagnosed Diabetes Mellitus Detected after First Acute Myocardial Infarction: from KAMIR-NIH Registry. 2018 , 48, 134-147	5
667	Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. 2018 , 35, 1742-1751	14
666	How is Bariatric Surgery Improving the Quality of Life of Obese Patients: A Portuguese Cross-Sectional Study. 2018 , 31, 391-398	5
665	Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. 2018 , 123, 886-904	90
664	Urinary sodium-to-potassium ratio and serum asymmetric dimethylarginine levels in patients with type 2 diabetes. 2018 , 41, 913-922	6
663	Hypertension Management in Diabetes: 2018 Update. 2018 , 31, 218-224	24
662	Optimizing adult diabetes care in community health. 2018 , 30, 443-449	1
661	Long-term mono- or dual-combination empagliflozin treatment for adults with type 2 diabetes mellitus. 2018 ,	78
660	The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. 2018 , 4, 1-6	38
659	GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. 2018 , 2018, 4020492	51
658	Fibrin Clot Strength in Patients with Diabetes Mellitus Measured by Thrombelastography. 2018 , 2018, 4543065	6
657	The Effect of Thyroid Dysfunction on the Cardiovascular Risk of Type 2 Diabetes Mellitus Patients in Ghana. 2018 , 2018, 4783093	3
656	Impact of the Discordance Between the American College of Cardiology/American Heart Association and American Diabetes Association Recommendations on Hypertension in Patients With Diabetes Mellitus in the United States. 2018 , 72, 256-259	6
655	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. 2018 , 7,	32

654	Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control. 2018 , 2018, 1067853		12
653	Influence of improvement or worsening of glucose tolerance on risk of stroke in persons with impaired glucose tolerance. 2018 , 13, 941-948		
652	Cerebral Ischemic Reperfusion Injuries (CIRI). 2018 ,		
651	Diabetes Mellitus. 2018 , 9-16		1
650	Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials. 2018 , 143, 34-42		5
649	The optimal blood pressure target in diabetes mellitus: a quest coming to an end?. 2018 , 32, 641-650		9
648	HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?. 2018 , 20, 66		30
647	Development of an algorithm to link electronic health record prescriptions with pharmacy dispense claims. 2018 , 25, 1322-1330		6
646	ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents. 2018 , 19 Suppl 27, 262-274		118
645	Fiber Intake and Insulin Resistance in 6374 Adults: The Role of Abdominal Obesity. 2018 , 10,		9
644	Effects of High Blood Pressure on Cardiovascular Disease Events Among Chinese Adults With Different Glucose Metabolism. <i>Diabetes Care</i> , 2018 , 41, 1895-1900	14.6	11
643	Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. 2018 , 17, 53		11
642	Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology. 2018 , 17, 21		11
641	Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. 2018 , 36, 1921-1928		1
640	Need for fixed combination therapy in type-2 diabetes: Findings from the SMART study. 2018 , 25, 1520-1522		
639	Endocrine Hypertension. 2018 , 390-401		
638	Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. 2018 , 25, 27-39		185
637	Dyslipidemia in Diabetes. 2019 , 186-198		2

636	Effect of Home Enteral Nutrition on Diabetes and Its Management. 2019 , 34, 250-256	3
635	Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial. 2019 , 21, 2712-2717	6
634	Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes. 2019 , 10, 2042018819861593	12
633	Atherosclerosis Pathogenesis and Microvascular Dysfunction. 2019 ,	2
632	Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. 2019 , 35, 431-441	2
631	Long-term prognostic value of coronary computed tomography angiography for asymptomatic patients with CAD in type 2 diabetes mellitus. 2019 , 18, 747-754	1
630	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. 2019 , 11, 1285-1303	13
629	Trauma in the Diabetic Limb. 2019 , 36, 499-523	1
628	The association between metabolic syndrome components and the development of atherosclerosis. 2019 , 33, 844-855	25
627	Progressive LDL Reduction to Very Low Levels Improves Dimeric Nitric Oxide Synthase, Nitric Oxide Bioavailability and Reduces Peroxynitrite in Endothelial Cells during Hyperglycemia. 2019 , 14, 7-16	2
626	Association of genetic and behavioral characteristics with the onset of diabetes. 2019 , 19, 1297	2
625	Gene Editing: Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein (Small 38/2019). 2019 , 15, 1970205	6
624	Orexin A-induced inhibition of leptin expression and secretion in adipocytes reducing plasma leptin levels and hypothalamic leptin resistance. 2019 , 471, 1407-1418	5
623	A data-driven approach to predicting diabetes and cardiovascular disease with machine learning. 2019 , 19, 211	75
622	The effect of guideline revisions on vascular complications of type 2 diabetes. 2019 , 10, 2042018819875408	3
621	Coronary artery calcium in the general population, patients with chronic kidney disease and diabetes mellitus. 2019 , 159-180	
620	Survival, cardiovascular morbidity, and reinterventions after elective endovascular aortic aneurysm repair in patients with and without diabetes: A nationwide propensity-adjusted analysis. 2019 , 24, 539-546	4
619	Smoking in men and women with type 2 diabetes: A qualitative gender-sensitive exploration of barriers to smoking cessation among people with type 2 diabetes. 2019 , 14, e0221783	6

618	Predicting the risk of stroke among patients with type 2 diabetes: a systematic review and meta-analysis of C-statistics. 2019 , 9, e025579	8
617	Long-term Survival and Cardiovascular Morbidity after Elective Open Aortic Aneurysm Repair in Patients with and without Type 2 Diabetes: A Nationwide Propensity-Adjusted Analysis. 2019 , 59, 110-118	4
616	Dimethylguanidino Valerate: A Lifestyle-Related Metabolite Associated With Future Coronary Artery Disease and Cardiovascular Mortality. 2019 , 8, e012846	15
615	Acute cardiovascular complications in patients with diabetes and hypertension: management consideration for minor oral surgery. 2019 , 45, 207-214	2
614	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. 2019 , 40, 1447-1467	85
613	Aortic stenosis and diabetes mellitus: An ominous combination. 2019 , 16, 310-323	20
612	Application of a fuzzy unit hypercube in cardiovascular risk classification. 2019 , 23, 12521-12527	0
611	Cholesterol-Lowering Agents. 2019 , 124, 354-363	17
610	Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend. 2019 , 45, 401-408	17
609	Association between high blood pressure with risk of type 2 diabetes, metabolic syndrome and its predictors: A cross-sectional study. 2019 , 13, 1549-1554	4
608	Metabolic health is more closely associated with decrease in lung function than obesity. 2019 , 14, e0209575	10
607	Metformin: time to review its role and safety in chronic kidney disease. 2019 , 211, 37-42	13
606	Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders. 2019 , 40, 789-824	93
605	Dietary Adherence of Saudi Males to the Saudi Dietary Guidelines and Its Relation to Cardiovascular Diseases: A Preliminary Cross-Sectional Study. 2019 , 6,	5
604	Suppression of Cardiac Autophagy by Hyperinsulinemia in Insulin Receptor-Deficient Hearts Is Mediated by Insulin-Like Growth Factor Receptor Signaling. 2019 , 31, 444-457	4
603	Paraoxonase 1 gene (Q192R) polymorphism confers susceptibility to coronary artery disease in type 2 diabetes patients: Evidence from case-control studies. 2019 , 13, 80-88	7
602	Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats. 2019 , 20,	35
601	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. 2019 , 21 Suppl 1, 6-16	7

600	The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes. 2019 , 21 Suppl 1, 17-27	6
599	Cardiovascular Risk in Type 1 Diabetes Mellitus. 2019 , 10, 773-789	48
598	Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. 2019 , 73, 1291-1299	16
597	The relationship of diabetes, periodontitis and cardiovascular disease. 2019 , 13, 1675-1678	32
596	Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. 2019 , 21, 1455-1463	17
595	Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial. 2019 , 21, 1464-1473	11
594	The association of serum 25-hydroxyvitamin D concentrations with elevated serum ferritin levels in normal weight, overweight and obese Canadians. 2019 , 14, e0213260	4
593	Autumn olive (Thunb.) berry reduces fasting and postprandial glucose levels in mice. 2019 , 13, 11-16	1
592	T-cell senescence contributes to abnormal glucose homeostasis in humans and mice. 2019 , 10, 249	32
591	The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes. 2019 , 21, 35	6
590	Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis. 2019 , 14, e0215362	18
589	[Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)]. 2019 , 131, 124-135	
588	L'optimisation de l'équilibre glycémique permet-elle de réduire les complications macroangiopathiques du diabète?. 2019 , 13, 36-41	1
587	Facteurs de risque et maladies chroniques : le diabète en exemple. 2019 , 13, 9-20	1
586	Impaired blood glucose levels in patients with dyslipidemia: what are the therapeutic implications? The PREVENDIAB study. 2019 , 15, 175-182	0
585	A review on coronary artery disease, its risk factors, and therapeutics. 2019 , 234, 16812-16823	165
584	Genetic determinants of blood pressure traits are associated with carotid arterial thickening and plaque formation in patients with type 2 diabetes. 2019 , 16, 13-21	1
583	[Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia]. 2019 , 139, 807-815	1

582	Clinical implications of cardiovascular outcome trials in type 2 diabetes. 2019 , 44, 192-202	3
581	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. 2019 , 34, 208-230	88
580	Predictive models for bariatric surgery risks with imbalanced medical datasets. 2019 , 280, 1-18	19
579	The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease. 2019 , 26, 101-111	13
578	Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. 2019 , 8, e011295	117
577	Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. 2019 , 9, e024935	13
576	Prevalence and pattern of dyslipidemia in patients with type 2 diabetes mellitus in Zaria, Northwestern Nigeria. 2019 , 34, 123	5
575	Exercise and Cardiovascular Risk among Masters Athletes with Type 2 Diabetes. 2019 , 19, 127	1
574	Prevalence and Risk factors for Silent Myocardial ischemia (PRISM): A clinico observational study in patients of type 2 diabetes. 2019 , 71, 400-405	3
573	Risk factor reduction in type 2 diabetes demands a multifactorial approach. 2019 , 26, 81-91	6
572	Risk and management of pre-diabetes. 2019 , 26, 47-54	20
571	Diabetes and Cardiovascular Disease: an Update. 2019 , 19, 161	20
570	Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study. 2019 , 34, 698-710	2
569	Management of Hypertension. 2019 ,	4
568	Management of Hypertension in Diabetes Mellitus. 2019 , 115-133	
567	Physical Exercise in Chronic Diseases. 2019 , 217-266	4
566	The effect of radial pulse spectrum on the risk of major adverse cardiovascular events in patients with type 2 diabetes. 2019 , 33, 160-164	8
565	Refining risk in diabetes and CAD with SPECT MPI: New insights and future challenges. 2019 , 26, 1103-1106	3

564	Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population. 2020 , 61, 15-22	10
563	Acute and chronic effects of muscle power training on blood pressure in elderly patients with type 2 diabetes mellitus. 2020 , 42, 153-159	4
562	A cross-sectional study to evaluate diabetes management, control and complications in 1631 patients with type 2 diabetes mellitus in Vietnam (DiabCare Asia). 2020 , 40, 70-79	6
561	A Personalized Care Plan Is Positively Associated With Better Clinical Outcomes in the Care of Patients With Type 2 Diabetes: A Cross-Sectional Real-Life Study. 2020 , 44, 133-138	10
560	Novel criteria to exclude the surrogate paradox and their optimalities. 2020 , 47, 84-103	0
559	Deep Learning Techniques for Biomedical and Health Informatics. 2020 ,	21
558	Ablating the Rab-GTPase activating protein TBC1D1 predisposes rats to high-fat diet-induced cardiomyopathy. 2020 , 598, 683-697	1
557	The long-term effectiveness of metabolic control on cardiovascular disease in patients with diabetes in a real-world health care setting - A prospective diabetes management study. 2020 , 14, 274-281	5
556	The quality of medication optimization among patients with transient ischemic attack or minor stroke. 2020 , 3, 36-46	0
555	Sleep heart rate variability assists the automatic prediction of long-term cardiovascular outcomes. 2020 , 67, 217-224	27
554	The Role of Physical Therapists in Fighting the Type 2 Diabetes Epidemic. 2020 , 50, 5-16	12
553	Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α -Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study. 2020 , 13, 3497-3506	0
552	Cardiovascular risk factors control according to diabetes status and prior cardiovascular events in patients managed in different settings. 2020 , 168, 108370	1
551	Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. 2020 , 2020, 9815016	7
550	Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?. <i>Diabetes Care</i> , 2020 , 43, 1684-1686	14.6 0
549	Diabetes and cardiovascular disease: it's time to apply the evidence. 2020 , 9, 586-588	
548	Brahma-Related Gene 1 Deficiency in Endothelial Cells Ameliorates Vascular Inflammatory Responses in Mice. 2020 , 8, 578790	5
547	Early Signs of Atherogenic Features in the HDL Lipidomes of Normolipidemic Patients Newly Diagnosed with Type 2 Diabetes. 2020 , 21,	4

546	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. 2021 , 396, 2019-2082	90
545	Taurine with combined aerobic and resistance exercise training alleviates myocardium apoptosis in STZ-induced diabetes rats via Akt signaling pathway. 2020 , 258, 118225	0
544	Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes. 2020 , 13, 2375-2388	5
543	Blood Pressure, Congestion and Heart Failure with Preserved Ejection Fraction Among Patients with and Without Type 2 Diabetes Mellitus. A Cluster Analysis Approach from the Observational Registry DICUMAP. 2020 , 27, 399-408	0
542	Risk of Cardiovascular Disease and Chronic Kidney Disease According to 2017 Blood Pressure Categories in Diabetes Mellitus. 2020 , 76, 766-775	2
541	Sleep disturbances: one of the culprits of obesity-related cardiovascular risk?. 2020 , 10, 62-72	2
540	Overexpression of YKL-40 (CHI3L1 gene) in patient fluids may be a potential predictive marker for early detection of comorbidity in non-communicable disease. 2020 , 143, 110076	
539	Blood pressure measurement methodology and technology in the SWEET diabetes centers: An international SWEET database survey. 2020 , 21, 1537-1545	4
538	Pathophysiology of atherosclerosis: Association of risk factors and treatment strategies using plant-based bioactive compounds. 2020 , 44, e13449	7
537	Cardiovascular risk factors in children and adolescents with type 1 diabetes in Italy: a multicentric observational study. 2020 , 21, 1546-1555	7
536	A Review: The Prospect of Inhaled Insulin Therapy via Vibrating Mesh Technology to Treat Diabetes. 2020 , 17,	2
535	Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles. 2020 , 127, 1198-1210	11
534	FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. 2020 , 10, 21655	7
533	Association between mandatory health examination attendance and diabetes treatment initiation among employees being treated for hypertension. 2020 , 62, e12183	0
532	Cardiovascular disease risk and the time to insulin initiation for Medicaid enrollees with type 2 diabetes. 2020 , 22, 100241	1
531	Worse cardiovascular prognosis after endovascular surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes. 2020 , 11, 2042018820960294	
530	Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes. 2020 , 7, 582826	2
529	Genetics of diabetes mellitus and diabetes complications. 2020 , 16, 377-390	172

528	An efficient convolutional neural network for coronary heart disease prediction. 2020 , 159, 113408	42
527	Extracellular vesicles in diabetes mellitus induce alterations in endothelial cell morphology and migration. 2020 , 18, 230	17
526	Supporting care for suboptimally controlled type 2 diabetes mellitus in general practice with a clinical decision support system: a mixed methods pilot cluster randomised trial. 2020 , 10, e032594	3
525	Metformin monotherapy for adults with type 2 diabetes mellitus. 2020 , 6, CD012906	9
524	Diabetes and coronary artery disease: not just a risk factor. 2020 , 106, 1357-1364	4
523	Circulating IgGs in Type 2 Diabetes with Atrial Fibrillation Induce IP-Mediated Calcium Elevation in Cardiomyocytes. 2020 , 23, 101036	2
522	Atherosclerotic disease and diabetes mellitus. 2020 , 8, 4	
521	Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor. 2020 , 7, 100	3
520	NADPH Oxidase Inhibition: Preclinical and Clinical Studies in Diabetic Complications. 2020 , 33, 415-434	23
519	Myocardial Changes in Diabetic and Nondiabetic Nonhuman Primates. 2020 , 57, 332-343	2
518	Correlates of autonomic nervous system function in a general population with special reference to HbA: The Nagahama study. 2020 , 163, 108126	2
517	Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. 2020 , 41, 3359-3362	4
516	Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines. 2020 , 22 Suppl 2, 33-42	3
515	Diabetic Cardiomyopathy and Ischemic Heart Disease: Prevention and Therapy by Exercise and Conditioning. 2020 , 21,	20
514	Association between IL-1beta and cardiovascular disease risk in patients with newly diagnosed, drug-naïve type 2 diabetes mellitus: a cross-sectional study. 2020 , 8, 225	3
513	Mechanisms of heart failure with preserved ejection fraction in the presence of diabetes mellitus. 2020 , 3, 1-5	3
512	Incidence of heart failure among diabetic patients with ischemic heart disease: a cohort study. 2020 , 20, 181	1
511	Influence of sex on the incidence of potential coronary artery disease and long-term outcomes in asymptomatic patients with diabetes mellitus. 2020 , 27, 100504	3

510	Left atrial structural and functional remodeling study in type 2 diabetic patients in sub-Saharan Africa: Role of left atrial strain by 2D speckle tracking echocardiography. 2021 , 38, 25-30	
509	The use of glycosylated hemoglobin (HbA1c) as a predictor of the severity of acute coronary syndrome among diabetic patients. 2021 , 190, 609-614	3
508	National diabetes registries: do they make a difference?. 2021 , 58, 267-278	7
507	Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry. 2021 , 26, 149-157	4
506	Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney. 2021 , 231, e13528	12
505	Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction. 2021 , 47, 101211	9
504	The genus <i>Cassia</i> L.: Ethnopharmacological and phytochemical overview. 2020 , 35, 2336	3
503	All-cause mortality, cardiovascular mortality, and incidence of cardiovascular disease according to a screening program of cardiovascular risk in South Korea among young adults: a nationwide cohort study. 2021 , 190, 23-29	1
502	Aerobic or resistance training improves autonomic control of circulation in oophorectomized rats with cardiometabolic dysfunctions: Impact on renal oxidative stress. 2021 , 145, 111181	
501	Lipid reference values in an Irish population. 2021 , 190, 117-127	2
500	Predictors of abnormality in thallium myocardial perfusion scans for type 2 diabetes. 2021 , 36, 180-188	0
499	Diabetes Detection and Sensor-Based Continuous Glucose Monitoring – A Deep Learning Approach. 2021 , 245-268	1
498	Updated management of dyslipidaemia in diabetes: A new step towards more stringent targets. 2021 , 1, 100001	0
497	The prevalence and predictors of Stroke among atrial fibrillation patients attending at Gondar University Referral Hospital, Northwest Ethiopia. 2021 , 9, 2050312121989509	
496	Basic Coagulation Profiles and Platelet Parameters Among Adult Type 1 and Type 2 Diabetes Patients at Dessie Referral Hospital, Northeast Ethiopia: Comparative Cross-Sectional Study. 2021 , 12, 33-42	1
495	An evaluation of lipid profile and pro-inflammatory cytokines as determinants of cardiovascular disease in those with diabetes: a study on a Mexican American cohort. 2021 , 11, 2435	3
494	Diabetes, the kidney and the heart-A tale of metabolic mayhem. 2021 , 14, 9-11	
493	Rate of achievement of therapeutic outcomes and factors associated with control of non-communicable diseases in rural east Malaysia: implications for policy and practice. 2021 , 11, 3812	

492	Casual blood glucose and subsequent cardiovascular disease and all-cause mortality among 159 731 participants in Cohort of Norway (CONOR). 2021 , 9,	
491	A Focused Review of the Metabolic Side-Effects of Clozapine. 2021 , 12, 609240	10
490	Repurposing a Cardiovascular Disease Drug of Cloridarol as hAPP Inhibitor. 2021 , 12, 1419-1427	3
489	Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real-life evidence of Under-treatment from the EPHEBUS registry. 2021 , 51, e13528	3
488	Preoperative Cardiac Diagnostics in Bariatric Patients with Diabetes and Perioperative Morbidity: Results of a Cohort of 258 Patients. 2021 , 31, 2607-2613	1
487	Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial. 2021 , 35, 107840	3
486	Higher long-term cardiovascular morbidity after open surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes - a nationwide observational cohort study. 2021 , 50, 224-230	0
485	Targets identified from exercised heart: killing multiple birds with one stone. 2021 , 6, 23	3
484	Different Indicators of Adiposity and Fat Distribution and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes. 2021 , 29, 837-845	0
483	Changes in diabetes mortality rate in Costa Rica 2007-2017. 2021 , 174, 108749	1
482	Risk of Typical Diabetes-Associated Complications in Different Clusters of Diabetic Patients: Analysis of Nine Risk Factors. 2021 , 11,	1
481	Tailoring the management of hypertension to comorbidities. 2021 , 36, 405-412	0
480	Group Medical Visit and Microfinance Intervention for Patients With Diabetes or Hypertension in Kenya. 2021 , 77, 2007-2018	3
479	Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from Scorzanera Undulata Tubers in Streptozotocin-Induced Diabetic Rats. 2021 , 19, 17-23	
478	Modulation of Antiviral Immunity and Therapeutic Efficacy by 25-Hydroxycholesterol in Chronically SIV-Infected, ART-Treated Rhesus Macaques. 2021 , 36, 1197-1209	2
477	Recommandations r^ tentes dans les dyslipid^ mies du diab^ tique : commentaire ^ partir de trois cas cliniques. 2021 , 15, 329-339	
476	Synthesis and αGlucosidase Inhibition Activity of 2-[3-(Benzoyl/4-bromobenzoyl)-4-hydroxy-1,1-dioxido-2-benzo[[1,2]thiazin-2-yl]-arylacetamides: An In Silico and Biochemical Approach. 2021 , 26,	4
475	Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. 2021 , 44, 897-905	2

474	Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the "Gordian Knot"?. 2021 , 47, 101225	13
473	Long-Term Impact of Diabetes Mellitus on Initially Conservatively Managed Patients With Severe Aortic Stenosis. 2021 , 85, 1083-1092	3
472	Inconvenient relationship of haemoglobin A1c level with endothelial function in type 2 diabetes in a cross-sectional study. 2021 , 11, e045415	0
471	Associations between sleep disturbances, diabetes and mortality in the UK Biobank cohort: A prospective population-based study. 2021 , 30, e13392	1
470	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. 2021 , 41, 2237-2251	2
469	Reactive Hyperglycaemia Connected with Low Glycated Haemoglobin âRisk Factor for Cardiovascular Adverse Events. 2021 , 2, 85-96	
468	Gaps in achieving coverage of diabetes treatments in low-income and middle-income countries. 2021 , 2, e306-e307	1
467	Incidence, predictors, and clinical impact of bleeding recurrence in patients with prior gastrointestinal bleeding undergoing LAAC. 2021 , 44, 1216-1223	2
466	Randomized Controlled Trial of Simple Salt Reduction Instructions by Physician for Patients with Type 2 Diabetes Consuming Excessive Salt. 2021 , 18,	
465	Diabetes induces remodeling of the left atrial appendage independently of atrial fibrillation in a rodent model of type-2 diabetes. 2021 , 20, 149	2
464	Lipids Abnormality and Type 2 Diabetes Mellitus: Causes and Consequences.	
463	Association between periodontal inflammation and serum lipid profile in a healthy population: A cross-sectional study. 2021 , 56, 1037-1045	1
462	Perioperative challenges in management of diabetic patients undergoing non-cardiac surgery. 2021 , 12, 1255-1266	0
461	Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort. 2021 , 290, 1219-1232	5
460	Coffee consumption and cardiovascular diseases and mortality in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of cohort studies. 2021 , 31, 2526-2538	5
459	1,5-Anhydroglucitol in type 2 diabetes mellitus patients with ST elevation myocardial infarction.. 2021 , 18, 52-57	0
458	Endothelial connexin-integrin crosstalk in vascular inflammation. 2021 , 1867, 166168	1
457	Cardiovascular Disease Risk Assessment in Diabetes. 2021 , 22, 168-173	

- 456 ADVANCE research 20 years later. **2021**, 36-45
- 455 Cross talk between complete blood count and progression of type II diabetes mellitus. **2021**, 33, 101492 2
- 454 [Factors associated with the optimum simultaneous control of diabetes, arterial hypertension and hypercholesterolemia in the diabetic population. BPC Diabetes study]. **2021**,
- 453 Protein overexpression of toll-like receptor 4 and myeloid differentiation factor 88 in oral squamous cell carcinoma and clinical significance. **2021**, 22, 786
- 452 Supplemental nutrition assistance program 2009 expansion and cardiometabolic markers among low-income adults. **2021**, 150, 106678 0
- 451 Prognostic Impact of Prediabetes on Patient Outcomes After Coronary Artery Bypass Grafting: A Single-center Cohort Study. **2021**, 20, 220-225
- 450 Prevalence and pattern of dyslipidemia in an Egyptian children and adolescents with type 1 diabetes. **2021**, 69, 1
- 449 Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Poorly Controlled Type 2 Diabetes: A Retrospective Study. **2021**, 3
- 448 Treatment of Hypertension in Patients with Diabetes Mellitus: a Contemporary Approach. **2021**, 23, 14 1
- 447 Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats. **2021**, 22, 3
- 446 Epidemiology of Macrovascular Disease and Hypertension in Diabetes Mellitus. 2
- 445 The Global Burden of Diabetes. 69-84 6
- 444 Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes. **2007**, 211-218 5
- 443 Autonomic Neuropathy and Heart Disease. **1998**, 209-226 1
- 442 Endothelins in the microvasculature and heart in diabetes. **2001**, 498, 97-108 2
- 441 The plasma glucose level--a continuous risk factor for vascular disease in both diabetic and non-diabetic people. **2001**, 498, 35-9 3
- 440 Smoking and Diabetic Nephropathy. **1998**, 209-216 1
- 439 Insulin Resistance and Blood Pressure. **1999**, 281-308 1

438	Obesity and Insulin Resistance. 1999 , 51-81	8
437	Treatment of Hypertension in the Elderly Patient With Diabetes. 2005 , 451-469	1
436	The Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity. 2009 , 3-54	4
435	Rat models of cardiac insulin resistance. 2007 , 139, 113-43	1
434	Diabetes Detection Using ECG Signals: An Overview. 2020 , 299-327	4
433	Interval Type-2 Fuzzy Logic Based Decision Support System for Cardiac Risk Assessment. 2020 , 995-1008	1
432	Atherosclerosis and Diabetic Nephropathy. 2019 , 357-372	1
431	Myocardial Perfusion Scintigraphy in Diabetes: Current Status and Limitations. 2009 , 305-323	1
430	Methylxanthines and human health: epidemiological and experimental evidence. 2011 , 509-48	32
429	Systemic Hypertension. 2002 , 1015-1064	2
428	Effects of early serum glucose levels on prognosis of patients with acute intracerebral hemorrhage. 2011 , 111, 393-7	6
427	Heart Disease Prediction System Using Intelligent Network. 2015 , 1377-1384	3
426	NHG-Standaard Cardiovasculair risicomanagement. 2011 , 361-408	1
425	The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. 1995 , 38, 318	7
424	Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. 1995 , 38, 585	6
423	Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. 1995 , 38, 1313	13
422	Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. 1996 , 39, 453	7
421	Type 2 Diabetes Mellitus. 2011 , 1371-1435	18

420	Complications of Diabetes Mellitus. 2011 , 1462-1551	7
419	D'ordres glyc' miques. 2010 , 51-76	1
418	High prevalence of arterial hypertension in a Brazilian Northeast population of low education and income level, and its association with obesity and metabolic syndrome. 2012 , 58, 209-214	6
417	Lipid Management. 2007 , 13, 40-47	0
416	Avant-propos Ars longaâudicium difficile . Lâexemple des recommandations dans les dyslipid' mies du diab' tique. 2018 , 12, 248-254	1
415	Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. 2001 , 249, 225-35	132
414	Metabolic syndrome, diabetes, and coronary heart disease. 2005 , 311-330	1
413	Diabetes Mellitus and Metabolic Syndrome. 2009 , 465-496	4
412	Cardiac and plasma catecholamine responses to exercise in patients with type 2 diabetes: prognostic implications for cardiac-cerebrovascular events. 2000 , 320, 24-30	16
411	Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. 2004 , 11, 412-415	36
410	Helicobacter pylori and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study. 2004 , 11, 471-476	8
409	Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. 2008 , 18, 279-87	49
408	Mortality in relation to smoking: 40 years' observations on male British doctors. 1994 , 309, 901-11	1180
407	Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study. 1996 , 313, 660-3	29
406	Differences in mortality and morbidity in African Caribbean and European people with non-insulin dependent diabetes mellitus: results of 20 year follow up of a London cohort of a multinational study. 1996 , 313, 848-52	57
405	Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. 1996 , 16, 1236-42	84
404	Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. 1995 , 91, 979-89	342
403	Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. 1996 , 94, 26-34	45

402	Relationship to blood pressure of combinations of dietary macronutrients. Findings of the Multiple Risk Factor Intervention Trial (MRFIT). 1996 , 94, 2417-23	157
401	Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). 1997 , 96, 1761-9	407
400	Hyperglycemia, hyperinsulinemia, overweight, and high blood pressure in young adults: the Rio de Janeiro Study. 1997 , 30, 650-3	15
399	Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. 1996 , 27, 210-5	190
398	Risk factors for death from stroke in middle-aged Lithuanian men: results from a 20-year prospective study. 1996 , 27, 672-6	19
397	HDL Cholesterol Level Predicts Survival in Men After Coronary Artery Bypass Graft Surgery. 2000 , 102,	2
396	The association of cardiovascular disease with impaired health-related quality of life among patients with type 2 diabetes mellitus. 2014 , 55, 209-16	6
395	Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. 2006 , 116, 1071-80	251
394	Pathophysiology and Clinical Management of Diabetes and Prediabetes. 2006 , 15-44	1
393	Diabetes Mellitus and Long-Term Risk for Heart Failure After Coronary Revascularization. 2020 , 84, 471-478	3
392	Prognostic Value of Hemoglobin A1c Levels in Postmenopausal Diabetic Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Coronary Syndrome. 2018 , 24, 9399-9405	1
391	Longevity-Associated Forkhead Box O3 (FOXO3) Single Nucleotide Polymorphisms are Associated with Type 2 Diabetes Mellitus in Chinese Elderly Women. 2019 , 25, 2966-2975	5
390	CVD prevention in diabetes. 2007 , 2007,	1
389	Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients. 2012 , 7, e52229	28
388	Genomic and metabolic disposition of non-obese type 2 diabetic rats to increased myocardial fatty acid metabolism. 2013 , 8, e78477	17
387	Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1. 2013 , 8, e80009	33
386	Increased risk of ischemic stroke after hyperosmolar hyperglycemic state: a population-based follow-up study. 2014 , 9, e94155	7
385	Twelve-Year Cardiovascular and Mortality Risk in Relation to Smoking Habits in Type 2 Diabetic and Non-Diabetic Men: Tehran Lipid and Glucose Study. 2016 , 11, e0149780	11

384	Influence of diabetes mellitus duration on the efficacy of ischemic preconditioning in a Zucker diabetic fatty rat model. 2018 , 13, e0192981	21
383	Modern antihyperglycemic therapy: safety and efficacy of glimepiride. 2012 , 15, 89-97	1
382	Impact of diabetes on cardiomyocyte apoptosis and connexin43 gap junction integrity: role of pharmacological modulation. 2007 , 48, 233-45	21
381	Five-year angiographic outcome in patients without restenosis following coronary balloon angioplasty: a comparison between non diabetic and diabetic lesions. 2003 , 44, 31-9	3
380	Value of diagnostic tools for myocardial ischemia used in routine clinical practice to predict cardiac events in patients with type 2 diabetes mellitus: a prospective study. 2006 , 50, 46-52	4
379	Aspirin therapy is still underutilized among patients with type 2 diabetes. 2006 , 50, 1014-9	1
378	[Percutaneous coronary intervention in diabetes mellitus: an updated analysis of medical practice]. 2007 , 51, 327-33	2
377	Physical Activity for the Prevention of Cardiometabolic Disease. 2017 , 79-99	7
376	[An assessment of cerebrolysin effect on BDNF level in patients with post stroke aphasia depending on carbohydrate metabolism disorders]. 2015 , 115, 57-63	3
375	[Specific features of neurological complications developing in patients with type 2 diabetes mellitus and metabolic syndrome: possibility for correction and prevention]. 2015 , 87, 109-114	3
374	Ultrasound measurement of peripheral endothelial dysfunction in type 2 diabetic patients: correlation with risk factors. 2010 , 10, 84-8	3
373	Stroke risk factors in patients with end-stage kidney disease: current status of the problem. 2020 , 101, 825-833	1
372	Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction. 2004 , 1, 175-84	23
371	The association of silent coronary artery disease and metabolic syndrome in Chinese with type 2 diabetes mellitus. 2004 , 1, 18-28	4
370	The prognostic significance of serum glucose levels after the onset of ventricular arrhythmia on in-hospital mortality of patients with acute coronary syndrome. 2008 , 5, 47-51	2
369	New frontiers in the treatment of diabetic dyslipidemia. 2013 , 10, 204-12	4
368	In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. 2005 , 1, 19-28	73
367	Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. 2006 , 2, 203-12	31

366	Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes. 2008 , 4, 123-30	24
365	Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors. 2020 , 27, 4494-4521	0
364	From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus. 2020 , 16, 230-237	9
363	Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection. 2020 , 16, 869-873	1
362	Docosahexaenoic Acid Inhibits Vascular Smooth Muscle Cell Proliferation Induced by Glucose Variability. 2017 , 11, 56-65	9
361	Therapeutic Duplication in Taiwan Hospitals for Patients With High Blood Pressure, Sugar, and Lipids: Evaluation With a Mobile Health Mapping Tool. 2020 , 8, e11627	4
360	Primary prevention strategy for cardiovascular disease in Lithuania. 2019 , 25, 14-39	4
359	Hypertension and Diabetes. 2007 , 417-436	0
358	Diabetes Mellitus and Cardiovascular Disease in the Elderly. 2008 , 179-214	2
357	Estimating Lifetime Duration of Diabetes by Age and Gender in the Korean Population Using a Markov Model. 2019 , 34, e74	4
356	Short-term administration of melatonin or ghrelin on diabetic rats: effects on angiotensin II and vasopressin-induced uterine contractility. 2017 , 66, 125-133	2
355	Diabetic dyslipidemia: evaluation and mechanism. 2019 , 1, 30-35	6
354	Protective effect of silymarin in streptozotocin-induced diabetic dyslipidaemia in rats. 2010 , 10, 165-172	1
353	Early detection of asymptomatic coronary artery disease in patients with type 2 diabetes mellitus. 2009 , 24, 183-9	9
352	Effect of Hexane Extract of Cassia fistula Barks on Blood Glucose and Lipid Profile in Streptozotocin Diabetic Rats. 2008 , 4, 292-296	26
351	Prevalence of Dyslipidemic Phenotypes Including Hyper-apoB and Evaluation of Cardiovascular Disease Risk in Normocholesterolemic Type 2 Diabetic Patients. 2006 , 9, 1536-1541	3
350	Randomized, Open Label, Multicenter Clinical Trial about the Effect of Cilazapril on Vascular Endothelial Function in Patients with Type 2 Diabetes Combined with Hypertension. 2006 , 30, 450	1
349	The Changes of Central Aortic Pulse Wave Analysis in Metabolic Syndrome. 2008 , 32, 522	3

348	Serum uric acid and low-density lipoprotein cholesterol levels are independent predictors of coronary artery disease in Asian Indian patients with type 2 diabetes mellitus. 2016 , 7, 161-5	16
347	Estimation of 10-Year Risk of Coronary Heart Disease in Nepalese Patients with Type 2 Diabetes: Framingham Versus United Kingdom Prospective Diabetes Study. 2015 , 7, 347-55	4
346	Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population. 2016 , 5, 82	7
345	Which Components of Metabolic Syndrome have a Greater Effect on Mortality, CVA and Myocardial Infarction, Hyperglycemia, High Blood Pressure or Both?. 2017 , 6, 121	5
344	Diabetes as "Coronary Artery Disease Risk Equivalent": A Historical Perspective. 2017 , 18, 34-37	14
343	Effect of 6 Months of Meditation on Blood Sugar, Glycosylated Hemoglobin, and Insulin Levels in Patients of Coronary Artery Disease. 2018 , 11, 122-128	9
342	High-density lipoprotein: Quality versus quantity in type 2 diabetes mellitus. 2019 , 8, 193	2
341	Atherosclerosis: A Link between Lipid Intake and Protein Tyrosine Nitration. 2008 , 2, LPI.S1030	6
340	Effects of Walnut on Lipid Profile as Well as the Expression of Sterol-Regulatory Element Binding Protein-1c(SREBP-1c) and Peroxisome Proliferator Activated Receptors &i>&i> (PPAR&i>&i>) in Diabetic Rat. 2012 , 03, 255-259	7
339	Efficacy and Safety of Insulin Glulisine in Intensive Insulin Therapy: Bolus Insulin Adjust Nice Control by apiDRA Study (BANDRA Study). 2015 , 05, 28-35	1
338	Association between Socio-Demographic Factors and Blood Sugar Levels in Type 2 Diabetes Mellitus Patients in Bangladesh. 2017 , 07, 151-159	5
337	Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Disease (CAD) in Patients with Angina Pectoris. 2013 , 03, 97-101	4
336	Comparison of the Hypoglycemic, Hypolipidemic and Hepatoprotective Effects of&i>&i> Asparagus racemosus&i>&i> Linn. in Combination with Gliclazide and Pioglitazone on Alloxan-Induced Diabetic Rats. 2017 , 08, 52-74	2
335	Evaluation of antihypertensive therapy in diabetic hypertensive patients: impact of ischemic heart disease. 2009 , 7, 40-6	6
334	Atypical presentation of acute and chronic coronary artery disease in diabetics. 2014 , 6, 802-13	21
333	A National Chronic Disease Management Model and Evaluation of Validity of Primary Care Physician(PCP) Model in Korea. 2009 , 19, 92-108	3
332	Estimation of absolute cardiovascular risk in individuals with diabetes mellitus: rationale and approaches. 2011 , 2011, 242656	7
331	Apoptosis induced by 7-ketocholesterol is enhanced in smooth muscle cells derived from OLETF rats. 2005 , 12, 92-7	4

- 330 The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue. **2017**, 5, e3664 7
- 329 Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study. **2020**, 8, e9905 1
- 328 Association of Risk Estimates of Three Different Cardiovascular Risk Assessment Tools with Carotid Intima Media Thickness in Patients with Type 2 Diabetes. **2016**, 10, OC09-12 4
- 327 Cardioprotective effects of GLP-1(9-36) against oxidative injury in H9c2 cardiomyoblasts: Potential role of PI3K/Akt/NOS pathway. **2021**, 2
- 326 Classer les diab tes qui surviennent chez lâ dulte : plus on y pense, plus câ st confus. **2021**,
- 325 Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy?. **2021**, 12, 760581 2
- 324 Cardiovascular Risk Calculators and their Applicability to South Asians. **2021**, 17, e100120186497
- 323 Insulin resistance: A pathogenic link between cardiovascular risk factors and atherosclerosis. **2000**, 171-178
- 322 Scientific Basis for New Guidelines for the Treatment of Hypertension in Type 2 Diabetes. **2000**, 611-621
- 321 Update of the Latest Intervention Trials in Hypertension and Type 2 Diabetes. **2000**, 601-610
- 320 Microalbuminuria and Cardiovascular Disease. **2000**, 39-53
- 319 Carbohydrate Metabolism and Aging. **2000**, 205-236
- 318 Glukose. **2001**, 605-805
- 317 Diabetes-mellitus-assoziierte kardiovaskul re Risikofaktoren. **2001**, 116-122
- 316 Hyperhomocysteinemia, Diabetes, and Cardiovascular Disease. **2001**, 127-145 3
- 315 Lipidstoffwechsel und Diabetes. **2001**, 271-286
- 314 Diabetes: A Growing CHD Epidemic. **2002**, 109-114
- 313 Vascular Disease in Diabetes Mellitus. **2002**, 995-1008

312 Hypertension, Diabetes and the Heart. **2002**, 65-84

311 Special Therapeutic Considerations. **2002**, 231-257

310 Management of Patients with Diabetes and Coronary Artery Disease. **2002**, 185-209

1

309 Management of type 2 diabetes. **2002**, 1-24

308 Oxidative Stress and Cardiovascular Risk in Type 2 Diabetes. **2003**, 140-149

307 Hyperglycaemia as Cardiovascular Risk in Type 2 Diabetes. **2003**, 22-26

306 Passive Smoking. **2003**, 248-284

305 Dyslipidemia and Cardiovascular Risk in Diabetes. **2003**, 53-62

304 Hypertension in Type 2 Diabetes Mellitus. **2003**, 63-84

1

303 Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes Mellitus: Evidence-based Approach to Primary and Secondary Prevention. **2003**, 204-211

302 Global Approach to Cardiovascular Risk in Type 2 Diabetic Persons. **2003**, 240-276

301 Cerebrovascular Disease in Diabetes Mellitus.

300 Clinical Features and Treatment of Coronary Heart Disease in Diabetes.

299 Metabolic Stress and Atherosclerosis.

298 Arterial Hypertension in Diabetes: Etiology and Treatment.

297 Níveis glicêmicos usados para o diagnóstico do diabetes mellitus alteram a função endotelial? Estudo em rim isolado de coelhos normais. **2003**, 47, 716-720

296 Coronary Artery Disease and Cardiomyopathy. **2004**, 685-700

295 Diabetische Herzerkrankung. **2004**, 341-351

- 294 Diabetes Mellitus: Classification and Epidemiology. **2004**, 1-9 1
- 293 BLOOD PRESSURE LOWERING TREATMENT AND THE PREVENTION OF STROKE IN THE DIABETIC PATIENT. **2004**, 633-652
- 292 Op^ õs terap^ õticas atuais para diabetes mellitus tipo 2 e doen^ õ arterial coronariana: preven^ õ secund^ õa intensiva focada no treinamento f^ sico versus revasculariza^ õ percut^ õea ou cir^ õgica. **2004**, 10, 220-223
- 291 Diabetes in Acute Coronary Syndrome. **2004**, 563-596
- 290 Statins and Plaque Stabilization. **2004**, 521-562
- 289 Noninvasive Assessment of Asymptomatic Individuals at Risk of Coronary Heart Disease. Part b. **2006**, 137-154
- 288 Tserebrovaskulyarnye zabolevaniya i sakharnyy diabet 2 tipa. **2006**, 9, 34-40 1
- 287 The Metabolic Syndrome: Time for a Critical Appraisal. **2006**, 12, 99-116 3
- 286 Angiotensin II antagonists, diabetes and metabolic syndrome. **2006**, 99-109
- 285 Type 1 Diabetes Mellitus. **2006**, 147-186
- 284 Type 2 Diabetes. **2006**, 187-254
- 283 Metabolic Syndrome and Type 2 Diabetes Mellitus. **2006**, 41-78
- 282 Management of Diabetic Dyslipidaemia. **2007**, 173-186
- 281 Multifactorial Intervention in Type 2 Diabetes. **2007**, 153-163
- 280 Overview of diabetes mellitus. **2007**, 1-16
- 279 Generik atorvastatina Tulip? v lechenii dislipidemii u bol'nykh s sakharnym diabetom 2 tipa. **2007**, 10, 47-51
- 278 Type 1 Diabetes Mellitus. **2007**, 147-185
- 277 Dyslipidemia and Diabetes. **2007**, 405-416

- 276 The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. **2007**, 437-461
- 275 Treatment of Hypertension in Type 2 Diabetes. **2008**, 251-263
- 274 The Joint Effect of Diabetes and Blood Transfusion on Ischemic Heart Disease Mortality in a Cohort Study in Japan. **2008**, 2, 17-22
- 273 5 Diabetes mellitus en het metabool syndroom. **2008**, 43-49
- 272 The Metabolic Syndrome and Cardiac Function. **2008**, 7, 332-336
- 271 Hypertension in Diabetes Mellitus. **2008**, 278-287
- 270 Long-Term Metabolic Complications Posttransplantation. **2009**, 135-144
- 269 Cardiometabolic Syndrome, Diabetes and Oxidative Stress. **2008**, 91-102
- 268 Factors Affecting on Impaired Blood Glucose and Diabetes in Residents of a Rural Area. **2008**, 9, 1374-1385
- 267 CB1 Antagonism in the Management of Abdominal Obesity. **2008**, 223-232
- 266 Abdominal Obesity in Type 2 Diabetes. **2008**, 11-17
- 265 Effects of Adding Ω 3 Fatty Acids to Simvastatin on Lipids, Lipoprotein Size and Subspecies in Type 2 Diabetes Mellitus with Hypertriglyceridemia. **2009**, 33, 494
- 264 Case 24. Coronary Artery Disease. **2009**,
- 263 Diabetes Mellitus and Exercise Physiology in the Presence of Diabetic Comorbidities. **2009**, 163-183
- 262 Literatuur. **2009**, 31-36
- 261 NHG-Standaard Cardiovasculair risicomanagement. **2009**, 106-152 2
- 260 Physiological difference of serum lipid and blood glucose levels between young and middle-aged Zen monks. **2009**, 20, 42-46
- 259 AP control of as the most efficacious tool for the prevention of cardiovascular complications in patients with type 2 diabetes mellitus. **2009**, 12, 10-13

- 258 Passive Smoking. **2010**, 247-288 0
- 257 Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care. **2009**, 47, 1053-61 4
- 256 Coronary Artery Disease and Cardiomyopathy. **2010**, 499-513
- 255 Dyslipidemia: Pathogenesis and Management. **2010**, 435-456
- 254 [The treatment of hypertension in the elderly]. **2010**, 47, 419-21
- 253 Diabetes Mellitus: Disease Management. **2010**, 350-354.e2
- 252 D'ordres cliniques et biologiques associ' s. **2010**, 77-98
- 251 Cardiovascular diseases in diabetic patients. **2010**, 1, 46-50 1
- 250 The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. 635-656 1
- 249 Congestive Heart Failure. 684-697
- 248 The Pathophysiology and Metabolic Impact of Hyperglycemia. **2011**, 267-280
- 247 Macrovascular Disease. **2011**, 169-186
- 246 Diabetes and Cardiovascular Disease. **2010**, 173-194
- 245 Metabolic Syndrome and Inflammation. **2011**, 69-92 1
- 244 Cost of Pycnogenol Supplementation and Traditional Diabetes Treatments per Unit of Improved Health Outcome. **2011**, 457-465
- 243 Relationship between Glycemic Control and Diabetic Retinopathy. **2010**, 14, 234-241 3
- 242 Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents. **2011**, 275-310
- 241 Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. **2011**, 161-181

- 240 Microparticles Novel Mechanisms of Intracellular Communication: Implication in Health and Disease. **2011**, 3, 18
- 239 Diabetes and Coronary Heart Disease. **2012**, 471-484
- 238 Pharmacological management of hypertension in diabetes. **2011**, 30-40
- 237 Small Dense Low-density Lipoprotein and Cardiovascular Disease. **2012**, 1, 1
- 236 Carvedilol vs. metoprolol: A comparison of effects on endothelial function and oxidative stress in response to acute hyperglycemia in patients with type 2 diabetes and hypertension. **2012**, 02, 146-151
- 235 Diet and the Prevention of Type 2 Diabetes. **2012**, 127-142
- 234 Public Health - Pages e1-e91. **2012**, e1-e91
- 233 Paraoxonase 1 gene (Gln[>]192[>]-Arg) polymorphism and the risk of coronary artery disease in type 2 diabetes mellitus. **2012**, 02, 29-37
- 232 Prevalence of combined atherosclerotic vascular lesions in patients with diabetes mellitus. **2012**, 15, 49-55 3
- 231 Percutaneous Coronary Intervention in Patients with Diabetes and Multivessel or Left Main Disease—A Review. **2012**, 9, 108-111
- 230 Vascular Complications in Diabetes. **2013**, 313-337
- 229 LOW-DENSITY LIPOPROTEIN SUBFRACTIONS AND VARYING DEGREE OF CORONARY STENOSIS. **2013**, 12, 16-20
- 228 [Statins and the risk of diabetes]. **2013**, 154, 1691-5
- 227 Vascular Complications of Diabetes Mellitus. **2014**, 1-65
- 226 D'ordres glyc^miques. **2014**, 47-69
- 225 Dyslipidemias in the Geriatric Chronic Kidney Disease Patients. **2014**, 255-267
- 224 Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidney Disease. **2014**, 1-8
- 223 Hypertension and Cardiovascular Disease and Its Management. 140-164

- 222 Effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes in patients with type 2 diabetes mellitus. **2014**, 17, 34-40 0
- 221 Smoking and Diabetic Nephropathy. **1994**, 133-140 1
- 220 Diabetes and Cardiovascular Risk: Epidemiologic Aspects. **1995**, 173-183
- 219 Smoking and Diabetic Nephropathy. **1996**, 165-172
- 218 Conclusion. **1996**, 252-259
- 217 Prevention of cardiovascular disease. **1996**, 495-517
- 216 Diabetes and Atherosclerosis: The Diabetes Atherosclerosis Intervention Study (Dais). **1996**, 405-411
- 215 Avoiding premature coronary deaths in Asians in Britain. Benefit from controlling blood pressure was understated. **1996**, 312, 376 1
- 214 Microalbuminuria and Cardiovascular Disease. **1998**, 39-50
- 213 Diabetes in the United States: epidemiology, scope, and impact. **1998**, 1-11
- 212 Lipoproteins and Cardiovascular Risk: From Genetics to Prevention of Coronary Heart Disease. **1998**, 217-228
- 211 Diabetes and Atherosclerosis: Risk Factors and Clinical Trials. **1998**, 165-170
- 210 The Metabolic Syndrome. **1999**, 221-242
- 209 Diabetes und koronare Herzkrankheit. **1999**, 345-418
- 208 HYPERTENSION IN DIABETES MELLITUS. **2014**, 402-413
- 207 Increased risk of acute coronary syndrome among patients with urinary stone disease: a nationwide population-based cohort study. **2014**, 9, e102349 0
- 206 A Study of the Cardiovascular Risk Factor Profile in Patients with Acute Coronary Syndrome with Particular Reference to Metabolic Syndrome. **2015**, 06, 859-866 1
- 205 Use of Myocardial Perfusion SPECT for Preoperative Risk Stratification of Non-Cardiac Surgery. **2015**, 1, 43-52

204 Diseases of Renal Microcirculation: Diabetic Nephropathy. **2015**, 3739-3768

203 Patients with arterial hypertension associated with metabolic disorders: characteristics and therapeutic approach. **2015**, 12, 52-57

202 DYNAMICS OF GLYCEMIC CONTROL AFTER RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS. **2015**, 14, 82-90

1

201 Secondary Stroke Prevention. **2016**, 173-182

200 Coronary Artery Disease and Cardiomyopathy. **2016**, 1-21

199 15. Cardiovascular Disease. **2016**,

198 Diabetic Retinopathy. **2016**, 89-130

197 Characteristics of Coronary Lesions in Small Vessel Disease Treated with Elective Stenting in Patients with Type 2 Diabetes Mellitus. **2016**, 1, 55-61

196 A STUDY ON RELATIONSHIP OF GLYCATED HAEMOGLOBIN WITH SEVERITY OF CORONARY ARTERY DISEASE IN TYPE 2 DIABETES USING SYNTAX SCORE. **2016**, 3, 4824-4828

195 Coronary Artery Disease and Cardiomyopathy. **2017**, 1-21

194 Coronary Artery Disease and Cardiomyopathy. **2017**, 637-657

193 Diabetes in Older Adults. **2017**, 1-18

192 Primary and Secondary Prevention of Stroke. **2017**, 1-9

191 Intermittent High Glucose Enhances the Proliferation of Rat Aortic Vascular Smooth Muscle Cells More Than Constant High Glucose via the Mitogen-Activated Protein Kinase Pathway. **2017**, 21, 131-137

190 Type 2 Diabetes in Ethnic Minority Groups in Europe. **2018**, 155-168

189 Cardiovascular Risk in Xavante Indigenous Population. **2018**, 110, 542-550

4

188 Cerebral Vascular Injury in Diabetic Ischemia and Reperfusion. **2018**, 163-169

187 Primary and Secondary Prevention of Stroke. **2018**, 715-723

- 186 Glucose Metabolism Disorder and Angioscopic Findings of Coronary Plaques. **2018**, 4, 33-38
- 185 RADIOLOGICAL AND CLINICAL EVALUATION OF LONG-STANDING DIABETIC PATIENTS FOR LIMB ISCHAEMIA AND ABDOMINAL VESSEL INVOLVEMENTS (SMA) AT NKP SALVE INSTITUTE OF MEDICAL SCIENCES, NAGPUR. **2018**, 7, 1030-1033
- 184 Elevated fasting blood glucose, but not obesity, is associated with coronary artery disease in patients undergoing elective coronary angiography in a referral hospital in Jordan. **2018**, 38, 111-117
- 183 Diabetes and cardiovascular risk. **2018**, 20, 58-61
- 182 Physical Inactivity is Related to Unheralded Myocardial Infarction More Than Uncomplicated Stable Angina. **2018**, 7, 46-52
- 181 Prevalence and knowledge of classical cardiovascular disease risk factors among patients with diabetes. **2018**, 12, 9-14 1
- 180 Association of cardiovascular risk estimate with degree of atherosclerosis in patients with type 2 diabetes mellitus. **2019**, 5, 94
- 179 D'ordres glyc^ miques. **2019**, 53-90
- 178 Diabetes and Cardiovascular Disease. **2019**, 709-730
- 177 Diabetes Management in the United States. **2019**, 255-271
- 176 D'ordres cliniques et biologiques associ^ s. **2019**, 91-110
- 175 Atherosclerosis Risk Factors. **2019**, 9-45
- 174 Exploring the Type 2 Diabetes Management in the Primary Care Setting in Ratchaburi Province, Thailand. **2019**, 12, 56-60 1
- 173 Glucose Fluctuation and Cardiovascular Diseases. **2020**, 61, 633-635
- 172 The Peculiarity of Process and Treatment of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus. **2020**, 16, 623-634
- 171 Diabetes Mellitus and Its Impact on Patient-Profile and In-Hospital Outcomes in Peripheral Artery Disease. **2021**, 10, 0
- 170 Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for Cardiovascular Disease in 2017 and Trends and Risk Analysis From 1990 to 2017 Using the Global Burden of Disease Study and Implications for Prevention. **2021**, 9, 559751 3
- 169 Cardiometabolism: Reducing Risks to Optimize Cardiovascular Disease Outcomes. **2021**, 227-248

168 Type II Diabetes Mellitus. **2020**, 693-720

167 Effect of admission glycated hemoglobin on short term outcome of acute ST elevation myocardial infarction in non-diabetic patient. **2020**, 12, 165-170

166 Diabetes in Older Adults. **2020**, 211-228

165 Traditional Risk Factors and Newly Recognized Emerging Risk Factors for Cardiovascular Disease. **2003**, 63-89

164 Epidemiologie koronarer Ereignisse bei Diabetes mellitus. **2005**, 3-12

163 Ern^ Brung. **2005**, 328-342

162 Lipide. **2005**, 13-26

161 Hypertonie. **2005**, 377-396

160 Stoffwechsel des Herzens bei Diabetes. **2005**, 101-121

159 Diabetes Mellitus. **2005**, 563-575

158 Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. **2006**, 113-143

157 Controversies in Evaluation and Management of Lipid Disorders in Diabetes. **2008**, 291-315

156 Peripheral Vascular Disease Stroke inType2Diabetes. **2008**, 321-331

155 Influence of Life-related Factors and Participation in Health Examination on Mortality in a 4.5-year Follow-up of a Rural Cohort.. **2000**, 5, 66-71

154 Myokardinfarktregister unter besonderer Ber^ cksichtigung des Diabetes. **2008**, 569-591

153 Passivrauchen (ETS). **2008**, 411-456

152 Glycated Haemoglobin and Outcomes of Percutaneous Coronary Intervention Among Type Two Diabetic Patients in Saudi Arabia. **2020**, 12, e11278

151 Fasting blood glucose to HDL-C ratio as a novel predictor of clinical outcomes in non-diabetic patients after PCI. **2020**, 40,

150	Study of Silent Myocardial Infarction in Type Two Diabetes Mellitus Patients in a Tertiary Care Center. 2020 , 9, 3305-3309	
149	Percutaneous Coronary Intervention in Diabetic Patients.	
148	Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. 1994 , 37, 585-591	
147	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. 1998 , 317, 703-13	1490
146	The cost of major comorbidity in people with diabetes mellitus. 2003 , 168, 1661-7	35
145	Preventive medicine in people at high risk for chronic disease: the value of identifying and treating diabetes. 1999 , 160, 1593-5; discussion 1595-6	4
144	Saint Vincent: a new responsibility for general practitioners?. 1996 , 46, 447-8	5
143	Risk and prevention of type II diabetes: offspring's views. 2001 , 51, 194-9	29
142	Prevalence of coronary risk factors, clinical presentation, and complications in acute coronary syndrome patients living at high vs low altitudes in Yemen. 2006 , 8, 28	9
141	Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. 2005 , 1, 209-15	9
140	Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. 2007 , 3, 165-71	4
139	Can we prevent high-risk patients from getting type 2 diabetes?. 2002 , 48, 279-81	2
138	Effect of statin therapy on total mortality. Trial in a more varied population. 2003 , 49, 757-9	
137	Comprehensive cardiovascular risk management--what does it mean in practice?. 2007 , 3, 587-603	11
136	A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. 2007 , 3, 721-31	4
135	Rationale for multiple risk intervention: the need to move from theory to practice. 2007 , 3, 985-97	11
134	Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. 2007 , 3, 783-95	19
133	Practical aspects of the control of cardiovascular risk in type 2 diabetes mellitus and the metabolic syndrome. 2007 , 12, 83-6	3

132	Arterial hypertension in diabetes mellitus: from theory to clinical practice. 2008 , 12, 74-80	8
131	Statins in type 2 diabetes mellitus: target on lipids and vascular wall function. 2003 , 11, 123-128	
130	Cardiac complications in type 2 diabetic patients with mild anginal symptoms and documented reversible myocardial perfusion defects: Results of the MERIDIAN trial. 2006 , 14, 409-416	3
129	Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. 2002 , 94, 1025-35	10
128	Factors of cardiovascular risk in patients with type 2 diabetes and incipient nephropathy. 2008 , 12, 221-4	1
127	Comparative analysis of lipid profiles among patients with type 2 diabetes mellitus, hypertension and concurrent type 2 diabetes, and hypertension: a view of metabolic syndrome. 2003 , 95, 328-34	6
126	Prevalence of hypercholesterolemia in black patients of a neighborhood health center. 1994 , 86, 500-5	
125	Stress echocardiography: a useful test for assessing cardiac risk in diabetes. 2009 , 5, 1-7	3
124	Assessing the prevalence of the Metabolic Syndrome according to NCEP ATP III in Germany: feasibility and quality aspects of a two step approach in 1550 randomly selected primary health care practices. 2006 , 4, Doc07	20
123	Angiographic characteristics of the coronary artery in patients with type 2 diabetes. 2002 , 7, 199-200	3
122	Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. 2008 , 83, 1350-7	18
121	Molecular biology of atherosclerosis. 2008 , 5, 57-62	17
120	Atherosclerosis: A Link Between Lipid Intake and Protein Tyrosine Nitration. 2008 , 2008, 75	12
119	Diabetes & coronary heart disease: current perspectives. 2010 , 132, 584-97	27
118	Hypertension in people with type 2 diabetes: Update on pharmacologic management. 2011 , 57, 997-1002, e347-53	35
117	Comparing angiography features of inferior versus anterior myocardial infarction regarding severity and extension in a cohort of Iranian patients. 2011 , 16, 484-9	2
116	Hypertension revisited. 2012 , 58, 634-6	
115	Aortic response to balloon injury in obese Zucker rats. 2012 , 62, 264-70	4

114	Elevated plasma homocysteine in type 2 diabetes mellitus: a risk factor for cardiovascular diseases. 2012 , 12, 48	23
113	The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. 2012 , 17, 191-6	2
112	The influence of diabetes on short-term outcome following a prosthetic above-the-knee femoro-popliteal bypass. 2009 , 20, 170-2	2
111	Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. 2008 , 14, 15-23	331
110	The impact of blood pressure variability on subclinical ventricular, renal and vascular dysfunction, in patients with hypertension and diabetes. 2013 , 8, 129-36	10
109	Interventional Revascularization of Coronary Artery Lesions in Diabetic Patients; In-hospital and One Year Follow up. 2012 , 6, 113-7	2
108	Diabetic hypertensive control and treatment: a descriptive report from the audit diabetes control and management (adcm) registry. 2010 , 5, 134-9	4
107	Acute myocardial infarction associated to DPP-4 inhibitors. 2014 , 6, 180-6	4
106	Urban-rural differences in atherogenic dyslipidaemia (URDAD Study): a retrospective report on diabetic and non-diabetic subjects of Northern India. 2014 , 32, 494-502	
105	Predicting of trend of hemoglobin a1c in type 2 diabetes: a longitudinal linear mixed model. 2014 , 5, 1274-80	8
104	The Diagnostic Value of Tc-99m MIBI Gated Myocardial Perfusion SPECT in Detection of Silent Myocardial Ischemia in Asymptomatic Patients with Type 2 Diabetes Mellitus. 2008 , 40, 62-7	
103	The Effects of Acute Blood Loss for Diagnostic Bloodwork and Fluid Replacement in Clinically Ill Mice. 2015 , 65, 202-16	1
102	Synergistic effect of hypertension with diabetes mellitus and gender on severity of coronary atherosclerosis: Findings from Tehran Heart Center registry. 2015 , 11, 317-22	7
101	Vitamin D3 Induces Gene Expression of Ox-LDL Scavenger Receptors in Streptozotocin-Induced Diabetic Rat Aortas: New Insight into the Role of Vitamin D in Diabetic Atherosclerosis. 2018 , 6, 170-177	2
100	Diabetes Mellitus and Cardiovascular Disease. 2003 , 14, 74-77	
99	Asymptomatic coronary artery disease in type II diabetes. 2014 , 111, 73-9	3
98	In-Hospital Outcome of Patients with Diabetes Mellitus after CTO Recanalization with Third-Generation Drug-Eluting Stents. 2019 , 14, 47-52	
97	Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCO-RCT). 2020 , 10, e040117	

96	Sex differences in cardiovascular risk factors of children and adolescents with type 1 diabetes mellitus: A role for diet?. 2021 ,	0
95	The links between Sleep Duration, Obesity and Type 2 Diabetes Mellitus. 2021 ,	9
94	Relationship between genomic risk scores (GRS) and coronary artery calcium (CAC) score: A pilot study.. 2022 , 47, 293-298	
93	Novel use of menstrual blood for monitoring glycaemic control in patients with diabetes: a proof-of-concept study. 2021 ,	1
92	Standards of Medical Care in Diabetes 2006. <i>Diabetes Care</i> , 2006 , 29, s4-s42	14.6 350
91	Les variabilit�s « m�taboliques » : fluctuations aigu�s et ondulations lentes, causes et cons�quences. 2022 , 16, 6-6	
90	Diabetes, hypertension, and cardiovascular disease development.. 2022 , 20, 9	2
89	The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes.. 2021 , 128, 154961	4
88	Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCOGO-RCT). 2020 , 10, e040117	1
87	Epidemiology of Stroke Patients with Diabetes. 2021 , 51-68	
86	Cardiovascular Statistics - Brazil 2021.. 2022 , 118, 115-373	4
85	Computerized Clinical Decision Support. 2022 , 469-497	
84	Factors related to the risk of stroke in the population with type 2 diabetes: A protocol for systematic review and meta-analysis.. 2022 , 101, e27770	0
83	Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.. 2022 , 23, 9	3
82	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. 2021 , 36, 108101	2
81	Lipoprotein (a) levels in newly diagnosed treatment naive type 2 diabetics & its correlation with glycemic & lipid parameters. 2022 , 4, 170-174	
80	Variability in the Control of Type 2 Diabetes in Primary Care and Its Association with Hospital Admissions for Vascular Events. The APNA Study.. 2021 , 10,	1
79	Simvastatin with or without ezetimibe in familial hypercholesterolemia. 2009 , 11, 3-5, 8	

- 78 Methods for Measuring Blood Pressure and Applications to Diabetes. **2022**, 1-21
- 77 Therapeutic RNA-silencing oligonucleotides in metabolic diseases.. **2022**, 4
- 76 Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases.. **2022**, 23, 2
- 75 Roles of Cardiometabolic Factors in Mediating the Causal Effect of Type 2 Diabetes on Cardiovascular Diseases: A Two-Step, Two-Sample Multivariable Mendelian Randomization Study.. **2022**, 9, 813208 0
- 74 Review - late toxicity of abdominal and pelvic radiotherapy for childhood cancer.. **2022**, 1
- 73 Prognostic Outcomes in Acute Myocardial Infarction Patients Without Standard Modifiable Risk Factors: A Multiethnic Study of 8,680 Asian Patients.. **2022**, 9, 869168 1
- 72 Blood Pressure Variability and Diabetes Mellitus. **2022**, 23, 21-27
- 71 Prospective study of breakfast frequency and timing and the risk of incident type 2 diabetes in community-dwelling older adults: The Cardiovascular Health Study.. **2022**, 1
- 70 Aspirin use in patients with diagnosed diabetes in the United States and China: Nationally representative analysis.. **2021**, 18, 14791641211067416
- 69 Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients.. **2021**, 11, 1
- 68 Recent Advances in Anxiety Disorders and Cardiovascular Diseases. **2022**, 12, 2638-2644
- 67 The effect of metabolic health and obesity on lung function: A cross sectional study of 114,143 participants from Kangbuk Samsung Health Study.. **2022**, 17, e0266885 0
- 66 Associations of genetic and infectious risk factors with coronary heart disease.
- 65 Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?. **2022**, 1 0
- 64 Cardiovascular risk and protective factors in adults with and without diabetes mellitus (Italy, 2016-19).. **2022**,
- 63 YKL-40 and its co-expression analysis with major non-communicable diseases biomarkers. **2022**,
- 62 Serum Tenascin-C and Alarin Levels Are Associated with Cardiovascular Diseases in Type 2 Diabetes Mellitus.. **2022**, 2022, 2009724 0
- 61 Precision Medicine for Diabetes and Cardiovascular Disease. **2022**, 53-64

60	Precision Medicine for Diabetes and Dyslipidemia. 2022 , 65-87	
59	Cardiovascular Risk Assessment in Metabolic Syndrome and Diabetes. 2022 , 89-105	
58	Hypertension in Patients with Insulin Resistance: Etiopathogenesis and Management in Children. 2022 , 23, 5814	2
57	Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.	7
56	Lipo-proteomic and metabolic fine-mapping of genetic lipid risk loci.	
55	Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities. 2022 , 23, 6500	o
54	Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target. 9,	o
53	Research in the Field of Exercise and Metabolomics: A Bibliometric and Visual Analysis. 2022 , 12, 542	
52	Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks.	
51	Dietary Plant Sterols and Phytosterol-Enriched Margarines and Their Relationship with Cardiovascular Disease among Polish Men and Women: The WOBASZ II Cross-Sectional Study. 2022 , 14, 2665	1
50	Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk. 2022 , 29, 327-336	o
49	SIRT3 attenuates coronary atherosclerosis in diabetic patients by regulating endothelial cell function.	o
48	Potential role of SGLT2 inhibitors in the management of hypertension. 2022 ,	
47	Smoking cessation in people with and without diabetes after acute coronary syndrome.	o
46	Exosomal microRNAs in diabetic heart disease. 2022 , 21,	o
45	Dyslipidemia in Diabetes. 2022 ,	o
44	Comparison between Machine Learning and Multiple Linear Regression to Identify Abnormal Thallium Myocardial Perfusion Scan in Chinese Type 2 Diabetes. 2022 , 12, 1619	
43	CORRELATION BETWEEN CAROTID INTIMA-MEDIA THICKNESS WITH URINE ALBUMIN CREATININE RATIO IN PATIENTS WITH TYPE 2 DABETES MELLITUS. 2022 , 11-14	

42	Glycemic status and the association of change in blood pressure with incident cardiovascular disease. 2022 ,	
41	Health-related quality of life and its influencing factors in elderly people with hypertension and type 2 diabetes mellitus based on Multi-level model: take the east coastal area of China as an example.	
40	Rev-erbs agonist SR9009 alleviates ischemia-reperfusion injury by heightening endogenous cardioprotection at onset of type-2 diabetes in rats: Down-regulating ferritinophagy/ferroptosis signaling. 2022 , 154, 113595	0
39	Glargine u300' n D^ k.Yoūnluklu Lipoprotein (LDL), Trigliserid (TG) ve Kan Bkeri D^ zeyleri ^ zerindeki Etkileri: Ger^ Bk Yaēm Sonu^ lbr=2022, 6, 137-142	0
38	Ketogenic diet modulates cardiac metabolic dysregulation in streptozocin-induced diabetic rats. 2022 , 109161	1
37	Need for improving immunization status and preventive care in diabetes mellitus patients.	0
36	Normalization of Vitamin D Serum Levels in Patients with Type Two Diabetes Mellitus Reduces Levels of Branched Chain Amino Acids. 2022 , 58, 1267	0
35	Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients.	1
34	Medication-related burden among patients with diabetes mellitus and its relation to diabetic control parameters: an observational study. 11, 1112	0
33	Methods for Measuring Blood Pressure and Applications to Diabetes. 2023 , 729-749	0
32	Association of pulse pressure with all-cause mortality in older Japanese patients with type 2 diabetes mellitus: A observational cohort study.	0
31	Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitusâ results from the TRIUMPH randomised controlled trial.	0
30	Diversified Shifts in the Cross Talk between Members of the Gut Microbiota and Development of Coronary Artery Diseases.	0
29	Ischemic Heart Disease in Native Americans.	1
28	Association of comorbid mental disorders with cardiovascular disease risk in patients with type 2 diabetes: A nationwide cohort study. 2022 , 79, 33-41	0
27	The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial. 2022 , 21,	5
26	Heart rate-corrected QT interval prolongation is associated with decreased heart rate variability in patients with type 2 diabetes. 2022 , 101, e31511	0
25	The effect of vitamin D and Physical exercise on glycaemic control in patients with Type 2 Diabetes Mellitus(DM). 2022 , 4697-4700	0

24	Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes. 2022 , 21,	0
23	Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. 2022 , 191-229	0
22	Cluster analysis identifies six clinical subtypes of hidradenitis suppurativa characterised by distinct comorbidities, inflammatory and metabolic profiles, patient-reported outcomes and treatment patterns.	0
21	Prevalence and Predictors of Renal Disease in a National Representative Sample of the Romanian Adult Population: Data from the SEPHAR IV Survey. 2022 , 12, 3199	1
20	ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes. 2022 , 23, 1432-1450	0
19	Peripheral Arterial Disease in Community-based Patients with Diabetes in Singapore: Results from a Primary Healthcare Study. 2010 , 39, 525-531	2
18	S-allyl Cysteine and Taurine revert peripheral metabolic and lipid profile in non-insulin-dependent diabetes mellitus animals: Combination vs Monotherapy. 58,	0
17	Characteristics of Postoperative Patients with Breast Cancer Aged 65 Years and Older. 2023 , 30, 673-680	0
16	Risk Stratification for Cardiovascular Disease Based on Prior Coronary Artery Disease, Cerebrovascular Disease and Diabetes Mellitus.	0
15	Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes. 2023 , 389-403	0
14	Effects of Exercise On Coronary Flow Reserve And Biochemical Parameters in Patients With Type 2 Diabetes Mellitus. 2022 , 7, 61-65	0
13	The association of glycated hemoglobin A1c with coronary artery disease, myocardial infarction, and severity of coronary lesions. 108155892211405	0
12	Individual patient-centered target-driven intervention to improve clinical outcomes of diabetes, health literacy, and self-care practices in Nepal: A randomized controlled trial. 14,	0
11	Current trends of hybrid myocardial revascularization. 2023 , 181, 108-114	0
10	Impact of diabetic status and contribution of office and home blood pressure across diabetic status for cardiovascular disease: the J-HOP study.	0
9	Luseoglitazone and caloric intake restriction increase superoxide dismutase 2 expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in diet-induced obese mice. 2023 , 14, 548-559	0
8	Associations of genetic and infectious risk factors with coronary heart disease. 12,	0
7	Development and validation of a nomogram for evaluating the incident risk of carotid atherosclerosis in patients with type 2 diabetes. 14,	0

- 6 Lifestyle intervention reduces risk score for cardiovascular mortality in company employees with pre-diabetes or diabetes mellitus â A secondary analysis of the PreFord randomized controlled trial with 3 years of follow-up. 14,
- 5 Early effects of insulin therapy on cholesterol synthesis and absorption markers in patients with type 2 diabetes. **2023**, 48, 64-74
- 4 Diabetes and Cardiovascular Disorder. **2023**, 41-61
- 3 New Routes of Insulin for Diabetes Treatment. 228-241
- 2 Diabetes: evolution of multifactorial vascular risk reduction. **2023**, 311-335
- 1 Metformin associates with improved myocardial perfusion reserve and survival in patients with Type 2 Diabetes Mellitus.